<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>   <meta charset="utf-8" />
<meta http-equiv=Content-Type content="text/html; charset=Windows-1254">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 10">
<meta name=Originator content="Microsoft Word 10">
<link rel=File-List href="pnp_dosyalar/filelist.xml">
<link rel=Edit-Time-Data href="pnp_dosyalar/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>POL�N�ROPAT�LER</title>
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;
	mso-font-alt:"MS Mincho";
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;
	mso-font-alt:Batang;
	mso-font-charset:129;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 151388160 16 0 524288 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:SimSun;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1 135135232 16 0 262144 0;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;
	mso-font-alt:PMingLiU;
	mso-font-charset:136;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1 134742016 16 0 1048576 0;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;
	mso-font-alt:"MS Gothic";
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;
	mso-font-alt:Dotum;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 151388160 16 0 524288 0;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:SimHei;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 135135232 16 0 262144 0;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;
	mso-font-alt:MingLiU;
	mso-font-charset:136;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134742016 16 0 1048576 0;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;
	mso-font-alt:Mincho;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;
	mso-font-alt:Gulim;
	mso-font-charset:129;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 151388160 16 0 524288 0;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 3 5 7 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:222;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:16777217 0 0 0 65536 0;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;
	mso-font-charset:222;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:16777217 0 0 0 65536 0;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:32768 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1048576 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:16778883 0 512 0 13 0;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangella Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1627421319 -2147483648 8 0 66047 0;}
@font-face
	{font-family:Shaker2Lancet-Bold;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:AdvTT6120e2aa;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:AdvPECFB95;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:AGaramond-Regular;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Shaker-R;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:AdvPS7C81;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS-Italic;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"MV Boli";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 5 6 2 2 2 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"\@Batang";
	mso-font-charset:129;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:150%;
	mso-pagination:widow-orphan;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
cite
	{color:green;
	font-style:normal;}
pre
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
span.msons
	{mso-style-name:mso\0131ns;
	text-decoration:underline;
	text-underline:single;}
span.msodel0
	{mso-style-name:msodel;
	color:red;
	text-decoration:line-through;}
ins
	{mso-style-type:export-only;
	text-decoration:none;}
span.msoIns
	{mso-style-type:export-only;
	mso-style-name:"";
	text-decoration:underline;
	text-underline:single;}
span.msoDel
	{mso-style-type:export-only;
	mso-style-name:"";
	text-decoration:line-through;
	color:red;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:70.85pt 70.85pt 70.85pt 70.85pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
 /* List Definitions */
 @list l0
	{mso-list-id:452334211;
	mso-list-template-ids:-1513055448;}
@list l1
	{mso-list-id:584874082;
	mso-list-template-ids:466940694;}
@list l2
	{mso-list-id:1377968236;
	mso-list-template-ids:-1442815446;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Normal Tablo";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
</style>
<![endif]-->
</head>

<body lang=EN-US link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:18.0pt;font-family:Tahoma;mso-ansi-language:TR'>PER�FER�K
S�N�RLER�N YAYGIN VE �OK ODAKLI HASTALIKLARI</span></b></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>A. Emre �GE, Ye�im G�L�EN PARMAN</span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Son g�ncelle�tirme tarihi: 09.06.2009</span></p>

</div>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Polin�ropati</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>, periferik sinirlerin ayn� nedene ve fizyopatolojik s�re�lere ba�l� olarak
hep birlikte, yayg�n �ekilde hastalanmas� ile ortaya ��kan bir klinik tablodur.
Polin�ropatileri olu�turan hastal�k s�re�leri �n planda h�cre g�vdesini
etkiliyorsa bir <i>n�ronopati</i>, ba�l�ca akson hasar�na neden oluyorsa bir <i>aksonopati</i>
ve sinir liflerinin miyelin k�l�f� primer olarak hasara u�ruyorsa bir <i>miyelinopati</i>
s�z konusudur. En iyi n�ronopati �rneklerini spinal �n boynuz h�crelerini
etkileyen ve sadece motor belirti ve bulgularla seyreden <i>motor n�ron
hastal���</i> ile spinal arka k�k gangliyonlar�n� haraplayarak ba�l�ca duyusal
belirtilere neden olan <i>inflamatuvar duyusal poligangliyonopati</i>ler (arka
k�k gangliyoniti) olu�turur. Birer polin�ropati tablosu olmamakla birlikte,
ilgili vir�s�n primer olarak etkiledi�i yerler s�ras� ile; spinal �n boynuz ve
arka k�k gangliyonu olan poliomiyelit ve&nbsp;varisella-zoster vir�s
infeksiyonlar� da n�ronopati kavram� i�inde ele al�nabilir. Miyelin k�l�f�n�n
�n planda hasara u�rad��� ba�l�ca polin�ropatiler akut&nbsp;ve kronik inflamatuvar
demiyelinizan polin�ropatiler, herediter motor ve duyusal n�ropatilerin baz�
formlar� ve difteriye ba�l� polin�ropatidir. Primer aksonal hasarla seyreden
polin�ropatiler geni� bir liste olu�turur. Toksik, metabolik ya da nutrisyonel
yetersizli�e ba�l� polin�ropatiler genellikle bu grupta yer al�rlar. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Monon�ropati multipleks</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>te ise ayn� hastal�k
s�reci periferik sinirleri genellikle birbirinden ayr� zamanlarda yerle�en
multipl odaklar halinde etkiler. Hastan�n �yk�s�nden klinik tablonun zaman
i�inde farkl� sinirlerin tutulmas�yla geli�ti�i anla��labilir, muayenede
asimetrik multifokal periferik sinir harabiyetine ait bulgular saptanabilir.
Buna kar��l�k, bazen multifokal lezyon odaklar� �ok h�zl� bir yay�lma g�sterir
veya klinik belirti ve bulgular birbirleri ile birle�erek (konfl�ans)
polin�ropatiden ayr�lamaz hale gelir. Monon�ropati multipleks i�in en tipik
�rnekleri <i>poliarteritis nodosa</i> ve <i>Churg-Strauss alerjik
granulomatozisi</i> gibi <i>nekrotizan vask�lit</i>lere ba�l� periferik
n�ropatiler olu�turur. </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Polin�ropatilerde klinik tan�, bir hastada polin�ropati tablosunun
varl���n�n g�sterilmesi ve daha sonra bunun hangi nedene ba�l� oldu�unun ortaya
konmas�ndan ibarettir. <b>Tablo 1�</b>de g�r�ld��� gibi polin�ropatiler �ok
de�i�ik nedenlere ba�l� olarak ortaya ��kabilir. Bir hastada temel olarak
ama�lanan, tedavisi olanakl� bir polin�ropatinin belirlenmesidir. Bu nedenle
hastada polin�ropati varl��� saptand�ktan sonra klinik ve laboratuvar
verilerine dayan�larak nedenin ara�t�r�lmas�na y�nelik bir analiz yap�lmas�
gerekir. <i>Buradaki y�ntem, klinik bulgular ve basit laboratuvar bulgular�n�n
ortaya koydu�u ipu�lar�n�n yard�m� ile geni� ay�r�c� tan� listelerini
daraltmak, sonra da bu daralt�lm�� ay�r�c� tan� olas�l�klar� �zerinde daha
derinlemesine laboratuvar ara�t�rmalar� yapmak �eklindedir.</i> Nedeni
bilinmeyen periferik n�ropati �n tan�s� ile �zelle�mi� t�p merkezlerine
g�nderilen hastalar�n (farkl� kliniklerin verilerine g�re) %76-87 sinde nedeni
ortaya koyan bir tan�ya var�labilmektedir. En s�k rastlanan tan� gruplar�
herediter, inflamatuvar demiyelinizan ve di�er hastal�klara (diyabet ve di�er
metabolik hastal�klar, nutrisyonel yetersizlik, toksinler ve kanser) ba�l�
polin�ropatilerdir.</span></p>

<p class=MsoNormal style='text-indent:135.0pt'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 1.</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Ba�l�ca periferik&nbsp;sinir hastal�klar� * </span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(RJ Barohn)</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>I.&nbsp;&nbsp;&nbsp; ED�NSEL</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Metabolik bozukluklar</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Diyabetes mellitus</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B�brek hastal���na ba�l�
n�ropatiler</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vitamin yetersizlikleri</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�mm�n bozuklu�a ba�l�</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Guillain-Barr� sendromu (GBS)</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kronik inflamatuvar
demiyelinizan polin�ropati (CIDP) ve varyantlar�</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vask�lit</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Monoklonal antikorlarla
birlikte n�ropati</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Pleksitler (servikal ve
lumbosakral)</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Multifokal motor n�ropati</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�nfeksiyona ba�l�</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Herpes zoster</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lepra, Lyme, HIV ve sarkoidozla
ili�kili</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kanser ve lenfoproliferatif hastal�klarla ili�kili</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lenfoma, miyeloma ve kanserle
ili�kili</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik subakut duyusal
n�ronopati</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Primer amiloidoz</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�la�lar veya toksinler</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kemoterapiye ba�l�</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di�er ila�lar</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A��r metaller ve end�striyel
toksinler</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Mekanik/kompresif</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Radik�lopati</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Monon�ropati</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Etyolojisi bilinmeyen</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kriptojenik duyusal ve
duyusal-motor n�ropati</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Amiyotrofik lateral skleroz</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>II.&nbsp;&nbsp;&nbsp; HERED�TER</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Herediter motor-duyusal
n�ropati (Charcot-Marie-Tooth hastal���)</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Herediter bas�nca duyarl�l�k
n�ropatisi</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ailesel brakiyal pleksopati</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ailesel amiloidoz</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Porfiri</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di�er nadir periferik
n�ropatiler (Fabry hastal���, metakromatik l�kodistrofi, adrenol�kodistrofi,
Refsum hastal��� vb.)</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Motor n�ron hastal���</span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:36.0pt'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Spinal
m�sk�ler atrofi</span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:36.0pt'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ailesel
amiyotrofik lateral skleroz.</span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:36.0pt'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>X-e ba�l�
bulbospinal m�sk�ler atrofi</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>*: Bu tabloda polin�ropatilerin yan� s�ra monon�ropati,
monon�ropati multipleks ve spinal �n boynuz hastal�klar� da yer almaktad�r.
Klinik uygulamada zaman zaman bu hastal�k tablolar�n�n birbirinden ayr�lmas�nda
g��l�kle kar��la��labilir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>POL�N�ROPAT�L� HASTADA TANI</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Klinik Belirti ve Bulgular</span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Polin�ropatilerde genellikle simetrik klinik bulgular ortaya ��kar.
Polin�ropatiyi ortaya ��karan patolojik s�re� yayg�n aksonal dejenerasyon
�eklinde de olsa, Guillain-Barr� sendromunda (GBS) oldu�u gibi multifokal
segmental demiyelinizasyonla da seyretse polin�ropatinin motor ve/ veya duyusal
belirti ve bulgular� s�kl�kla <i>simetrik</i> olarak yerle�ir. Bir �ok
polin�ropati tablosunun alt�nda yatan aksonal dejenerasyon s�reci, periferik
sinir aksonlar�n�n distalden ba�layarak proksimale do�ru ilerleyen hasar� ile
seyreder (�<i>dying-back� n�ropati</i> veya <i>distal aksonopati</i>). Bunun
nedeni h�cre g�vdesinin akson distali i�in gerekli proteinleri ya da enzimleri
�retememesi veya aksonal transport sistemindeki bozukluk olabilir. Bu durumda
periferik n�ropati bulgular� en uzun aksonlar�n ula�t��� ekstremite
distallerinden ba�layarak ilerler. Polin�ropatilerin bu tipik klinik
g�r�n�m�nde, duyusal belirtiler alt ekstremite distallerinden ba�layan
parestezi ve a�r�lardan olu�ur. Hastal�k ilerledik�e yak�nmalar alt
ekstremitelerde proksimale do�ru yay�l�rken �st ekstremite distallerinde ortaya
��kar ve zaman i�inde burada da proksimale yay�l�r. N�rolojik&nbsp; muayenede
ekstremite distallerinde eldiven ve �orap tarz�nda duyu kusuru saptan�r. Kas
kuvvetsizli�i varsa �ncelikle alt, daha sonra �st ekstremite distallerdedir.
�zellikle ayak ekstensor kaslar�ndaki zaaf, y�r�rken aya��n yere tak�lmas� ya
da topuklar �zerinde y�r�me g��l��� �eklinde ortaya ��kar. Tendon
reflekslerinin azalmas� veya&nbsp; kaybolmas� da ekstremite distallerinden
ba�lar. A�il reflekslerinin kayb�n� zaman i�inde di�er tendon reflekslerinin
azalmas� izler. Klinik muayenede duyusal, motor ve refleks bozukluklar�n�n birlikte,
distal ve simetrik da��l�mda oldu�u bu tipik klinik g�r�n�me bir�ok
duyusal-motor polin�ropati tablosunda&nbsp; rastlan�r (diyabetik distal
simetrik polin�ropatide oldu�u gibi). Bununla birlikte, <i>hastan�n �yk�s� ve
muayene bulgular�nda saptanan baz� ayr�nt�lar ya da kural d���l�klar nedene
y�nelik tan�da yard�mc� olacak ipu�lar� sa�layabilir:</i></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Motor, duyusal ve otonom sinir liflerinin tutulmas�:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Baz� n�ropatilerde
motor, duyusal veya otonom fonksiyonlardan biri yaln�z ba��na ya da di�erlerine
oranla �ok bask�n �ekilde bozulmu� olabilir. Sadece motor belirti ve bulgularla
(kas kuvvetsizli�i, atrofi, fasik�lasyonlar) seyreden, duyusal bulgular�
olmayan bir periferik sinir sistemi hastal��� tablosunda <i>motor n�ron
hastal���</i> ya da daha nadiren <i>multifokal motor n�ropati</i> en kuvvetli
tan� olas�l�klar�d�r.<b> </b>Baz� periferik n�ropatilerde ise motor belirti ve
bulgular bask�n olmakla birlikte muayenede genellikle daha hafif d�zeyde
duyusal bulgular da saptan�r <b>(Tablo 2)</b>.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 2.</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp; �n planda motor belirtilerle seyreden n�ronopati ve n�ropatiler </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(RJ
Barohn, EP Bosch ve BE Smith, de�i�tirilerek)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Motor n�ron hastal���* &nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Multifokal motor n�ropati*</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Guillain-Barr� Sendromu**&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Akut motor aksonal n�ropati*</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Porfiriye ba�l� n�ropati*</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Monomelik amiyotrofi (Hirayama sendromu)*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kronik inflamatuvar demiyelinizan polin�ropati
(CIDP)**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Osteosklerotik miyeloma**</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Diyabetik lumbosakral radik�lopleksopati**</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kur�un intoksikasyonu**</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Herediter motor-duyusal n�ropati (Charcot-Marie-Tooth
hastal���)**</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>*&nbsp; Duyusal
sinir iletimlerinin de normal ya da normale yak�n oldu�u saf motor sendromlar</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>**Muayenede
genellikle duyusal bulgular da saptan�r</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Baz� polin�ropatilerde otonom sinir sistemi tutulmas�na ili�kin bulgular
belirgindir (<b>Tablo 3</b>). Ortostatik ba�d�nmesi ve bayg�nl�k, azalm�� veya
artm�� terleme, s�cak intolerans�, mesane, barsak ve seks fonksiyonu
bozukluklar� hasta �yk�s�nde dikkatle ara�t�r�lmal�, gere�inde ortostatik
hipotansiyon ba�ta olmak �zere yatak ba�� otonom sinir sistemi muayenesi
y�ntemleri klinik muayeneye eklenmelidir. Diyabeti olmayan bir hastada otonom
polin�ropati belirti ve bulgular�n�n olmas� ilk olarak amiloid n�ropatisini
akla getirmelidir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 3.</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Otonom sinir sistemi tutulmas� ile seyreden polin�ropatiler </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(BE
Smith, de�i�tirilerek)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut</span></b></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut pandizotonomik n�ropati
(idyopatik, otoimmun, paraneoplastik)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Guillain-Barr� sendromu</span></p>

<p class=MsoNormal style='margin-left:36.0pt;page-break-after:avoid'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Porfiri</span></p>

<p class=MsoNormal style='margin-left:36.0pt;page-break-after:avoid'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Toksik:
vinkristin, vacor</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kronik</span></b></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Diyabetes mellitus</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Amiloid n�ropatisi (ailesel ve
primer)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik duyusal
n�ronopati (malin inflamatuvar duyusal poligangliyonopati)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>HIV�le ili�kili otonom n�ropati</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Herediter duyusal-otonom
n�ropati</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Bir�ok duyusal veya duyusal-motor polin�ropatide uyu�ukluk, parestezi ve
a�r� gibi yak�nmalar ve muayenede ekstremite distallerinde belirgin duyu kusuru
bulunur.&nbsp; Bunlar aras�nda diyabet, kanser, Sj�gren sendromu,
disproteinemiler, AIDS, B12 vitamini yetersizli�i, sisplatin ve pridoksin
intoksikasyonuna ba�l� polin�ropatiler ile, herediter ve idyopatik duyusal
polin�ropatiler say�labilir. Bu derecede yayg�n rastlan�r olmalar�, duyusal
belirti ve bulgulardan ay�r�c� tan�da yararlanmam�z� g��le�tirmektedir. Bununla
birlikte, baz� duyusal �zellikler ay�r�c� tan� listesini daraltmakta i�e
yarayabilir. Bunlardan ilki polin�ropatinin a�r�l� olmas�d�r.&nbsp;<i>A�r�</i>,
polin�ropatili bir hastan�n ba�l�ca yak�nmas�n� olu�turuyorsa <b>Tablo 4</b>�de
g�r�len hastal�klar� �n planda g�z �n�nde bulundurmak gerekir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 4.</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> A�r�l� polin�ropatiler&nbsp;</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(RJ Barohn)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kriptojenik duyusal veya duyusal-motor polin�ropati</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Diyabetes mellitus</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Vask�litler</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Guillain-Barr�
sendromu</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Amiloidoz</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Toksik (arsenik, talyum)</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>HIV�le ili�kili distal simetrik polin�ropati</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Fabry hastal���</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Kriptojenik duyusal polin�ropati ve diyabete ba�l� distal simetrik
polin�ropati, a�r�l� n�ropatiler aras�nda en s�k rastlananlard�r. Hastalarda
alt ekstremite distallerinde (tabanlar ve ayak parmaklar�) bask�n, istirahatte
ve geceleri belirginle�en a�r�lar vard�r. Diyabette g�r�len bir di�er a�r�l�
n�ropati �ekli <i>diyabetik lumbosakral radik�lopleksopati</i>dir (diyabetik
amiyotrofi, proksimal asimetrik n�ropati). Vask�lite ba�l� n�ropatilerde en
a��r �ekilde tutulan ekstremitede belirgin olan distal ve asimetrik bir a�r�
vard�r. Guillain-Barr� sendromunda ekstremitelerdeki simetrik uyu�ma ve
parestezilere ek olarak �iddetli s�rt ve bel a�r�s� olabilir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Ay�r�c� tan� listesini daraltabilecek di�er bir duyusal bozukluk, �iddetli <i>propriyoseptif
duyu kayb�</i>d�r. Bu durumda hastan�n anamnezinde a��r denge bozuklu�u
(�zellikle karanl�kta belirginle�en) ve ekstremitelerde inkoordinasyon,
n�rolojik muayenede ise belirgin vibrasyon ve pozisyon duyusu kayb� (ve bazen
buna ba�l� olarak ellerde <i>ps�doatetoz</i>) vard�r. Di�er duyu
modalitelerinde daha geri planda bir azalma olabilir. Bu klinik tablo �n planda
arka k�k gangliyonlar�n� etkileyen bir duyusal n�ronopatiyi d���nd�rmelidir (<b>Tablo
5</b>). </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Derin duyu bozuklu�u, subakut kombine dejenerasyonda
oldu�u gibi, medulla spinalis arka kordonlar�n�n tutulmas�n� da g�steren bir
bulgudur. Ancak, arka kordon tutulmas�ndaki derin duyu bozukluklar� genellikle
duyusal gangliyonopatilerde g�r�lenlere oranla daha az belirgindir. Duyusal
n�ronopatilerde klinik bulgular asimetrik olma e�iliminde iken arka kordon
tutulmas�nda daha simetriktir. Arka kordon lezyonlar�nda s�k olarak piramidal
traktus tutulmas�na ba�l� bulgular da g�r�l�rken, duyusal n�ronopatilerde bu
bulgulara genellikle rastlanmaz. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 5.</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Duyusal-ataksik n�ropatiler ve n�ronopatiler </span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(BE Smith)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Duyusal n�ronopatiler (poligangliyonopatiler)</span></b></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik duyusal
n�ronopati (malin inflamatuvar duyusal poligangliyonopati)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sj�gren sendromu</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�dyopatik</span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Toksik polin�ropatiler</span></b></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sisplatin ve analoglar�</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Taksol ve di�er taksanlar</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bortezomib</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vitamin B6 megadozu</span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�nflamatuvar demiyelinizan</span></b></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Guillain-Barr� sendromu (Miller
Fisher varyant�)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�mmunoglobulin M monoklonal
gamopatisi</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>GALOP sendromu</span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�nfeksiyon</span></b></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Tabes dorsalis</span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Herediter</span></b></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Friedreich ataksisi</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Biemond ataksisi </span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Skolyozla birlikte duyusal
n�ropati (Robinson) </span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Spinoserebellar ataksi (SCA 4)</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Herediter duyusal ataksi
(SNAX1)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Daha genel bir yakla��mla, belirli duyu modalitelerinin �n planda
tutulmas�na dayanarak polin�ropatileri <i>kal�n lif</i> ve <i>ince lif
n�ropatileri</i> �eklinde ay�r�p tan� listesini daraltmaya �al��abiliriz.
Periferik sinirlerde vibrasyon, pozisyon duyusu gibi derin duyular ve tendon
refleks yay�n�n aferent b�l�m� kal�n miyelinli liflerle, buna kar��l�k a�r� ve
�s� duyusu miyelinsiz ve ince miyelinli liflerle ta��n�r. �nce dokunma duyusu
ise kal�n ve ince miyelinli liflerce merkez sinir sistemine g�t�r�l�r. Kal�n
miyelinli liflerin se�ici olarak tutuldu�u klinik tablolarda yayg�n arefleksi,
duyusal ataksi, ps�doatetoz, vibrasyon ve pozisyon duyusu kayb� olur. Bu
hastalarda duyusal ataksinin en g�ze �arpan klinik g�sterisi <i>Romberg
belirtisi</i>dir. Hemen dikkati �ekece�i gibi, say�lan klinik&nbsp;�zellikler
duyusal ataksik n�ropatileri i�aret etmekte ve duyusal gangliyonopatiler �n
planda olmak �zere <b>Tablo 5</b>�te g�sterilen hastal�klar�n d���n�lmesini
gerektirmektedir. �nce sinir liflerinin �n planda tutuldu�u n�ropatilerde ise (<b>Tablo
6</b>) altta belirgin olmak �zere ekstremite u�lar�nda a�r� ve �s� duyusu
kayb�, a�r�l� paresteziler ve otonom disfonksiyon g�r�l�r. �zellikle hastal���n
erken d�nemlerinde di�er duyu modaliteleri, motor fonksiyonlar&nbsp;ve denge
korunmu�tur; tendon refleksleri de korunmu� olabilir </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Periferik n�ropatilerin g�sterilmesi ve ay�r�c� tan�s�nda
yayg�n olarak kullan�lan sinir iletim incelemeleri, �n planda kal�n miyelinli
sinirlerin i�levine dayand���ndan ince lif n�ropatilerinde s�kl�kla normal
bulunur. Bu nedenle, ince sinir liflerinin se�ici olarak tutuldu�u
n�ropatilerde objektif verilerin elde edilmesi g��t�r. Gere�inde kantitatif
duyusal test, otonom sinir sistemine y�nelik yatak ba�� testleri ve
elektrofizyolojik incelemelerden, sinir ve deri biyopsilerinden
yararlan�labilir. </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�nce sinir liflerinin se�ici olarak tutuldu�u polin�ropatilerin ba�l�calar�
amiloid n�ropatisi, herediter duyusal-otonom n�ropatiler, kriptojenik duyusal
polin�ropati ve <i>Fabry hastal���</i>d�r. Baz� erken d�nem diyabetik distal
simetrik n�ropati olgular�nda benzer �zelliklere rastlanabilir.
Polin�ropatileri kal�n ve ince lif n�ropatisi tarz�nda ay�rmak bir �l��de
yapayl�k ta��r. Bir �ok polin�ropatide, �zellikle hastal�k progresyon
g�sterdik�e ilk tutulan duyu modalitesine di�erlerinin kat�ld��� g�r�l�r.
�rne�in diyabetik distal simetrik polin�ropatisi olan bir hastada dikkatli bir
klinik muayene ile a�r� ve �s� duyusu kayb�na dokunma ve derin duyu
bozuklu�unun eklendi�i ortaya konabilir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 6. </span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�nce lif n�ropatileri </span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(BE Smith, de�i�tirilerek)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�dyopatik</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Amiloid n�ropatisi (ailesel ve primer) </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Bozulmu�&nbsp; glikoz tolerans� n�ropatisi</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Diyabetes mellitus (nadir)</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Lepra</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Herediter duyusal-otonom n�ropatiler</span></p>

<p class=MsoNormal><span lang=TR style='font-size:8.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Fabry hastal���</span></p>

<p class=MsoNormal><span lang=TR style='font-size:8.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tangier hastal���</span></p>

<p class=MsoNormal><span lang=TR style='font-size:8.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Ciguatera intoksikasyonu </span></p>

<p class=MsoNormal><span lang=TR style='font-size:8.0pt;font-family:Tahoma;
mso-ansi-language:TR'>So�ukta terleme sendromu </span></p>

<p class=MsoNormal><span lang=TR style='font-size:8.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Artropatili Navajo n�ropatisi</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Belirti ve bulgular�n da��l�m�:</span></i></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> Periferik n�ropatilerde ortaya
��kan belirti ve bulgular�n v�cut �zerindeki da��l�m �ekli ay�r�c� tan�ya
yard�mc� olabilir. Polin�ropatilerde motor ve duyusal belirtiler genellikle
ekstremite distallerinde belirgin olan simetrik bir yerle�im g�stermekle birlikte,
bu kural�n d���nda kalan ve bu �zellikleri ile tan�ya yard�mc� olan durumlar
vard�r. Kas kuvvetsizli�i ekstremite proksimal kaslar�nda hakimse ya da distal
kaslara ek olarak bu kas gruplar�n� da tutuyorsa �n planda inflamatuvar
demiyelinizan polin�ropatileri (Guillain-Barr� sendromu ve CIDP) d���nmek
gerekir. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Distal simetrik polin�ropatilerin uzunlu�a ba��ml�
�zelli�i nedeniyle, belirti ve bulgular alt ekstremite distallerinde daha �nce
ba�lar ve daha bask�nd�r. Bu kural�n d���na ��karak �st ekstremitelerden
ba�layan n�ropatiler aras�nda kur�un n�ropatisi (�d���k el� tablosu ile
ba�lang��), multifokal motor n�ropati, Guillain-Barr� sendromunun baz�
varyantlar�, familyal amiloid n�ropati tip 2, Charcot-Marie-Tooth hastal���n�n
H�nel varyant�, nadir olarak porfiri ve eri�kin ba�lang��l� Tangier hastal���
say�labilir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Belirti ve bulgular�n asimetrik veya fokal da��l�m� da ay�r�c� tan�
listesini daraltmada yard�mc� olur. Kas kuvvetsizli�i ve atrofinin duyusal
belirtiler olmaks�z�n bir ekstremitede bask�n bir asimetriyle ortaya ��kmas� <i>motor
n�ron hastal���</i>n� ya da <i>multifokal motor n�ropati</i>yi akla getirir.
Buna kar��l�k, duyusal ve motor belirtilerin multifokal ve asimetrik �ekilde
yerle�ti�i bir klinik tablo, vask�litler ba�ta olmak �zere <i>monon�ropati
multipleks</i> nedenlerinin ara�t�r�lmas�n� gerektirir. <b>Tablo 7</b> de fokal
ve asimetrik n�rolojik bulgulara neden olan n�ropatiler g�r�lmektedir. Genel
ay�r�c� tan� yakla��m�n� g�stermek amac�yla bu tabloya asimetrik n�rolojik
tutuluma neden olan t�m periferik sinir hastal�klar� (polin�ropati,
monon�ropati multipleks ve monon�ropatiler) al�nm��t�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Polin�ropati tablosuna eklenen
kranyal sinir tutulmalar� da dikkatle de�erlendirilmelidir. <b>Tablo 8�de</b>
fasiyal sinir tutulmas� g�r�len n�ropatiler verilmi�tir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 7.</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Fokal/asimetrik bulgulara yol a�an n�ropatiler </span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(RJ Barohn,
de�i�tirilerek)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Motor n�ron
hastal��� </span></b></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Amiyotrofik lateral skleroz</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Radik�lopati-
servikal veya lumbosakral</span></b></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Radiks kompresyonu-disk
f�t�klanmas� veya osteoartropatiye ba�l�</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Herpes zoster infeksiyonu
(zona)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Meningeal karsinomatoz ve
lenfomatoz</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Pleksopati -
brakiyal veya lumbosakral </span></b></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�mmun/idyopatik (Ba�l�ca
brakiyal pleksus)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Neoplastik infiltrasyon</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Diyabetik radik�lopleksopati
(Ba�l�ca lumbosakral)</span></p>

<p class=MsoNormal style='margin-left:36.0pt;page-break-after:avoid'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ailesel
brakiyal pleksopati</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Herediter bas�nca duyarl�l�k
n�ropatisi </span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Monon�ropati multipleks </span></b></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vask�lit</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Multifokal motor n�ropati (MMN)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Multifokal edinsel
demiyelinizan duyusal ve motor n�ropati (MADSAM)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Multifokal edinsel motor
aksonopati (MAMA)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lyme hastal���</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sarkoidoz </span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lepra</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>HIV infeksiyonu</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Herediter bas�nca duyarl�l�k
n�ropatisi </span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kriyoglobulinemi</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lenfomatoid gran�lomatoz</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kompresyon/Tuzak
n�ropatileri</span></b></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 8.</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Fasiyal sinir
tutulmas� g�r�len n�ropatiler </span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(BE Smith)</span></p>

<div class=MsoNormal align=center style='text-align:center;page-break-after:
avoid'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Guillain-Barr�
sendromu (s�kl�kla bilateral)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kronik inflamatuvar
demiyelinizan polin�ropati (CIDP) (Nadiren)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lyme hastal���
</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sarkoidoz </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>HIV
infeksiyonu</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gelsolin
familyal amiloid n�ropati (Fin tipi) </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lepra</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tangier
hastal���</span></p>

<div class=MsoNormal align=center style='text-align:center;page-break-after:
avoid'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�st motor n�ron tutulmas� bulgular�:</span></i></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> Duyusal belirti ve bulgular�
olmayan bir hastada zaaf, atrofi ve fasik�lasyon gibi alt motor n�ron tutulmas�
bulgular�na �st motor n�ron bulgular�n�n eklenmesi kuvvetle motor n�ron
hastal���n� d���nd�r�r (Bak�n�z: <a
href="http://www.itfnoroloji.org/ozdemir/motornoron.htm">Motor N�ron
Hastal�klar�</a>).</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�st ekstremitelerde (genellikle asimetrik) alt motor
n�ron tutulmas� bulgular� ile birlikte alt ekstremitelerde belirgin piramidal
bulgular, spondilotik miyelopati ba�ta olmak �zere servikal spinal lezyonlarda
da g�r�l�r. Bu hastalarda genellikle servikal radik�lopatileri i�aret eden
duyusal yak�nma ve bulgular vard�r. Ancak baz� hastalarda klinik verilerle
motor n�ron hastal��� ve servikal spondilotik miyelopatiyi ay�rt etmek m�mk�n
olmaz. B�yle olgularda servikal spinal g�r�nt�leme (tercihen MR) ve
elektromiyografi bulgular� birlikte de�erlendirilerek ay�r�c� tan� yap�lmaya
�al���l�r. (Bak�n�z: <a href="http://www.itfnoroloji.org/omurilik/omurilik.htm">Omurilik
Hastal�klar�</a>).</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�st motor n�ron tutulmas� bulgular� duyusal belirtileri �n planda olan bir
distal simetrik polin�ropatiye ekleniyorsa, polin�ropati ile birlikte olan bir
kombine sistem hastal���n� d���nmek gerekir. Bunun en �nde gelen nedeni B12
vitamini yetersizli�idir (Bak�n�z:</span><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><a
href="http://www.itfnoroloji.org/omurilik/omurilik.htm">Omurilik Hastal�klar�</a>).
Gere�inde ayn� klinik tabloya neden olan HIV infeksiyonu, karaci�er hastal���,
adrenomiyelon�ropati gibi di�er nadir nedenler de ara�t�r�l�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Klinik tablonun yerle�im �ekli:</span></i></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> Belirti ve bulgular�n
ba�lang�� �ekli, geli�me h�z� ve seyri ile ilgili �zellikler ay�r�c� tan�
listesini daraltmakta �ok yard�mc� olur. N�rolojik tablonun akut (4 haftadan
az), subakut (4-8 hafta) ya da kronik �ekildeki (2 aydan uzun) yerle�imi;
monofazik, progresif veya tekrarlay�c� seyri hakk�nda bilgi edinilmeye
�al���lmal�d�r. Guillain-Barr� sendromu, porfiriye ba�l� n�ropati, vask�litler,
baz� toksik polin�ropatiler, diyabetik lumbosakral radik�lopleksopatiler
akut-subakut seyir g�sterirler. Tekrarlay�c� klinik seyir CIDP, akut porfiri,
Refsum hastal���, herediter bas�nca duyarl�l�k n�ropatisi, ailesel brakiyal
pleksus n�ropatisi ve baz� toksinlere aral�kl� maruz kalma hallerinde g�r�l�r.
Yava� kronik progresyonla seyir, herediter n�ropatilerde ve bir �ok metabolik,
toksik ya da nutrisyonel yetersizli�e ba�l� polin�ropatide g�r�lebilir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Herediter n�ropatiyi d���nd�ren veriler:</span></i></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> Herediter n�ropatiler,
polin�ropatiler i�inde en s�k rastlanan gruplardan birini olu�turur. Y�llar
i�inde �ok yava� bir seyirle ilerlemeleri, batma, i�nelenme, kar�ncalanma gibi
pozitif duyusal yak�nmalar�n �o�u kez bulunmamas� nedeni ile hastalar ve
�zellikle onlar�n hafif belirtili akrabalar� taraf�ndan uzun s�re fark
edilmezler. Bu nedenle hastalar�n aile fertleri ve akrabalar�nda benzer bir
hastal���n bulunmad���na ili�kin ifadeleri yan�lt�c� olabilir. Hastan�n yan�
s�ra ula��labilen akrabalar�n�n n�rolojik muayenesi, bu ki�ilerde �ukur ayak,
�eki� parmak deformitelerinin ara�t�r�lmas� ve sinir iletim incelemelerinin
yap�lmas� bir herediter n�ropatinin tan�nmas�n� sa�layabilir. Tekrarlayan
kompresyon monon�ropatileri olan hastalarda herediter bas�nca duyarl�l�k
n�ropatisi akla getirilmelidir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�yk� ve muayeneye ili�kin di�er �zellikler:</span></i></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> Bir �ok polin�ropati sistemik
hastal�klara ba�l� olarak ortaya ��kar. Hastan�n �yk�s�ndeki halsizlik,
i�tahs�zl�k, kilo kayb� gibi �zellikler b�yle bir hastal��a dikkati �ekebilir.
Hastan�n �zge�mi�inde diyabet, hipotiroidizm, kronik b�brek yetersizli�i,
karaci�er hastal���, intestinal malabsorbsiyon, habis hastal�klar, konnektif
doku hastal�klar�, HIV seropozitifli�i, ila� kullan�m�, alkol ve beslenme
al��kanl�klar�, toksik maddelere maruz kalma, ge�irilmi� infeksiyonlar gibi
�zellikler �zerinde �zellikle durulmal�d�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>N�rolojik muayenenin yan� s�ra yap�lacak dikkatli bir sistemik muayene ile
polin�ropatiye yol a�an hastal�k hakk�nda ipu�lar� elde edilebilir. Sinirlerin
palpe edilmesi bazen tan�ya yararl� veriler sa�layabilir. Tek bir sinirin
hipertrofisi neoplastik bir olu�umu (n�rofibrom, malin sinir k�l�f� t�m�r� vb)
veya lokalize hipertrofik n�ropatiyi d���nd�r�r.&nbsp; Genel veya multifokal
sinir hipertrofisi lepra, Tip I ve III n�rofibromatoz, Charcot-Marie-Tooth
hastal���, akromegali, Refsum hastal��� ve nadiren CIDP�de g�r�l�r. Polin�ropatili
bir hastada bulunabilecek baz� deri belirtileri tan� koydurucu olabilir. Talyum
zehirlenmesinde ortaya ��kan alopesi, arsenik ve talyum zehirlenmesinde g�r�len
transvers t�rnak �izgileri (<i>Mees �izgileri</i>), Fabry hastal���nda abdomen ve
kal�alarda g�r�len telanjiektaziler,&nbsp;kriyoglobulinemilerdeki purpurik deri
d�k�nt�leri, POEMS sendromundaki (a�a��ya bak�n�z) deri hiperpigmentasyonu ve
hipertrikoz bunlara �rnektir (<b>Tablo 9</b>).</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 9.</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Deri, t�rnak ve sa� belirtileri olan n�ropatiler </span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(BE Smith)</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=307 valign=top style='width:230.3pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Hastal�k</span></b></p>
  </td>
  <td width=307 valign=top style='width:230.3pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Belirtiler</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=307 valign=top style='width:230.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Vask�lit</span></p>
  </td>
  <td width=307 valign=top style='width:230.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Purpura, livedo retik�laris</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=307 valign=top style='width:230.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kriyoglobulinemi</span></p>
  </td>
  <td width=307 valign=top style='width:230.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Purpura</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=307 valign=top style='width:230.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Fabry hastal���</span></p>
  </td>
  <td width=307 valign=top style='width:230.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Anjiokeratoz</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=307 valign=top style='width:230.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Lepra</span></p>
  </td>
  <td width=307 valign=top style='width:230.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Deride hipopigmentasyon</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=307 valign=top style='width:230.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Osteosklerotik miyelom (POEMS sendromu)</span></p>
  </td>
  <td width=307 valign=top style='width:230.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Deride hiperpigmentasyon</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=307 valign=top style='width:230.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Porphyria variegata</span></p>
  </td>
  <td width=307 valign=top style='width:230.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>B�ll� lezyonlar</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=307 valign=top style='width:230.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Refsum hastal���</span></p>
  </td>
  <td width=307 valign=top style='width:230.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�htiyoz</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=307 valign=top style='width:230.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Arsenik ve talyum zehirlenmesi</span></p>
  </td>
  <td width=307 valign=top style='width:230.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Mees �izgileri</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=307 valign=top style='width:230.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Talyum zehirlenmesi</span></p>
  </td>
  <td width=307 valign=top style='width:230.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kellik</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;mso-yfti-lastrow:yes'>
  <td width=307 valign=top style='width:230.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Dev aksonal n�ropati</span></p>
  </td>
  <td width=307 valign=top style='width:230.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>S�k-k�v�rc�k sa�</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Yukar�da s�z edilen&nbsp; klinik �zelliklere dayan�larak periferik
n�ropatilerin ba�l�ca klinik prezantasyon �ekilleri <b>Tablo 10�da</b>
�zetlenmi�tir (RJ Barohn, 1999). �ok ve farkl� nedenlere ba�l� olarak ortaya
��kt���n� bildi�imiz n�ropatilerde klinik&nbsp;g�sterilerin bir ka� maddede ele
al�nmas� a��r� bir basitle�tirme gibi g�r�nse de, b�yle bir tablo ay�r�c�
tan�ya yakla��m i�in yararl� olacakt�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 10</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>.
N�ropatilerde 10 tutulma �ekli (RJ Barohn)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='text-indent:36.0pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�ekil 1:&nbsp;
Duyu kayb� ile birlikte simetrik proksimal ve distal kuvvetsizlik</span></u></b><u><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></u></p>

<p class=MsoNormal style='text-indent:36.0pt'><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D���n�lmesi
gereken:</span></i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&nbsp; �nflamatuvar demiyelinizan polin�ropati (GBS
ve CIDP)</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�ekil 2:
Kuvvetsizli�in bulundu�u veya bulunmad���&nbsp; simetrik&nbsp;distal duyu kayb�
</span></u></b></p>

<p class=MsoNormal style='text-indent:36.0pt'><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D���n�lmesi
gereken:</span></i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&nbsp; Kriptojenik duysal polin�ropati, metabolik
hastal�klar, droglar, toksinler, herediter (Charcot-Marie-Tooth, amiloidoz vb.)</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�ekil 3: Duyu
kayb� ile birlikte asimetrik distal kuvvetsizlik</span></u></b></p>

<p class=MsoNormal style='text-indent:36.0pt'><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>M�ltipl sinir,
d���n�lmesi gereken:</span></i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Vask�lit, herediter bas�nca
duyarl�l�k n�ropatisi (HNPP), multifokal edinsel demiyelinizan duysal ve motor
n�ropati (MADSAM), infeksiy�z (lepra, lyme, sarkoidoz, HIV)</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tek sinir veya
tek b�lge, d���n�lmesi gereken:</span></i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> sinir kompresyonuna ba�l�
monon�ropati veya radik�lopati</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�ekil 4:&nbsp;
Duyu kayb� ile birlikte asimetrik proksimal ve distal kuvvetsizlik</span></u></b></p>

<p class=MsoNormal style='text-indent:36.0pt'><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D���n�lmesi
gereken: </span></i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Karsinomatozis veya lenfomatozise ba�l�, idyopatik veya
herediter (HNPP, familyal) poliradik�lopati veya pleksopati<i>.</i> </span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�ekil 5:&nbsp;
Duyu kayb� olmadan asimetrik distal kuvvetsizlik.</span></u></b></p>

<p class=MsoNormal style='text-indent:36.0pt'><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D���n�lmesi
gereken: &nbsp; </span></i><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>�st motor n�ron bulgular� varsa: motor n�ron
hastal���</span></p>

<p class=MsoNormal style='margin-left:105.6pt;text-indent:36.0pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�st
motor n�ron bulgular� yoksa: &nbsp;</span></p>

<p class=MsoNormal style='margin-left:141.6pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1. �lerleyici m�sk�ler atrofi
(PMA)</span></p>

<p class=MsoNormal style='margin-left:177.0pt;text-autospace:none'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>a.
Brakial amiyotrofik dipleji</span></p>

<p class=MsoNormal style='margin-left:177.0pt;text-autospace:none'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>b.
Bacak amiyotrofik diplejisi</span></p>

<p class=MsoNormal style='margin-left:141.6pt;text-autospace:none'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2.
Multifokal motor n�ropati (MMN)</span></p>

<p class=MsoNormal style='margin-left:141.6pt;text-autospace:none'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3.
Multifokal edinsel motor aksonopati (MAMA)</span></p>

<p class=MsoNormal style='margin-left:141.6pt;text-autospace:none'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.
Juvenil motor amiyotrofi</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�ekil 6: �st
motor n�ron tutulmas� bulgular� ile birlikte simetrik distal duyu kayb� ve
arefleksi</span></u></b></p>

<p class=MsoNormal style='text-indent:36.0pt'><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D���n�lmesi
gereken:</span></i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> &nbsp; B12 yetersizli�i ve di�er kombine sistem
dejenerasyonu nedenleri.</span></p>

<p class=MsoNormal style='margin-left:105.6pt;text-indent:36.0pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Herediter
hastal�klar (ALS, MLD, Friedreich)</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�ekil 7: Duyu
kayb� olmaks�z�n simetrik kuvversizlik</span></u></b></p>

<p class=MsoNormal style='text-indent:36.0pt'><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D���n�lmesi
gereken: &nbsp; </span></i><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>A. Proksimal ve distal kuvvetsizlik: Spinal
m�sk�ler atrofi</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
B. Distal kuvvetsizlik: Herediter motor n�ropati</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-indent:36.0pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�ekil 8. Orta
hatta fokal proksimal simetrik kuvvetsizlik</span></u></b></p>

<p class=MsoNormal style='text-indent:36.0pt'><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D���n�lmesi
gereken:&nbsp;&nbsp; </span></i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Boyun ekstensor kaslar�nda
kuvvetsizlik: ALS, PLS</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bulber zaaf: ALS</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�ekil 9:&nbsp;
Kuvvetsizlik olmaks�z�n asimetrik porprioseptif duyu kayb�</span></u></b></p>

<p class=MsoNormal style='text-indent:36.0pt'><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D���n�lmesi
gereken:</span></i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> Duyusal n�ronopati (ganglionopati) (<b>Tablo 5</b>),
kronik imm�n duysal poliradik�lopati. </span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�ekil
10:&nbsp; Otonom belirti ve bulgular</span></u></b></p>

<p class=MsoNormal style='text-indent:36.0pt'><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D���n�lmesi
gereken:</span></i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> Otonom fonksiyon bozuklu�u ile birlikte olan n�ropatiler
(<b>Tablo 3</b>)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Polin�ropatilerde Laboratuvar �ncelemeleri</span></b></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Elektrofizyolojik testler&nbsp;</span></i></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Sinir iletim incelemeleri ve i�ne elektromiyografisi polin�ropatilerin
tan�s�nda �o�u kere vazge�ilemeyecek bir yere sahiptir. G�n�m�zde sa�l�k
kurulu�lar�nda yayg�n olarak bulunan cihazlarla yap�lan bu testler, hafif bir
polin�ropatinin objektif olarak ortaya konmas�n� ya da bir hastada ortaya ��kan
kas zaaf�n�n, polin�ropatilerin de aralar�nda bulundu�u hangi n�rom�sk�ler
hastal�k grubuna ba�l� oldu�unun belirlenmesini sa�larlar. Bu testler yard�m�
ile aksonal ve demiyelinizan n�ropatiler aras�nda ayr�m yapmak ve b�ylece
ay�r�c� tan� listesini �nemli �l��de daraltmak m�mk�n olur (Bak�n�z: <a
href="http://www.itfnoroloji.org/mertas/anatomofizy.htm">Periferik sinirlerin
anatomi, fizyoloji ve patolojik s�re�leri</a>). </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Aksonal polin�ropatilerde sinir iletim h�zlar� normal
veya hafif yava�, duyusal ve bile�ik kas aksiyon potansiyeli amplit�dleri
d���kt�r. Demiyelinizan polin�ropatilerde ise (<b>Tablo 11</b>) sinir iletim
h�zlar� belirgin derecede yava�lam��t�r (normal alt s�n�r�n�n %70�inden daha
yava�). Sinir iletim incelemeleri herediter ve edinsel demiyelinizan
polin�ropatilerin birbirinden ayr�lmas�nda da yard�mc� olur. Herediter
polin�ropatilerde sinir iletimlerinde homojen bir yava�lama izlenirken, edinsel
demiyelinizan polin�ropatilerde (GBS, CIDP gibi) sinir iletim h�zlar� ayn�
ekstremite segmentindeki farkl� sinirler, ayn� sinirin farkl� segmentleri ve
kar��l�kl� iki ekstremitenin ayn� isimli sinirleri aras�nda belirgin de�i�iklik
g�sterir. Edinsel demiyelinizan n�ropatilerde sinirler �zerinde iletim bloklar�
g�sterilebilir ya da GBS�nun erken d�neminde oldu�u gibi F yan�tlar�n�n
kaybolmas�, latanslar�n�n uzay�p persistanslar�n�n azalmas� ba�l�ca
elektrofizyolojik bulguyu olu�turabilir. �yi planlanarak yap�lan
elektrofizyolojik testler, klinik muayene ile saptanamayan asimetrik ve fokal
sinir lezyonlar�n�n ortaya konmas�na (ve <b>Tablo 7</b> de yer alan
n�ropatilerin belirlenmesine) yard�mc� olabilir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 11.</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Ba�l�ca demiyelinizan polin�ropatiler </span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(CH Chalk ve
RAC Hughes, de�i�tirilerek</span><span lang=TR style='font-size:11.0pt;
font-family:Tahoma;mso-ansi-language:TR'>)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�mm�n K�kenli</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Guillain-Barr� sendromu (GBS)
ve varyantlar�</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kronik inflamatuvar
demiyelinizan poliradik�lon�ropati (CIDP)</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Multifokal motor n�ropati</span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-autospace:none'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Paraproteinemik
demiyelinizan polin�ropatiler</span></p>

<p class=MsoNormal style='margin-left:70.8pt;text-autospace:none'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nedeni
belirsiz monoklonal gamopati ile birlikte</span></p>

<p class=MsoNormal style='margin-left:70.8pt;text-autospace:none'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Soliter
miyelomla birlikte</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�nfeksiyon </span></p>

<p class=MsoNormal style='margin-left:35.4pt;page-break-after:avoid'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Difteri</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Toksik</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Perheksilen toksisitesi</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Herediter</span></p>

<p class=MsoNormal style='margin-left:35.4pt;page-break-after:avoid'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Charcot-Marie-Tooth
hastal���, Tip 1 ve di�er demiyelinizan formlar</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Herediter bas�nca duyarl�l�k
n�ropatisi</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di�er genetik nedenler (Refsum
hastal���, metakromatik l�kodistrofi gibi)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Sinir biyopsisi</span></i></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Periferik sinir biyopsileri olduk�a az say�daki n�ropati nedeninin tan�s�
i�in gereklidir. Sinir biyopsisinden bilgi verici sonu�lar al�nabilmesi i�in
g�nderilen materyalin bu konuda uzmanla�m��, standard parafin ve dondurulmu�
kesitlerin yan�nda ���k ve elektron mikroskopisi i�in plastik g�mme preparatlar
haz�rlayabilen ve sinir lifi ay�rma (�teasing�) y�ntemini kullanabilen
laboratuvarlarda incelenmesi gerekir. Bu nedenle, bazen komplikasyonlara (yara
kapanma g��l�kleri, biyopsi yerinde infeksiyon, sinir g�d��� n�romalar�,
biyopsi yap�lan sinirin innervasyon alan�nda huzursuz edici duyusal bozukluklar
gibi) yol a�abilen sinir biyopsilerinin polin�ropati d���n�len her hastaya
yap�lmamas� gerekir. Sinir biyopsisinin tan�sal de�er ta��d��� durumlar�n
ba��nda vask�lite ba�l� n�ropatiler ve amiloid n�ropatileri gelir. Biyopsi ile
yararl� bilgiler elde edilebilecek di�er periferik n�ropatiler <b>Tablo 12</b>�de
�zetlenmi�tir. Bunlar�n bir �o�unda da tan� i�in sinir biyopsisi kesin bir
gereklilik ta��maz. �rne�in Charcot-Marie-Tooth hastal��� tip 1-A, herediter
bas�nca duyarl�l�k n�ropatisi, ailesel amiloidoz gibi durumlarda molek�ler
genetik tan� testleri biyopsiyi gereksiz k�labilir. Leprada aside diren�li
mikroorganizmay� deri biyopsisinde g�stermek sinir biyopsisi yapmaya oranla
daha pratik olabilir. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 12</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>. Sinir biyopsisi indikasyonlar� </span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(EP Bosch ve BE Smith)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Sinir biyopsisinde tan� koydurucu bulgu g�r�lenler:</span></b></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vask�lit*</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Amiloidoz*</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sarkoidoz*</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lepra</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Herediter bas�nca duyarl�l�k
n�ropatisi (tomak�ler n�ropati)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Paraproteinemik n�ropati
(Anti-MAG antikorla birlikte IgM monoklonal gamopati)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Metakromatik l�kodistrofi</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Fabry hastal���</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Krabbe hastal��� </span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dev aksonal n�ropati</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Poliglukozan cisimci�i
hastal���</span></p>

<p class=MsoNormal style='text-indent:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sinirde t�m�r infiltrasyonu</span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Sinir biyopsisinde tan�y� d���nd�r�c� bulgu g�r�lenler:</span></b></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Charcot-Marie-Tooth hastal���
tip I ve III</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Refsum hastal���</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kronik inflamatuvar
demiyelinizan poliradik�lon�ropati</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Amiodaron toksisitesi </span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Klorokin toksisitesi</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Perheksilen toksisitesi</span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�nce lif n�ropatileri</span></p>

<div class=MsoNormal align=center style='text-align:center;text-indent:36.0pt'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>*: Kombine sinir ve kas biyopsisi yap�lmas� yararl� olur.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>MAG: miyelinle birlikte olan (myelin-associated)
glikoprotein.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Periferik sinir biyopsilerinde distal sural sinir,
al���lm�� ve s�k kullan�lan bir �rnekleme yeridir. Alternatif olarak
s�perfisiyel peroneal sinirin kullan�lmas�, ayn� insizyon ile peroneus brevis
kas�na ula��larak kas biyopsisi yap�lmas�na olanak sa�lar. Baz� durumlarda
radiyal sinirin el s�rt�ndaki y�zeyel deri dal� da biyopsi i�in kullan�labilir.
Periferik sinirle birlikte al�nan kas �rne�i �zellikle vask�litlerin ortaya
konmas�nda yararl� olur.</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Deri biyopsisi</span></i></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�ntraepidermal sinir liflerini incelemek amac�yla
uygulanan&nbsp; bir tan� y�ntemidir. Bu y�ntemde al�nan yakla��k 3 mm �ap�ndaki
punch biyopsiler basit ve a�r�s�z oldu�undan kolayl�kla tekrarlanabilir.
Biyopsi materyalinde epidermis i�indeki miyelinsiz aksonlar PGP 9.5 gibi
n�ropeptidlerle boyanarak konfokal mikroskop yard�m�yla incelenir ve say�l�r.
Hen�z yayg�nla�mam�� olan bu y�ntem,&nbsp;elektrofizyolojik incelemelerin
genellikle normal kald���, ince sinir liflerini tutan a�r�l� distal
polin�ropatilerin incelenmesi ve takibi i�in kullan�lmaktad�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kantitatif Duyusal Test (QST):</span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bir cihaz
yard�m� ile hastaya sunulan vibrasyon, s�cak ve so�uk uyaranlar�na ili�kin
duyum e�iklerinin �e�itli bilgisayar algoritmalar� kullan�larak belirlenmesi ve
say�salla�t�r�lmas�n� ama�layan bir y�ntemdir. Kal�n miyelinli liflerin
fonksiyonlar� vibrasyon tan�ma e�i�i ile incelenirken, ince sinir lifleri so�uk,
s�cak, so�uk a�r�s� ve s�cak a�r�s� tan�ma e�ikleri ile ara�t�r�l�r. �zellikle
objektif klinik ve elektrofizyolojik bulgular� olmayan a�r�l� ince lif
n�ropatisi olgular�nda C ve A<span style='mso-char-type:symbol;mso-symbol-font-family:
Tahoma'><span style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'>&#61540;</span></span>
liflerinin fonksiyon bozukluklar�n�n ortaya konmas�nda �nem ta��r. Tan�da
oldu�u kadar tedavinin etkilerini takipte de yararl� olabilir. Bu y�ntemle
ilgili sorunlar, �zel cihaz gerektirmesi, zaman al�c� olu�u ve tek tek
hastalar�n incelenmesinde anormal sonu� verme y�n�nde bir e�ilimi olmas�d�r.
�imdilik klinik tan� amac� i�in yayg�n hale gelmemi� olan bu y�ntem
epidemiyoloji ve tedavi �al��malar�nda kullan�lacak d�zeye eri�mi�tir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Di�er laboratuvar incelemeleri</span></i></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Ayr�nt�l� bir klinik muayene ve elektrofizyolojik testler, incelenmede
kullan�lacak di�er laboratuvar testlerinin se�iminde yard�mc� olur.
Polin�ropatili bir hastan�n incelenmesinde yararl� olacak tarama ama�l�
laboratuvar testlerinin ba�l�calar� �unlard�r: Tam kan say�m� ve&nbsp; l�kosit
form�l�, eritrosit sedimentasyon h�z�, genel kan biyokimyas� parametreleri (�zellikle
a�l�k kan �ekeri ve glikozile hemoglobin, kreatinin), T4 ve TSH, romatoid
fakt�r, anti-n�kleer antikor (ANA), vitamin B12 d�zeyi, serum protein
elektroforezi, serum (ve m�mk�nse idrar) immunelektroforezi (immunofiksasyon
ile). Nedeni bilinmeyen kronik seyirli&nbsp; polin�ropatisi olan, �zellikle 60
ya��n �zerindeki hastalarda monoklonal proteinlerin ara�t�r�lmas� -bu
hastalar�n %10 kadar�nda monoklonal gamopati bulundu�undan- �nemlidir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Laboratuvar incelemelerinden kolay ve ucuz olanlar ile
ba�lay�p, bunlarla polin�ropati nedeninin a��klanamamas� halinde daha g�� ve
pahal� y�ntemlere do�ru ilerlenmesi bir genel siyaset olarak belirlenmelidir.
Antigangliozid antikorlar ile baz� paraneoplastik n�ropatilerin tan�s�nda
kullan�lan antikorlar�n ara�t�r�lmas� nadir durumlarda tan�ya yard�mc� olan
pahal� y�ntemlerdir. Genel tarama amac�yla kullan�lmamas� gereken bu testler ve
�e�itli polin�ropatilerin tan�s� i�in ba�vurulabilecek di�er incelemeler
&nbsp;ilgili konularda&nbsp; anlat�lm��t�r. Bir �rnek olu�turmas� amac�yla,
polin�ropati varl��� d���n�len hastada kullan�labilecek daha genel ama�l�
tan�-tarama testleri <b>Tablo 13</b>�te, hastal�k paternine g�re se�ilebilecek
daha ileri a�ama testleri ise <b>Tablo 14</b>�te verilmi�tir. </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Lomber ponksiyon</span></i></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�nflamatuvar demiyelinizan poliradik�lon�ropatiler (GBS ve CIDP) ve sinir
k�klerinde tutulman�n oldu�u di�er baz� periferik n�ropatilerde BOS proteini
artar. Meningeal karsinomatozis ve lenfomatozise ba�l� poliradik�lopati ile
seyreden olgularda BOS�ta habis h�crelere rastlanabilir.</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 13. </span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Polin�ropati tan�s�nda ilk ve ikinci.a�amada ba�vurulabilecek testler</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> (RAC
Hughes�den de�i�tirilerek)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>1. A�ama</span></b></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�drar: Glikoz, protein</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hematoloji: Tam kan say�m�,
sedimentasyon, B12, folat</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Biyokimya:A�l�k kan glikozu,
A1C, b�brek fonksiyonlar�, karaci�er fonksiyonlar�, TSH</span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>2. A�ama</span></b></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>N�rofizyolojik testler (Sinir
iletim incelemeleri ve EMG)</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Biyokimya: Protein
elektroforezi, �mmunfiksasyon</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di�er: Akci�er grafisi</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 14. </span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Polin�ropatinin klinik
�ekline g�re ileri tan� testleri </span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(DS Saperstein)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=667
 style='width:500.4pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=163 valign=top style='width:122.4pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'>Klinik �zellik</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'>Muhtemel etyoloji</span></b></p>
  </td>
  <td width=348 valign=top style='width:261.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'>Yararl� olabilecek testler</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=163 valign=top style='width:122.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Proksimal
  kuvvetsizlik</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CIDP</span></p>
  </td>
  <td width=348 valign=top style='width:261.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>BOS, sinir
  biyopsisi</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=163 valign=top style='width:122.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut veya
  subakut ba�lang��</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CIDP</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B12
  yetersizli�i</span></p>
  </td>
  <td width=348 valign=top style='width:261.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>BOS, sinir
  biyopsisi</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Anti-Hu ve
  anti-CV2; BT, PET </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vitamin B12,
  MMA, Homosistein </span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=163 valign=top style='width:122.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Asimetri</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vask�lit</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>HNPP</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CIDP</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Diyabetik
  amiyotrofi</span></p>
  </td>
  <td width=348 valign=top style='width:261.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>ANA, RF,
  Sedimentasyon, ANCA, sinir biyopsisi</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Genetik test
  </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>BOS, sinir
  biyopsisi</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Anti-Hu ve
  anti-CV2; BT, PET </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Oral glikoz
  tolerans testi (OGTT)</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=163 valign=top style='width:122.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Duyusal
  ataksi</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sj�gren
  sendromu</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>DADS </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CISP</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tabes
  dorsalis</span></p>
  </td>
  <td width=348 valign=top style='width:261.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Anti-Hu ve
  anti-CV2; BT, PET </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>ANA,
  Sedimentasyon, SSA, SSB, dudak biyopsisi</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Serum
  protein eletroforezi, IFE, anti MAG</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>BOS, MR,
  SEP, sinir k�k� biyopsisi</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sifiliz
  serolojisi</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=163 valign=top style='width:122.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ellerden
  veya ayn� zamanda el ve ayaklardan ba�lang��</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B12
  yetersizli�i</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CIDP</span></p>
  </td>
  <td width=348 valign=top style='width:261.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vitamin B12,
  MMA, Homosistein</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>BOS, sinir
  biyopsisi</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=163 valign=top style='width:122.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�nce lif
  bask�n, otonom n�ropati, kalp/b�brek hastal���</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Diyabet</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Amiloidoz</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=348 valign=top style='width:261.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>OGTT</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Serum
  protein eletroforezi, IFE, genetik test, sinir biyopsisi</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;mso-yfti-lastrow:yes'>
  <td width=163 valign=top style='width:122.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Miyelopati
  ve n�ropati</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B12
  yetersizli�i</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bak�r
  yetersizli�i</span></p>
  </td>
  <td width=348 valign=top style='width:261.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vitamin B12,
  MMA, Homosistein</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bak�r ve
  �inko</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>MMA:
metilmalonik asit, HNPP: herediter bas�nca duyarl�l�k n�ropatisi, DADS: distal
edinsel demiyelinizan, simetrik n�ropati, CISP: kronik immun duyusal
poliradik�lopati, SEP: Somatosensoriyel uyand�r�lm�� potansiyeller .</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>HERED�TER POL�N�ROPAT�LER</span></b></p>

<p class=MsoNormal><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoBodyText style='line-height:normal'><span lang=TR style='font-size:
11.0pt;font-family:Tahoma;mso-ansi-language:TR'>Genetik defekt sonucu ortaya ��kan
herediter n�ropatiler nadir g�r�len hastal�klard�r. Baz�lar�na <span
class=msodel0><span class=msoDel><del cite="mailto:can%20baykal"
datetime="2009-06-10T23:08">&nbsp;</del></span></span>merkezi sinir sistemi
tutulumu da e�lik edebilir. Fenotipik �zellikler aileden aileye de�i�ebilir
veya ayn� aile i�inde de�i�kenlikler g�r�lebilir. Son y�llarda molek�ler
biyoloji alan�nda olan �nemli geli�meler herediter n�ropatilerin bir b�l�m�ne
tan� konmas�n� kolayla�t�rm��t�r. B�ylelikle hem bu n�ropatilerin tan�s� i�in
ba�vurulabilen sinir biyopsisine gerek kalmamakta, hem de daha �nceleri klinik,
elektrofizyolojik ve histopatolojik temellere dayand�r�lan s�n�flamalar�n
yerini art�k genetik s�n�flamalar almaktad�r. Bulunan genetik defektler ayr�ca
h�cre biyolojisinde rol oynayan proteinlerin i�levleri konusunda �nemli
ipu�lar�na ula�mam�z� sa�lamaktad�r. Gelecekte b�y�k bir olas�l�kla yeni
mutasyonlardan �ok, bu proteinlerin h�cre i�inde �stlendikleri fonksiyonlar ve
birbirlerini nas�l etkiledikleri konusunda daha �ok bilgi edinilecektir. Son
birka� y�ld�r ara�t�rmalar a��rl�kla bu y�nde ilerlemektedir. B�ylece h�cre
i�indeki proteinlerin i�levleriyle (protein trafficking) ilgili sis perdesi
ortadan kalkt�k�a, yeni tedavi perspektifleri olu�mas� y�n�ndeki �al��malar da
ivme kazanacakt�r. Bu b�l�mde herediter n�ropatiler i�inde en s�k g�r�len
Charcot-Marie-Tooth Hastal���ndan s�z edilecektir (<b>Tablo 16</b>). Tablo 16</span><span
lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:TR'>
incelendi�inde hem demiyelinizan hem de aksonal �zellikteki n�ropatilere ayn�
genlerin mutasyonunun yol a�abildi�i g�r�lmektedir. Buradan mutasyonlar�n tek
ba��na belirleyicili�inden �ok proteinler aras� etkile�imin nihai fenotipe yol
a�t��� anla��labilir. </span><b><span lang=TR style='font-size:11.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Tablo 15�</span></b><span lang=TR
style='font-size:11.0pt;font-family:Tahoma;mso-ansi-language:TR'> de ise di�er
herediter n�ropatiler ve n�ropatilerin e�lik etti�i hastal�klar yer almaktad�r
. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>&nbsp;<b>Tablo 15.</b> Herediter polin�ropatiler </span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-1.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
  <td width=609 style='width:456.6pt;border:solid gray 1.0pt;background:yellow;
  padding:0cm .75pt 0cm .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>1. Herediter Motor-Duyusal N�ropatiler (HMSN veya
  CMT)&nbsp; </span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(Ayr�ca bak�n�z: <b>Tablo 16)</b></span></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></b></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>2. Herediter motor sendromlar</span></b></p>
  <p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>a) Herediter ALS -dominant,
  resesif, X�e ba�l�, �ocukluk �a��nda ba�layanlar</span></p>
  <p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>b) Bulber sendromlar</span></p>
  <p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>c) Spinal m�sk�ler atrofi
  (SMA) </span></p>
  <p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>d) Distal SMA -Herediter
  motor n�ropati (HMN). Dominant, resesif, X�e ba�l�</span></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></b></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>3. -Herediter duyusal n�ropatiler ve familyal
  disotonomi</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'> </span></p>
  <p class=MsoNormal style='margin-left:36.9pt;text-indent:-1.5pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:36.9pt;text-indent:-1.5pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>a)
  Otozomal dominant duyusal n�ropatiler <br>
  Herediter duyusal n�ropati tip 1 (HSN-1) <br>
  b) Otozomal resesif duyusal n�ropatiler <br>
  Konjenital duyusal otonomik n�ropati tip 2 (HSAN-2) <br>
  Familyal disotonomi (HSAN-3 veya Riley-Day Sendromu) <br>
  Konjenital duyusal n�ropati ve anhidrozis (HSAN-4) </span></p>
  <p class=MsoNormal style='margin-left:36.9pt;text-indent:-1.5pt'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4. <b>Metabolik
  defektlere ba�l� n�ropatiler</b> </span></p>
  <p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>a) Lipid <br>
  b) Lipoprotein <br>
  c) Fitanik asid <br>
  d) Alfa-galaktozidaz <br>
  e) Amiloidoz <br>
  f) Porfiri</span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>5- Merkez
  sinir sistemi tutulumuyla birlikte giden herediter n�ropatiler</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></p>
  <p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>a) Dev aksonal n�ropati <br>
  b) Friedreich Hastal��� <br>
  c) N�roakantositoz</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:12.0pt;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>Herediter Motor-Duyusal N�ropatiler (Charcot-Marie-Tooth
Hastal���-CMT)</span></b><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'> </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>Ondokuzuncu y�zy�l�n sonlar�nda Charcot, Marie ve Tooth
taraf�ndan tan�mlanmas�ndan bu yana, molek�ler biyoloji alan�ndaki geli�melerin
en �ok ayd�nlatabildi�i herediter n�ropati grubudur. Ayr�ca herediter
n�ropatiler i�inde en s�k rastlan�lan�d�r (prevalans� 1/2500). Genellikle ilk
dekadlarda ba�lar ve yava� progresyon g�sterir. Klinik tablonun a��rl��� ayn�
aile i�inde hasta bireyler aras�nda de�i�kenlik g�sterebilir. Nadiren ciddi
k�s�tl�l��a yol a�ar. </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Bu n�ropatiler, 1968�de Dyck ve Lambert taraf�ndan
klinik, elektrofizyolojik ve histopatolojik verilere g�re s�n�flanarak doksanl�
y�llar�n ba��na kadar <b>H</b>erediter <b>M</b>otor <b>Duyusal</b> <b>N</b>�ropati
(HMSN) ad�yla an�lm��t�r. Molek�ler biyoloji alan�ndaki geli�melere ba�l�
olarak ilintili gen defektleri bulunmaya ba�lad�ktan sonra, bu gruptaki
n�ropatilere ilk tan�mlayanlara atfen yeniden Charcot-Marie-Tooth hastal���
(CMT) ad� verildi.&nbsp; Buna g�re d���k sinir ileti h�zlar�yla seyreden, sinir
biyopsisinde demiyelinizasyon<span style='color:black'>, remiyelinizasyon ve
�so�an zar�� g�r�n�m�n�n hakim oldu�u tipine </span>CMT tip 1 (HMSN-1), ileti
h�zlar�n�n normal ya da hafif d���k olup, biyopside akson kayb�n�n �n planda
oldu�u tipine CMT tip 2 (HMSN-2) denmi�tir. Her iki tipte de genetik ge�i�
genellikle otozomal dominant olup, otozomal resesif ge�i�e de rastlanmaktad�r<b>.</b>
&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�ocukluk �a��nda ba�lay�p demiyelinizan �zellikler g�steren ve otozomal
resesif ge�ti�i d���n�len tipe de HMSN-3 (Dejerine-Sottas Hastal���) ad�
verilmi�tir. Genetik alan�nda yap�lan �al��malar bu hastal�ktaki ge�i�in de
otozomal resesiften �ok dominant oldu�unu g�stermi�tir. CMT hastal���n�n mutant
genlere g�re yeniden yap�lan s�n�flamas�nda&nbsp; genetik olarak heterojen bir
hastal�k grubuyla kar�� kar��ya olundu�u&nbsp; anla��lm��t�r (<b>Tablo 16</b>).</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;[</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Harding ve Thomas��n geni� bir hasta serisi �zerinde
yapt�klar� ara�t�rmaya dayanarak, elektrofizyolojik incelemede median sinirin
motor ileti h�z�n�n 38 m/s�den d���k saptand��� hastalarda demiyelinizasyonun,
y�ksek olanlar da ise �n planda akson kayb�n�n oldu�unu kabul etmek gelenek
olmu�tur.] </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Bu s�n�flamada di�erlerine g�re daha nadir g�r�len HMSN-4, HMSN-5, HMSN-6,
HMSN-7 de yer almakta, bunlardan 4. tip Refsum hastal��� olarak an�lmakta<span
style='color:black'>, di�er n�ropatilere ise s�ras�yla piramidal belirtiler,
optik atrofi ve retinitis pigmentoza e�lik etmektedir. </span></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>Tablo 16.</span></b><span lang=TR style='font-family:
Tahoma;color:black;mso-ansi-language:TR'> Herediter Motor Duyusal N�ropatiler </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;mso-ansi-language:
TR'>(D. Pareyson ve Washington University Home Page, de�i�tirilerek) </span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-4.85pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
  <td width=306 valign=top style='width:229.2pt;border:solid gray 1.0pt;
  padding:0cm 2.25pt 0cm 2.25pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>CMT &amp; HMSN: Demiyelinizan</span></b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><br>
  &nbsp;<b>Dominant<br>
  </b>&nbsp;&nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#IA#IA">CMT
  1A</a>: PMP-22; 17p11<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#IB#IB">CMT
  1B</a>: P<sub>0</sub> protein; 1q22<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#cmt1c#cmt1c">CMT 1C</a>:
  LITAF; 16p13<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#egr2#egr2">CMT 1D</a>:
  EGR2; 10q21<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#p0var#p0var">CMT 1E</a>:
  P<sub>0</sub> protein; 1q22<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#cmt1f#cmt1f">CMT 1F</a>:
  Neurofilament light chain; 8p21<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#pp#pp">HNPP</a>:
  PMP-22 deletion; 17p11<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#ds#ds">HMSN
  3</a> (Dejerine-Sottas)<br>
  &nbsp; &nbsp; &nbsp; &nbsp; PMP-22; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#IB#IB">P<sub>0</sub></a>;
  <a href="http://neuromuscular.wustl.edu/time/hmsn.html#dss8q23#dss8q23">8q23</a>;
  <a href="http://neuromuscular.wustl.edu/time/hmsn.html#egr2#egr2">EGR2</a><br>
  &nbsp;</span></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Resesif</span></b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'><br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#4A#4A">CMT
  4A</a>: GDA P1; 8q21<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#4b1#4b1">CMT
  4B</a>: MTMR2; 11q23<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#cmt4e#cmt4e">CMT 4B2</a>:
  SBF2; 11p15<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#4C#4C">CMT
  4C</a>: SH3TC2 (KIAA1985); 5q32<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#lom#lom">CMT
  4D (Lom)</a>: NDRG1; 8q24<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/child.html#chn">CMT
  4E</a>: EGR2; 10q21<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#cmt4f#cmt4f">CMT 4F</a>:
  Periaxin; 19q13<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#hmsnr#hmsnr">HMSN-Russe</a>
  (4G): 10q23<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#4hcmt#4hcmt">CMT 4H</a>:
  FGD4; 12q12<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#4jcmt#4jcmt">CMT 4J</a>:
  FIG4; 6q21<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#ds#ds">HMSN
  3</a> (Dejerine-Sottas)<br>
  &nbsp; &nbsp; &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#IB#IB">P<sub>0</sub></a>;
  <a href="http://neuromuscular.wustl.edu/time/hmsn.html#IA#IA">PMP-22</a>; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#egr2#egr2">EGR2</a>; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#cmt4f#cmt4f">Periaxin</a><br>
  &nbsp; &nbsp;&nbsp;Konjenital hipomyelinizan<br>
  &nbsp; &nbsp; &nbsp; &nbsp; P<sub>0</sub>, PMP-22 &amp; EGR-2<br>
  &nbsp;<b> </b></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>X�e ba�l�</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#x1#x1">Connexin-32</a>
  (GJB1): Xq13</span></p>
  </td>
  <td width=325 valign=top style='width:244.0pt;border:solid gray 1.0pt;
  border-left:none;padding:0cm 2.25pt 0cm 2.25pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>CMT &amp; HMSN: Aksonal</span></b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><br>
  &nbsp;<b>Dominant<br>
  </b>&nbsp; &nbsp;<a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#2a1#2a1">CMT 2A1</a>:
  KIF1B; 1p36<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#2a2#2a2">CMT
  2A2</a>: MFN2; 1p36<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#2b#2b">CMT
  2B</a>: RAB7; 3q13-q22<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#2c#2c">CMT
  2C</a>: 12q23-q24<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#2d#2d">CMT
  2D</a>: GARS; 7p15<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#2nfl#2nfl">CMT 2E</a>:
  Neurofilament light chain; 8p21<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#2f#2f">CMT
  2F</a>/Distal HMN: HSPB1; 7q11-q21<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#cmt2g#cmt2g">CMT 2G</a>:
  12q12<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#p0axonal#p0axonal">CMT 2I</a>:
  P<sub>0</sub>; 1q22<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#p0axonal#p0axonal">CMT 2J</a>:
  P<sub>0</sub>; 1q22</span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;
  CMT 2K: GDAP1; 8q21<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#cmt2l#cmt2l">CMT 2L</a>:
  HSPB8; 12q24<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/synmot.html#hmsnp">HMSN-Proksimal</a>:
  3q13<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#5#5">HMSN
  5</a>: Piramidal bulgular<br>
  &nbsp; &nbsp; HMSN + Optik atrofi<br>
  &nbsp; &nbsp; HMSN + Sa��rl�k<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#gjb3#gjb3">Connexin-31
  (GJB3)</a><br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#vi#vi">HMSN
  6 (+ g�rme kayb�)</a>: MFN2; 1p36<br>
  &nbsp; &nbsp; HSMN + Ulsero-mutilasyon<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/sensory-small.html#hsan1">HSAN I</a><br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#smna#smna">HSMN + Ataksi</a>:
  7q22<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/synmot.html#dsmavb">HMN
  5B</a>: BSCL2; 11q13</span></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Resesif<br>
  </span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#armoroc#armoroc">AR-CMT2A</a>:
  Lamin A/C; 1q21<br>
  &nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#arcr#arcr">AR-CMT2B</a>:
  19q13.3</span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;
  AR-CMT+piramidal belirtiler
  (CMT2H):&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  8q21.3<br>
  &nbsp; &nbsp; AR-CMT + seste kal�nla�ma&nbsp; (CMT 2K): GDAP1; 8q21<br>
  &nbsp; &nbsp; AR-CMT/distal HMN: HSPB1; 7q11-q21</span></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>X�e ba�l�<br>
  </span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp; &nbsp; <a
  href="http://neuromuscular.wustl.edu/time/hmsn.html#x1#x1">Connexin-32</a>
  (kad�nlar): Xq13<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#x2#x2">2</a>:
  Xp22.2<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#x3#x3">3</a>:
  Xq26<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#cow#cow">4</a>
  (Cowchock): Xq24<br>
  &nbsp; &nbsp; <a href="http://neuromuscular.wustl.edu/time/hmsn.html#x5#x5">5</a>:
  PRPS1; Xq22<br>
  &nbsp;&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
color:black;mso-ansi-language:TR'>DSH: Dejerine-Sottas Hastal���, <br>
HNPP: (Hereditary Neuropathy with liability to Pressure Palsies= Ailesel
Bas�nca Duyarl�l�k N�ropatisi) Genlerle ilgili k�saltmalar i�in ilgili
b�l�mlere bak�n�z</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>CMT-1 (HMSN-1)</span></i></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>Otozomal dominant olarak ge�en bu hastal�k genellikle ilk
ya da ikinci dekadda ba�lar. Ayaklarda pes kavus ve �eki� parmak deformitesi
g�r�l�r&nbsp; (<b>�ekil 1a</b>). Alt ekstremitelerde belirgin olan distal zaaf
ve atrofi klinik tabloya hakimdir. Atrofi daha �ok peroneal kaslar� tutar. Bu
nedenle ince bilekli ve yukar�da ad� ge�en ayak deformiteleri olan hastalarda
ilk tan� olas�l��� CMT Hastal���d�r. Subjektif duyusal yak�nmalar geri
plandad�r. Buna kar��l�k muayenede daha �ok u�lar� tutan hipoestezi
bulunabilir, vibrasyon duyusu bozuktur. Kemik veter refleksleri hastal���n
hafif formlar�nda ya da ba�lang�c�nda al�nabilir fakat hastalar�n yar�s�ndan
fazlas�nda tamam�yla kay�pt�r. Elektrofizyolojik ve histopatolojik (<b>�ekil 1b</b>)
incelemeler demiyelinizan �zellikler ta��r, buna akson kayb� e�lik eder.<br>
&nbsp; </span></p>

<p class=MsoNormal style='margin-top:5.0pt;margin-right:36.0pt;margin-bottom:
5.0pt;margin-left:36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><a href="pnp1a.jpg"><b>�ekil 1a.</b></a> <span
style='color:black'>&nbsp;Charcot Marie Tooth hastal���nda bacak distallerinde
atrofi, </span>pes kavus ve �eki� parmak deformitesi. </span></p>

<p class=MsoNormal style='margin-top:5.0pt;margin-right:36.0pt;margin-bottom:
5.0pt;margin-left:36.0pt'><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'><a href="pnp1b.jpg"><b><span style='font-size:10.0pt'>�ekil
1b</span></b><b><span style='font-size:10.0pt;color:lime'>.</span></b></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;mso-ansi-language:
TR'> Charcot Marie Tooth Tip IA. Y�zeyel peroneal sinir biyopsisinde miyelinli
aksonlar�n k�smen yok oldu�u, t�m alana Schwann h�cre proliferasyonuna ba�l�
olarak so�an zar� g�r�n�m�n�n hakim oldu�u izlenmekte (Thioninle boyanm�� enine
yar� ince kesit. X40).</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'><br>
</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
mso-ansi-language:TR'>G�n�m�ze kadar saptanan gen defektlerine g�re 4 formu
tan�mlanm��t�r: </span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
color:black;mso-ansi-language:TR'>CMT-1A:</span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:black;mso-ansi-language:TR'> T�m
CMT-1 olgular�n�n %70-90�n� olu�turur. Onyedinci kromozomda, kompakt&nbsp;
miyelin proteinlerinden �Peripheral Myelin Protein 22� (PMP22)&nbsp; ile ilgili
olan b�lgenin (17p11.2) duplikasyonu sonucu ortaya ��kar. �ok az say�da hastada
(CMT-1 olgular�n�n %1�i) PMP22 genine ait nokta mutasyonu saptanm��t�r.<i>&nbsp;</i></span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
color:black;mso-ansi-language:TR'>CMT-1B:</span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:black;mso-ansi-language:TR'>
Birinci kromozomda yine bir kompakt miyelin proteini olan �Protein Zero�
(P0)&nbsp; geninin nokta mutasyonu sonucu olu�ur (1q22-23). T�m CMT-1
olgular�n�n % 4�� bu mutasyona ba�l�d�r.</span></p>

<p class=MsoBodyText style='line-height:normal'><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:black;mso-ansi-language:TR'>CMT-1C:</span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;mso-ansi-language:
TR'> </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Bu form CMT-1A ve CMT-1B d���nda, az say�da hastada 16.
kromozomda (16p13.3-p12) yer alan, protein degradasyonunda rol oynad���
d���n�len LITAF (lipopolysaccharide-induced tumor necrosis factor) genindeki
mutasyon sonucu ortaya ��kar.</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
color:black;mso-ansi-language:TR'>CMT-1D:</span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:black;mso-ansi-language:TR'>
Bu grupta,&nbsp; DNA�ya ba�lanarak gen ekspresyonunda d�zenleyici rol �stlenen
ve Schwann h�cre geli�imini etkileyen Early Growth Response&nbsp; 2 (EGR2)
proteinine ait mutasyonu olan&nbsp; hastalar yer almaktad�r.</span></p>

<p class=MsoBodyText style='line-height:normal'><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CMT-4</span></i></p>

<p class=MsoBodyText style='line-height:normal'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Otozomal resesif (OR) ge�en
demiyelinizan CMT hastal���na CMT 4 ad� verilir. Klinik �zellikler a��s�ndan
otozomal dominant forma benzer, fakat semptomlar�n ba�lang�c� genellikle daha
k���k ya�tad�r ve daha a��r seyreder. Yapt���m�z �al��malarda, �lkemizde akraba
evliliklerinin s�kl���ndan dolay� literat�re g�re daha y�ksek oranda otozomal
resesif ge�i� oldu�unu saptad�k. En s�k g�r�len genotipler ve bunlara yol a�an
mutasyonlara ait proteinler �unlard�r: CMT 4A: �Gangliozide-induced
differentiation-associated protein� (GDAP1-kromozom 8q21.1), CMT 4B:
�Myotubularin-related protein-2� (MTMR2-kromozom 11q22.1), CMT 4C: �zellikle
skolyoz e�lik eder, (KIAA1985 ,kromozom-5q23-q33),&nbsp; CMT 4D Lom: �ingene
�rk�nda g�r�l�r, �N-myc Downstream-Regulated Gene 1� (NDRG1-kromozom 8q24), CMT
4F: Periaxin-kromozom 19q13.</span></p>

<p class=MsoBodyText style='line-height:normal'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoBodyText align=left style='text-align:left;line-height:normal'><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CMT X</span></i></p>

<p class=MsoBodyText align=left style='text-align:left;line-height:normal'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>X
kromozomunun uzun kolundaki (Xq13-22) Connexin 32 geninin mutasyonuna ba�l�
geli�ir. Bu gen miyelinin kompakt olmad���, Ranvier bo�umuna yak�n b�lgelerdeki
iyon al��-veri�ini d�zenleyen proteinleri (gap-junction proteins) kodlar.
CMT-1A dan sonra en s�k g�r�len genotiptir, t�m demiyelinizan olgular�n
%10-16�n� olu�turur. Erkeklerde klinik tablo daha a��rd�r. Elektrofizyolojik ve
histopatolojik �al��malar demiyelinizasyonla birlikte aksonal tutulumun da
olabilece�ini g�stermi�tir. Aksonal tutulum genellikle ta��y�c� kad�nlarda
g�r�l�r. Son y�llarda yap�lan �al��malar CMT�nin bu formunda ayr�ca merkezi
sinir sistemi tutulumuna ait bulgular da olabilece�ini g�stermektedir. Bu
hastalar�n kranyal manyetik rezonans (MR) incelemelerinde ak maddeyi tutan,
multipl skleroz hastal���ndaki lezyonlara benzer lezyonlar g�r�lebilece�i
bildirilmi�tir. Bunun da&nbsp; oligodendrositlerin Connexin 32 proteinini
bar�nd�rmas�na ba�l� oldu�u anla��lm��t�r.</span></p>

<p class=MsoBodyText style='line-height:normal'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>CMT-2 (HMSN-2) </span></i></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>CMT-1�e g�re daha nadir g�r�l�r. Ba�lang�� ya�� da daha
ge�tir. Otozomal dominant ge�er. Klinik �zellikler CMT-1�deki gibidir. Daha
�nce de belirtildi�i gibi akson kayb�n�n elektrofizyolojik ve histopatolojik
�zelliklerini ta��r (<b>�ekil 2</b>). Molek�ler biyoloji alan�ndaki son
y�llardaki �al��malar bu fenotipe neden olan bir �ok gen defekti ortaya
koymu�tur.&nbsp; Bulunan genlerden biri CMT 2A1 fenotipine yol a�an sinaptik
vesik�llerin anterograd transportundan sorumlu bir kinezin olan KIF 1B ,
di�eri&nbsp; (CMT2A2) mitokondrilerde f�zyon i�levini �stlenen&nbsp; Mitofusin
2 (MFN2) mutasyonu sonucu&nbsp; ortaya ��kar. CMT2B ve CMT2D ise s�ras�yla GTP
ba�layan ve vezik�ler transportta rol �stlenen RAB7, protein sentezinde etkin
olan<a name=2d></a> </span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Glycyl tRNA Sentetaz�n (<span style='color:black'>GARS) mutasyonlar�na
ba�l� olarak geli�ir. CMT2B� de a��r duyu kayb�na ba�l�, �zellikle ayaklarda
�lserlere rastlan�r. CMT2D ise herediter distal motor n�ropati tip V�le
aleliktir.&nbsp; CMT 2E fenotipindeki hastalarda mutasyonu bulunan, akson
transportunda rol alan n�rofilamentlerle ilgili neurofilament light chain
(NF-L) genidir.&nbsp;�Heat shock� proteinlerinden olan HSPB1�in mutasyonu ise
CMT2F ye yol a�ar.&nbsp; Otozomal dominant ge�i�li di�er CMT2�ler i�in
ayr�nt�l� bilgi <b>Tablo 16</b>�da yer almaktad�r.&nbsp;&nbsp; </span></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>OR-CMT 2:</span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>Otozomal resesif ge�i�li, OR-CMT 2A fenotipindeki
hastalarda, ayr�ca Emery-Dreifus M�sk�ler Distrofi ve Kav�ak tipi M�sk�ler
Distrofi gibi hastal�klara da yol a�an Lamin A/C genine ait mutasyon
bulunmu�tur. Laminler n�kleer laminada yer alan proteinlerdir. OR-CMT+ses
k�s�kl��� grubunda yer alan hastalarda ise, yine resesif ge�i�li, demiyelinizan
CMT�lerden CMT 4A�ya da neden olan �Gangliozide-induced differentiation
associated� protein 1 (GDAP 1) geninde mutasyon saptanm��t�r. GDAP 1 hem
merkezi sinir sisteminde hem de Schwann h�crelerinde bulunan bir proteindir.
Anla��ld��� gibi CMT-2 de CMT-1 gibi genetik olarak heterojendir. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>&nbsp; </span></p>

<p class=MsoNormal style='margin-top:5.0pt;margin-right:36.0pt;margin-bottom:
5.0pt;margin-left:36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><a href="pnp2.JPG"><b>�ekil 2</b>.</a> Charcot
Marie Tooth Tip II (GDAP1 mutasyonu). Sural sinir biyopsisinde miyelinli akson
yo�unlu�unda �nemli �l��de azalmayla birlikte, geriye kalan aksonlar�n miyelin
k�l�flar�n�n genellikle ince oldu�u g�r�lmekte (Literat�rde bunun&nbsp; CMT
II�ye ait histopatolojik �zelliklerden biri oldu�u vurgulan�r). Ayr�ca yine bu
n�ropatiye ait �zelliklerden rejenerasyon odaklar�n�n varl��� g�zlenmekte
(Oklar) (Thioninle boyanm�� enine yar� ince kesit. X40).</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'><br>
<i>Dejerine-Sottas Hastal��� (HMSN-3)</i></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>Bu hastal�k �ocukluk �a��n�n, motor geli�me gerili�i, �ok
d���k ileti h�zlar� (&lt;10m/s), histopatolojik olarak hipo/demiyelinizasyonla
karakterize a��r duyusal-motor n�ropatisidir. Tabloya genellikle pes kavus,
�eki� parmak, skolyoz gibi kemik deformiteleri e�lik eder. Palpe edilebilen
hipertrofik sinirler bulunur. �lk tarif edildi�inde otozomal resesif olarak
ge�ti�i d���n�lse de, son y�llarda yap�lan genetik �al��malar ge�i�in daha �ok
otozomal dominant oldu�unu g�stermi�, hastal�ktan sorumlu olan genlerin CMT-1�e
neden olan PMP-22, P0 ve EGR2 genlerindeki nokta mutasyonlar�na ba�l� oldu�unu
kan�tlam��t�r. Daha sonra Dejerine ve Sottas��n tarif etti�i gibi otozomal
resesif ge�i� g�steren az say�da aile de tarif edilmi�tir. Ayr�ca yine son
yay�nlara g�re, otozomal ge�i� g�steren ailelerde, Schwann h�cresinde
miyelinizasyonda rol oynad���, h�cre d��� ile i�i aras�ndaki sinyal iletiminde
�nemli g�revler �stlendi�i anla��lan <i>Periaxin</i> geninde mutasyonu olan
hasta say�s� da giderek artmaktad�r. DSH ile ilgili olan gen defektlerinin CMT
tip 1�de g�sterilenlerle ayn� olmas� ve ailelerin �o�unda dominant ge�i�in
saptanmas�, Dejerine-Sottas Hastal���n�n CMT-1�in bir varyant� oldu�unu
d���nd�rmektedir. Buna kar��l�k son y�llarda literat�rde ilk tarifine uygun bir
�ekilde otozomal resesif ge�i� g�r�len ailelerin varl���n�n da g�sterilmesi bu
hastal���n s�n�flamadaki yeri hakk�nda bir �ok tart��maya yol
a�m��t�r.&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a href="pnp3.jpg"><b>�ekil 3.</b></a>&nbsp;
Fokal olarak k�vr�mlanan miyelin: Sural sinir biyopsisinin elektron
mikroskopisindeki �rne�inde fokal olarak kendi �zerine katlanm�� miyelin k�l�f�
g�r�nt�s�. MTMR13 mutasyonu olan CMT4B2 hastas�. </span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>Ailesel bas�nca duyarl�l�k n�ropatisi (Tomak�ler
N�ropati)</span></i></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>Otozomal dominant ge�er. Gelip ge�ici, a�r�s�z
duyusal-motor defisitlerle karakterizedir. Elektrofizyolojik olarak, �zellikle
sinirlerin s�k tuzakland��� yerlerde iletim bloklar�n�n hakim oldu�u
demiyelinizan bir n�ropatidir. En �ok etkilenen sinirler, peroneal, ulnar,
radyal sinirlerdir. Brakiyal pleksus da tutulabilir. Baz� hastalarda
tekrarlay�c� defisitler kronik progresif bir seyre de yol a�abilir. Sinir
biyopsisindeki tipik g�r�n�m fokal miyelin kal�nla�mas�d�r, buna Latince�de
sosis anlam�na gelen �tomak�la� ad� verilir (<b>�ekil 4a ve �ekil 4b</b>).
Genetik �al��malar&nbsp; bu n�ropatinin 17. kromozomda, PMP22�yi&nbsp; kodlayan
b�lgenin (17p11.2) delesyonu sonucu ortaya ��kt���n� kan�tlam��t�r. Yukarda da
s�z edildi�i gibi ayn� b�lgenin duplikasyonu CMT 1A fenotipine neden
olmaktad�r. <br>
&nbsp; </span></p>

<p class=MsoNormal style='margin-top:5.0pt;margin-right:36.0pt;margin-bottom:
5.0pt;margin-left:36.0pt;text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a href="pnp4a.jpg"><b>�ekil
4.a</b></a> Ailesel bas�nca duyarl�l�k n�ropatisi. Tek tek sinir liflerini
izole etme y�ntemi uygulamas�nda (teasing) paranodal tomak�la (ok) ve
kom�ulu�unda &nbsp;demiyelinizasyon izlenmekte (*) (Osmium tetroksid).</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a href="pnp4b.jpg"><b>�ekil
4b.</b></a> Ailesel bas�nca duyarl�l�k n�ropatisi. Thioninle boyanm�� enine
yar� ince kesitte hipermiyelinize lif&nbsp;&nbsp;(tomak�la, ok) (X40).</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tedavi</span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
11.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bu grup hastal�klar�n bilinen
tedavisi olmamakla birlikte, son y�llarda demiyelinizan form i�in hayvan
deneyleri baz�nda baz� y�z g�ld�r�c� sonu�lar al�nm��t�r. Bu tedavi
denemelerinin ba��nda progesteron antagonistleri, n�rotrofin ve C-vitamini ile
olanlar dikkati �ekmektedir. Bu ajanlardan n�rotrofinle ilgili yay�nlanan
kontroll� �al��ma y�z g�ld�r�c� sonu�lar vermi�tir ve demiyelinizan CMT nin
tedavisi i�in gelecek vaad etmektedir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;
margin-left:0cm'><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>Bundan sonraki b�l�mde CMT hastal���na k�yasla �ok daha
nadir g�r�len baz� herediter n�ropatiler <b>Tablo 15�</b>teki s�raya g�re
anlat�lacakt�r. </span></p>

<p class=MsoNormal style='margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;
margin-left:0cm'><b><i><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>&nbsp;</span></i></b></p>

<p class=MsoNormal style='margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;
margin-left:0cm'><b><i><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>Ailesel Amiloid N�ropatisi</span></i></b></p>

<p class=MsoNormal style='margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;
margin-left:0cm'><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>�lkemizde �ok nadir de olsa g�r�ld���nden bu n�ropati s�z
edilmeye de�er bulunmu�tur. Otozomal dominant ge�i�lidir. Mutasyona g�re
isimlendirilir. En s�k g�r�len Portekiz tipidir. �lk kez Portekiz�in Porto b�lgesinde
tan�mland���ndan bu adla an�lmaktad�r. Portekiz tipi ailesel amiloid n�ropatisi
genellikle 3. dekadda ba�lar. Genetik defekt 18. kromozomdaki (18q11.2-12.1),
�transtiretin� proteinini kodlayan gendedir, 30. pozisyondaki valin yerine
metionin ge�mesiyle olu�ur (Val30Met). Dokulara ��ken amiloid maddesinin mutant
transtiretin oldu�u anla��lm��t�r. �ncelikle duyusal ve otonomik yak�nmalar
ba�lar, motor zaaf daha ge� yerle�ir. N�ropati d���nda multi-sistemik tutulum
belirtileri de ortaya ��kar. Hastalar kalpte ileti, ritm bozukluklar�, g�z ve
renal tutulum a��s�ndan izlenmelidir. Bu hastal���n tan�s� genetik olarak ya da
sinir biyopsisinde, �zellikle endon�riyumda ve damar �evresinde kendini
g�steren amiloid depolar�n�n varl���yla konabilir (<b>�ekil 5</b>). Prognoz
k�t�d�r. Denenen bir�ok tedavi y�nteminin yarars�z oldu�u g�r�lm��t�r. Son
y�llarda hastal���n ba�lang�� d�neminde yap�lan karaci�er transplantasyonunun
iyi sonu�lar verdi�i g�r�lm��t�r. B�ylece karaci�erde sentez edilen mutant
transtiretin v�cuttan uzakla�t�r�lm�� olmaktad�r. <br>
&nbsp; </span></p>

<p class=MsoNormal style='margin-top:5.0pt;margin-right:36.0pt;margin-bottom:
5.0pt;margin-left:36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><a href="pnp5.jpg"><b>�ekil 5.</b></a>
&nbsp;Ailesel amiloid n�ropatisi (Portekiz tipi). Endon�riumda lifler aras�n�
infiltre etmi� amiloid (A) deposu&nbsp; (Hematoksilen eosinle boyanm�� boyuna
parafin kesit X10.)</span></p>

<p class=MsoNormal style='margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;
margin-left:0cm'><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'><br>
<b>Porfiri </b>�Heme� sentezindeki defekt sonucu geli�ir. Suksinil CoA ve
glisinden �Heme� olu�ana kadar ge�en a�amalardaki enzim defektlerine g�re 3
�e�idi tan�mlanm��t�r. Otozomal dominant ge�i�lidir. N�ropati kar�n a�r�s�
ataklar� ve psikiyatrik bozukluklar� takiben 2-3 g�n i�inde ortaya ��kar. Akut
ba�lang��l� yayg�n kas kuvvetsizli�i ile seyretti�inden Guillain-Barr�
sendromuna benzer. Tablonun ba�lang�c�nda proksimal olan zaaf&nbsp; genellikle
asimetriktir. Solunum s�k�nt�s� ve otonomik belirtiler e�lik edebilir.
Elektrofizyolojik olarak aksonal tutulumun �n planda olmas� Guillain-Barr�
sendromundan ay�r�r. N�ropatinin d�zelmesi akson hasar�n�n derecesine ba�l�d�r.
Sulfonamid, griseofulvin, barbit�rat, fenitoin gibi ila�lar porfiri ataklar�n�n
ortaya ��kmas�na neden olur. </span></p>

<p class=MsoNormal style='margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;
margin-left:0cm'><b><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;
margin-left:0cm'><b><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>Dev Aksonal N�ropati</span></b></p>

<p class=MsoNormal style='margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;
margin-left:0cm'><span lang=TR style='font-family:Tahoma;color:black;
mso-ansi-language:TR'>�ocukluk �a��nda ba�layan motor a��rl�kl� n�ropatiye
neden olan bir hastal�kt�r. Sporadik veya otozomal resesif ge�i�lidir. �skelet
deformitelerinin de e�lik etti�i tabloda giderek bozulan y�r�menin yan�nda,
santral sinir sistemi tutulumuna ait bulgular da bulunur. Bunlar ba�l�ca,
piramidal belirtiler, ataksi ve mental geriliktir. Bu hastalar 20 ya��na
gelmeden kaybedilirler. Fenotipik �zelliklerinden biri sert, k�v�rc�k sa�lard�r
(�kinky hair�). Histopatolojik olarak nodal veya internodal yerle�imli,
segmanter olarak �ap geni�lemesi g�steren aksonlar�n varl��� tan� koydurtucudur
(<b>�ekil 6</b>). <br>
&nbsp; </span></p>

<p class=MsoNormal style='margin-top:5.0pt;margin-right:36.0pt;margin-bottom:
5.0pt;margin-left:36.0pt;text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a href="pnp6.jpg"><b>�ekil 6.</b></a>
Dev aksonal n�ropati. Sural sinir biyopsisinde genel olarak akson �ap�na g�re
ince miyelin k�l�f�na sahip olan ya da demiyelinizasyona u�ram�� (*) lifler ve
dev aksonlar (DA) g�r�lmekte (Thioninle boyanm�� enine yar� ince kesit. X40).</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Friedreich Hastal���</span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Otozomal resesif ge�i�lidir. Molek�ler biyoloji alan�ndaki �al��malar 9q13
lokusundaki GAA trin�kleotid art���na ba�l� oldu�unu g�stermi�tir. �lk ya da 2.
dekadda ba�lar. Refleks kayb� ve propriyoseptif&nbsp;defisitle karakterize,
ilerleyici nitelikteki duyusal n�ropatiye serebellar ataksi ve dizartri e�lik
eder. Babinski delili bulunur. Ayr�ca, kardiyomiyopati, endokrin bozukluklar,
katarakt gibi multi-sistemik tutulum bulgular� da g�r�l�r. Prognoz k�t�d�r,
hastalar genellikle 35 ya� civar�nda kaybedilir. Son y�llarda, sentetik bir
koenzim Q<sub>10 </sub>analo�u olan ve mitokondri membran�nda elektron ta��nmas�nda
d�zenleyici rol� olan <i>idebenon</i>un Friedreich ataksisi tedavisinde olumlu
sonu�lar verdi�i bildirilmi�tir. Bu etki n�rolojik semptomlar �zerine oldu�u
gibi kardiyomiyopatiyi de tedavi edici nitelikte bulunmu�tur (Ayr�ca bak�n�z:<b><i>
</i></b><a href="http://www.itfnoroloji.org/norodej/harboz.htm">Hareket
Bozukluklar�</a> /Ataksiler.)</span></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'>BA�I�IKLIK
BOZUKLU�UNA BA�LI POL�N�ROPAT�LER</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>�NFLAMATUVAR DEM�YEL�N�ZAN
POL�N�ROPAT�LER</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Guillain-Barr� Sendromu (GBS)</span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Poliomiyelitin toplumdaki s�kl���n�n azalmas�ndan sonra GBS, akut yayg�n
gev�ek felce neden olan hastal�klar�n en s�k g�r�leni halini alm��t�r
(insidens: 1-2/100.000). �ocukluktan ileri ya�lara kadar her ya� grubunda
rastlanan otoimmun k�kenli bir hastal�kt�r. Genellikle ba�ka bir hastal���
olmayan ki�ilerde ortaya ��kar. Ba�ka bir sistemik veya otoimmun hastal�kla
birlikte olmas� s�k kar��la��lan bir durum de�ildir. Birbirlerinden bazen
klinik y�nleriyle, bazen de daha �ok laboratuvar �zellikleri ile ayr�lan farkl�
alt gruplar� vard�r (<b>Tablo 17</b>). </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 17.</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Guillain-Barr� sendromlar�n�n s�n�flanmas� </span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(EP Bosch ve
BE Smith)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Akut inflamatuvar demiyelinizan poliradik�lon�ropati
(AIDP)</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Akut motor aksonal n�ropati (AMAN)</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Akut motor-duyusal aksonal n�ropati (AMSAN)</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Miller Fisher sendromu (MFS) ve di�er b�lgesel varyantlar</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Faringeal-servikal-brakiyal</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Paraparetik</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Y�z fel�leri</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Saf ok�lomotor</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>GBS�nun fonksiyonel varyantlar�</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut pandizotonomi</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Saf duyusal GBS</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ataksik GBS</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Akut �nflamatuvar Demiyelinizan Poliradik�lon�ropati (AIDP)</span></i></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>GBS terimi, pratikte hastal���n bu en s�k rastlanan klasik inflamatuvar
demiyelinizan formu i�in kullan�l�r. ��nk� bu form Bat� d�nyas�nda&nbsp;GBS
olgular�n�n %90��ndan fazlas�nda g�r�l�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Hastalar�n b�y�k k�sm�nda GBS�na ait yak�nmalar�n ba�lang�c�ndan �nceki 1-4
haftal�k s�re i�erisinde ge�irilen bir �st solunum yolu ya da gastrointestinal
traktus infeksiyonu, cerrahi giri�im ya da a��lanma gibi bir olay vard�r.
Hastal���n en s�k yerle�me �ekli, bacaklardan ba�lay�p kollara, daha sonra
y�ze, orofaringeal kaslara ve a��r olgularda solunum kaslar�na do�ru <i>y�kselen</i>
kas kuvvetsizli�i ile olur. Daha seyrek olarak kollarda veya kranyal alan
kaslar�nda g��s�zl�kle de ba�layabilir. Bir�ok kere&nbsp;polin�ropati sendromu
i�in tan�mlanan genel da��l�m �eklinin d���na ��kan ve ekstremite
proksimallerinde de belirgin olan bir kas kuvvetsizli�i g�r�l�r. Duyusal
yak�nmalar genel olarak daha geri plandad�r ve ekstremite u�lar�nda parestezi
ya da nadir olmayarak s�rt, bel ve bacak a�r�lar� �eklindedir. N�rolojik
muayenede, tan�mlanan alanlardaki kas kuvvetsizli�ine ek olarak, hemen daima,
tendon reflekslerinin yayg�n �ekilde kayboldu�u ya da azald��� g�r�l�r.
Objektif duyusal bulgular daha �ok ekstremite u�lar�ndaki hafif y�zeyel
hipoestezi veya azalm�� vibrasyon ve pozisyon duyusu ile s�n�rl�d�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Olgular�n 1/3 kadar�nda mekanik ventilasyonu gerektiren solunum
yetersizli�i geli�ir. Hastalar�n yar�s�nda, en s�k fasiyal paralizi olmak �zere
kranyal sinir fel�leri g�r�l�r. Orofaringeal kaslarda kuvvetsizlik olgular�n
yar�s�nda, g�z hareketi fel�leri %10-20 kadar�nda geli�ir. Nadir olarak papilla
�demi g�r�lebilir ve �ok artm�� BOS proteini ile birlikte olur (&gt;200 mg %).
Otonom sinir sistemi bozukluklar� hastalar�n yar�s� kadar�nda g�r�l�r ve
�iddetli motor disfonksiyonu, solunum yetersizli�i olan olgularda&nbsp;daha
s�kt�r. Otonom belirti ve bulgular aras�nda EKG de�i�iklikleri (T dalgas�
anormallikleri, ST segment depresyonu, QRS geni�lemesi, QT uzamas� ve �e�itli
kalp bloklar�), kalp aritmileri (sin�zal ta�ikardi, bradikardi, ventrik�ler
ta�ikardi, atrial flatter, atrial fibrilasyon ve asistoli), ortostatik
hipotansiyon ve hipertansiyon krizleri, daha nadiren ge�ici idrar retansiyonu,
terleme bozukluklar� ve paralitik ileus say�labilir (<i>ciddi ve kal�c�
nitelikte sfinkter kusuru GBS tan�s�ndan uzakla�t�r�c� bir kriter olarak ele
al�nmal�d�r</i>). <b>Tablo 18</b>�de GBS tan�s�n� kuvvetlendiren ve bu tan�dan
uzakla�t�ran fakt�rler ele al�nm��t�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 18.</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Tipik bir GBS tablosu i�in tan�y� kuvvetlendiren ve bu tan�dan
uzakla�t�ran fakt�rler </span><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>(van Doorn ve ark.�dan de�i�tirilerek)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><b><u><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>Tan� i�in gerekli</span></u></b></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kol ve bacaklarda ilerleyici kuvvetsizlik (sadece
bacaklardan ba�layabilir)&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Azalm��, kay�p tendon refleksleri</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><b><u><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>Tan�y� kuvvetle destekler</span></u></b></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Semptomlar�n g�nler boyunca-4 haftaya kadar ilerlemesi</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Hafif duyusal belirti ve bulgular</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kranyal sinir tutulmas� (�zellikle bilateral fasiyal kas
kuvvetsizli�i)</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Otonom fonksiyon bozuklu�u</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>A�r� (s�kl�kla vard�r)</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Y�ksek BOS proteini</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tipik elektrofizyolojik bulgular</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tan�dan ��phe
ettirir</span></u></b></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Ba�lang��ta �iddetli pulmoner fonksiyon bozuklu�u ve
ekstremitelerde s�n�rl� kuvvetsizlik </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Ba�lang��ta �iddetli duyusal bulgular ve s�n�rl�
kuvvetsizlik </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Ba�lang��ta mesane-barsak fonksiyon bozuklu�u </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Ba�lang��ta ate�</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Keskin duyu seviyesi</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>S�n�rl� kuvvetsizlik, solunum bozuklu�u yok, yava�
ilerleme (CIDP akla gelmeli) </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kuvvetsizlikte belirgin ve �srarl� asimetri</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kal�c� mesane ve barsak fonksiyon bozuklu�u</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>BOS�ta artm�� monon�kleer h�cre (&gt;50/mm<sup>3</sup>)</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>BOS�ta polimorfon�kleer h�cre varl���</span></p>

<div class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Kas kuvvetsizli�i, �iddet ve da��l�m alan� olarak progresyonunu genellikle
1-3 hafta i�erisinde tamamlar (olgular�n %50�si 1, %80�i 3 ve %90�� 4 haftada
maksimum kas zaaf�na ula��r). �ki aydan daha uzun s�re progresyon
g�steren&nbsp;edinsel demiyelinizan polin�ropati olgular�n�n <i>kronik
inflamatuvar demiyelinizan polin�ropati</i> (CIDP) olarak de�erlendirilmesi
gerekir. Progresyon a�amas�nda fulminan bir seyir izleyerek&nbsp;24-48 saat
i�inde solunum yetersizli�ine kadar ilerleyen hastalar da g�r�lebilir.
Progresyonun durmas�ndan sonra hastal�k 2-4 haftal�k bir plato ve bunu izleyen
yava� bir iyile�me d�nemine girer. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>GBS seyrinde ortaya ��kan kas kuvvetsizli�inin �iddeti b�y�k de�i�kenlik
g�sterir. Hastalar�n bir k�sm� ekstremite ve y�z kaslar�nda hafif
kuvvetsizlikle ambulatuvar kalabilirken, bir k�sm�nda kuadripleji ve mekanik
ventilasyon gerektiren solunum yetersizli�i geli�ir. �a�da� yo�un bak�m
ko�ullar�na ra�men olgular�n %2-12�sinde hastal�k solunum yetersizli�ine ba�l�
sorunlar, pulmoner embolizm ya da otonom bozukluklara ba�l� kardiovask�ler
olaylar nedeni ile �l�mle sonlan�r. Di�er hastalar&nbsp;6-12 ay s�ren (a��r
seyirli olgularda 1.5-2 y�la kadar uzayan) bir iyile�me d�nemi ge�irirler.
Hastalar�n %75 kadar� yeterli bir iyile�me g�stererek i�ine d�nebilir hale
gelir. Yakla��k % 5-10�unda hareketi engelleyecek �iddette motor defisitler
kal�r. Olgular�n %2-5�inde GBS rek�rrans� g�zlenir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Akut Motor Aksonal N�ropati (AMAN)</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Kuzey �in�de yaz aylar�nda g�r�len ve epidemiler olu�turan bir GBS formu
olarak tan�mlanm��t�r. Di�er �lkelerde de sporadik olarak g�r�len bu form Bat�
�lkelerinde rastlanan GBS�lerin %5�ten az�n� olu�turur. Klinik tablo ba�l�ca
motor belirti ve bulgularla seyreder, duyusal bulgular g�r�lmez. Kranyal sinir
tutulmas� nadirdir. Periferik sinirlerde inflamasyonun geri planda oldu�u ve
demiyelinizasyonun bulunmad��� bir aksonal hasar s�z konusudur. Prognoz
genellikle AIDP�de kar��la��landan farkl� de�ildir. Olgular�n bir k�sm�nda
yava� ve yetersiz iyile�me g�r�l�rken �o�u h�zl� �ekilde iyile�ir. Akson
hasar�n� izleyen sinir rejenerasyonunun beklenen yava�l��� g�z �n�ne
al�nd���nda bu h�zl� iyile�me patterni �a��rt�c� g�r�nmektedir&nbsp;(a�a��ya
bak�n�z).</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Akut Motor-Duyusal Aksonal N�ropati (AMSAN)</span></i></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Motor ve duyusal belirtilerle seyreden ve periferik sinirlerde
inflamasyon-demiyelinizasyon yerine aksonal hasar�n s�z konusu oldu�u bir GBS
formudur <i>(Feasby ve ark., 1986)</i>. Kas zaaf�n�n progresyonu daha h�zl�,
�iddeti daha fazlad�r. Akson hasar�n� izleyen yava� sinir rejenerasyonu nedeni
ile iyile�me yava� ve �o�u kere yetersizdir. AMAN��n daha a��r ve yayg�n
seyreden (motor ve duyusal sinir liflerini tutan) bir �ekli oldu�u
d���n�lmektedir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Miller Fisher Sendromu (MFS)</span></i></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>GBS�nun ekstremite ataksisi, arefleksi ve eksternal oftalmopleji ile
seyreden bir di�er subtipidir <i>(C. Miller Fisher, 1956)</i>. Hastalar
oftalmoplejiye ba�l� �ift g�rme, dengesizlik, hareketlerinde beceriksizlik ve
bazen ekstremitelerde parestezilerden yak�n�r. Pupillalar genellikle normaldir.
Ptoz, orofaringeal kaslar ve y�z kaslar�nda kuvvetsizlik olabilir. Olgular�n
yakla��k 1/3 �nde ekstremite ve solunum kaslar�nda da kuvvetsizlik geli�ir.
Bickerstaff beyinsap� ensefaliti ile MFS aras�nda bir ili�ki oldu�u, benzer
otoimmun s�re�lerin periferik ve merkez sinir sistemi yap�lar�n� etkileyerek bu
iki tabloyu ve bazen her ikisinin �zelliklerini bir arada bar�nd�ran olgular�
ortaya ��karabildi�i ileri s�r�lm��t�r (<b>Tablo 19</b>).</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Hastal�k �ncesi olaylar</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yukar�da belirtildi�i gibi
GBS�li olgular�n %90 kadar�nda hastal���n 1-3 hafta �ncesinde ge�irilmi� bir
infeksiyon s�z konusudur &nbsp;(�st solunum yolu infeksiyonu % 60,
gastrointestinal infeksiyon % 30).<i><span style='color:#231F20'> En s�k olarak
belirlenen infeksiyon ajan� </span>Campylobacter jejuni�dir (<b>Tablo 21</b>). </i>&nbsp;Ebstein-Barr
vir�s�, sitomagalovir�s (CMV), <i><span style='color:#231F20'>Haemophilus
influenzae ve </span>Mycoplasma pneumoniae</i> GBS ile ili�kisi bilinen
infeksiyon ajanlar�d�r. Hepatit A ve B, HIV ve herpesvir�s infeksiyonlar�n�n da
GBS ile ili�kisi bildirilmi�tir. <i>C. jejuni</i> infeksiyonunu izleyen GBS�ler
daha �ok motor belirtilerle ve aksonal tutulma ile seyretmektedir. CMV infeksiyonundan
sonra geli�en GBS olgular�n�n ise daha gen�, duyusal belirti ve bulgular�
belirgin, daha s�k kranyal sinir tutulmas� ve solunum yetersizli�i olan
hastalar oldu�u bildirilmi�tir. GBS�na �ncelik etti�i bildirilen di�er olaylar,
a��lanmalar (influenza, kuduz, tetanoz ve difteri toksoidleri, oral
poliomiyelit a��s�), cerrahi giri�imler ve baz� ila�lar�n kullan�m�d�r
(streptokinaz, suramin, gangliozidler ve eroin). GBS, sistemik lupus
eritematozus gibi hastal�klar�n seyrinde ya da Hodgkin hastal���, erken HIV
infeksiyonu veya organ transplantasyonu nedeniyle yap�lan farmakolojik
immunosupresyon gibi immun yetersizlik durumlar�nda da&nbsp;ortaya ��kabilir.
GBS ile a��lanmalar aras�nda bir ili�ki bulunsa bile bu zay�f ve d���k
olas�l�kl� bir ili�kidir. Bununla birlikte, GBS ge�iren olgularda relaps
riskini d���rmek i�in influenza a��lamas�n� 1 y�l kadar geciktirmek yerinde bir
davran��t�r. Herhangi bir a��laman�n ard�ndan GBS geli�ti�inden ku�kulan�lan
bir hastada ayn� a��n�n yeniden uygulanmas�ndan ka��nmak gerekir.</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Patoloji ve patogenez</span></i></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>GBS�nun AIDP formunda ba�l�ca histopatolojik bulgular endon�riumda
monon�kleer inflamatuvar infiltrasyon ve sinir liflerinde segmental
demiyelinizasyondur. Sinir k�klerinden distal intram�sk�ler sinir dallar�na
kadar periferik sinirlerin her taraf�nda bu lezyonlar g�r�lmekle birlikte, daha
�ok motor k�kler ve proksimal pleksus segmentleri tutulur. AMAN ve AMSAN
formlar�nda ise iltihabi infiltrasyonun g�r�lmedi�i bir akson hasar� s�z
konusudur.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>GBS�na yol a�an patolojik s�re�leri
periferik sinirlerin yap�s�nda yer alan antijenlere kar�� olu�an
otoantikorlar�n ba�latt��� kabul edilmektedir. GBS�li hastalar�n kanlar�nda
olduk�a y�ksek oranda (yakla��k %60) antigangliozid antikorlar g�sterilmi�tir.
Gangliozidler periferik sinir membranlar�nda �lipid sallar�� denen katmanlarda
bulunur ve membran b�t�nl���n�n korunmas�nda g�rev al�rlar. IgG anti GM1, GM1b,
GD1a ve GalNAc-GD1a antikorlar motor a��rl�kl� olgular ya da AMAN ve AMSAN�l�
hasta gruplar�nda daha y�ksek oranda g�r�l�rler. GD3, GT1a, and GQ1b�ye kar��
antikorlar ise oftalmopleji ve MFS ile ili�kili g�r�nmektedr. Antigangliozid
antikorlar i�erisinde belirli bir GBS alt grubu ile en anlaml� ili�kiyi
g�steren IgG anti-GQ1b antikorudur. Bu antikor MFS olgular�n�n yakla��k %90��nda
akut fazda y�ksek titrelerde saptan�r ve klinik d�zelmeyle birlikte kaybolur (<b>Tablo
19 ve 20</b>). Baz� antikorlar ise tek tek gangliozidlere de�il, farkl�
gangliozid komplekslerinin olu�turdu�u yeni konformasyonel epitoplara
ba�lan�rlar. Yak�n zamanda GD1a/GD1b ve GD1b/GT1b komplekslerine kar��
antikorlar�n daha a��r seyirli GBS formlar�ndan sorumlu oldu�u g�sterilmi�tir.</span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tablo 19.</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Anti-glikolipid antikorlar ve
ili�kili olduklar� otoimmun polin�ropati sendromlar� (Willison ve Yuki).</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=215 valign=top style='width:161.35pt;border:inset 1.0pt;padding:
  0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Klinik Sendrom</span></b></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border:inset 1.0pt;border-left:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Antikorun kar�� oldu�u glikolipid</span></b></p>
  </td>
  <td width=158 valign=top style='width:118.45pt;border:inset 1.0pt;border-left:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Antikor izotipi</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=215 valign=top style='width:161.35pt;border:inset 1.0pt;border-top:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kronik duyusal-motor demiyelinizan n�ropati</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>SGPG, SGLPG</span></p>
  </td>
  <td width=158 valign=top style='width:118.45pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IgM (monoklonal)</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=215 valign=top style='width:161.35pt;border:inset 1.0pt;border-top:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kronik ataksik n�ropati</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>GD1b, GD2, GD3, GT1b, GQ1b</span></p>
  </td>
  <td width=158 valign=top style='width:118.45pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IgM (monoklonal)</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=215 valign=top style='width:161.35pt;border:inset 1.0pt;border-top:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Multifokal motor n�ropati</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>GM1, GD1b, asialo-GM1</span></p>
  </td>
  <td width=158 valign=top style='width:118.45pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IgM&nbsp; (poliklonal vaya monoklonal)</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=215 valign=top style='width:161.35pt;border:inset 1.0pt;border-top:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Akut&nbsp; motor aksonal n�ropati</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>GM1, GM1b, GD1a,&nbsp; GalNac-GD1a</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=158 valign=top style='width:118.45pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IgG</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=215 valign=top style='width:161.35pt;border:inset 1.0pt;border-top:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Miller Fisher sendromu</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>GQ1b, GT1a</span></p>
  </td>
  <td width=158 valign=top style='width:118.45pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IgG</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;mso-yfti-lastrow:yes'>
  <td width=215 valign=top style='width:161.35pt;border:inset 1.0pt;border-top:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Bickerstaff beyinsap� ensefaliti</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Akut oftalmoparezi</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Ataksik Guillain-Barr� sendromu</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Faringeal-servikal-brakiyal fel�</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>GT1a (GQ1b)</span></p>
  </td>
  <td width=158 valign=top style='width:118.45pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IgG</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tablo 20.</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> GBS�unda antigangliozid antikorlar,
gangliozid lokalizasyonlar� ve birlikte olan klinik tablolar (S. Kusunoki ve
ark)&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=103 valign=top style='width:77.4pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hedef
  antijen</span></b></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>S�n�f </span></b></p>
  </td>
  <td width=276 valign=top style='width:207.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Antijenin bulundu�u yer</span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Klinik �zellikler</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=103 valign=top style='width:77.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>GQ1b</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IgG</span></p>
  </td>
  <td width=276 valign=top style='width:207.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>III, IV, VI. Kranyal sinirlerin paranodal miyelini,</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Baz� arka k�k gangliyon n�ronlar�</span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>MFS</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Oftalmoplejili GBS</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Bickerstaff beyinsap� ensefali</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=103 valign=top style='width:77.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>GD1</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp; monospesifik</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IgG</span></p>
  </td>
  <td width=276 valign=top style='width:207.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;color:black;mso-ansi-language:
  TR'>Paranodal myelin </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;color:black;mso-ansi-language:
  TR'>Arka k�k ganglionu b�y�k n�ronlar�</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>AIDP</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Ataksik GBS</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=103 valign=top style='width:77.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>GalNAc-GD1a </span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IgG</span></p>
  </td>
  <td width=276 valign=top style='width:207.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Periaksonal membran</span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>AMAN</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Saf motor GBS</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=103 valign=top style='width:77.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>LM1</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IgG</span></p>
  </td>
  <td width=276 valign=top style='width:207.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Miyelin</span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>AIDP</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=103 valign=top style='width:77.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>GM1</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IgG</span></p>
  </td>
  <td width=276 valign=top style='width:207.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Belirlenmemi�</span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>AMAN</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Saf motor GBS</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;mso-yfti-lastrow:yes'>
  <td width=103 valign=top style='width:77.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>GD1a</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IgG</span></p>
  </td>
  <td width=276 valign=top style='width:207.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Belirlenmemi�</span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>AMAN</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tablo 21.</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> N�ropati ile ili�kisi g�sterilmi�
mikroorganizmalar�n taklit ettikleri glikolipidler (Willison ve Yuki)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=253 valign=top style='width:189.7pt;border:inset 1.0pt;padding:
  0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Mikroorganizma</span></b></p>
  </td>
  <td width=337 valign=top style='width:253.1pt;border:inset 1.0pt;border-left:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Taklit edilen glikolipid</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=253 valign=top style='width:189.7pt;border:inset 1.0pt;border-top:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Campylobacter
  jejuni</span></i></p>
  </td>
  <td width=337 valign=top style='width:253.1pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>GM1, GM1b, GD1a, GalNac-GD1a, GD3, GT1a, GQ1b</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=253 valign=top style='width:189.7pt;border:inset 1.0pt;border-top:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Haemophilus
  influenzae</span></i></p>
  </td>
  <td width=337 valign=top style='width:253.1pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>GM1, GT1a</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=253 valign=top style='width:189.7pt;border:inset 1.0pt;border-top:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Mycoplasma pneumoniae</span></i></p>
  </td>
  <td width=337 valign=top style='width:253.1pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Galaktoserebrosid</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;mso-yfti-lastrow:yes'>
  <td width=253 valign=top style='width:189.7pt;border:inset 1.0pt;border-top:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Sitomegalovir�s</span></p>
  </td>
  <td width=337 valign=top style='width:253.1pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>GM2</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>AIDP formunda Schwann h�cresi y�zeyindeki epitoplara
ba�lanan antikorlar�n kompleman aktivasyonuna yol a�t���, bunun da miyelinin
vakuolizasyonu, y�k�m� ve makrofajlarla fagositozuna varan bir s�reci
ba�latt��� �ne s�r�lm��t�r. AMAN ve AMSAN�da ise otoimmun olaylar�n ilk
hedefinin Ranvier nodlar�nda aksonal membranda yer alan gangliozid yap�s�ndaki
antijenler oldu�u, buralara ba�lanan&nbsp; antikorlar�n bir yandan muhtemelen
iyon kanal� disfonksiyonuna yol a�an olaylar� ba�latt���, di�er yandan
kompleman aktivasyonunu izleyerek Ranvier nodlar�na makrofajlar�n �ekilmesi,
periaksonal mesafenin a��lmas�, buraya makrofajlar�n migrasyonu ve sonu�ta
akson dejenerasyonu ile giden bir s�rece yol a�t��� d���n�lmektedir. AMAN�l�
olgular�n bir k�sm�nda geli�en aksonal hasarla uyumlu �ekilde a��r kas zaaf�,
yava� ve yetersiz&nbsp;iyile�me ile belirlenen bir klinik seyir g�r�lmektedir.
Bir k�s�m olgularda ise, iyi seyirli AIDP olgular�nda g�r�lenden farks�z h�zl�
ve tam bir klinik d�zelme dikkati �ekmektedir. Aksonal dejenerasyonu izleyen
rejenerasyon i�in gereken uzun zaman g�z �n�ne al�nd���nda bu durum �a��rt�c�
g�r�nmektedir. Bu olgularda aksonal membrana&nbsp;ba�lanan antikorlar�n iyon
ak�mlar�n� etkileyerek iletim bloklar�na yol a�t��� ya da aksonal hasar�n
ba�l�ca intram�sk�ler terminal sinir liflerinde oldu�u; sonu�taki h�zl�
iyile�menin ise&nbsp;iletim bloklar�n�n d�zelmesi ya da en distal lezyon
yerlerinden rejenerasyonla sa�land��� d���n�lmektedir. Hafif kas kuvvetsizli�i
ve h�zl� iyile�me ile seyreden AMAN olgular�nda �a��rt�c� bir di�er bulgu
olarak tendon reflekslerinin korunmu� oldu�u da g�r�lebilir. </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>GBS�na yol a�an otoantikorlar�n ortaya ��k��
mekanizmalar� ile ilgili bilimsel veriler, bunlar�n bir infeksiyon ajan�na
kar�� olu�turuldu�unu ve periferik sinirlere y�neldi�ini d���nd�rmektedir. GBS
ile ve �zellikle onun aksonal formlar� ile ili�kisi en s�k g�sterilen
bakteriyel organizma olan <i>C. jejuni,</i> d�nya �ap�nda yayg�n bir bakteriyel
enterit nedenidir. &nbsp;�e�itli olgu serilerinde,&nbsp;yak�nda ge�irilmi� bir <i>C.
jejuni</i> infeksiyonu&nbsp;ile ba�l�ca motor bulgular ve akson hasar� ile
seyreden GBS ve y�ksek anti GM1, anti GD1a veya anti GQ1b antikor titreleri
aras�nda ili�ki oldu�u g�r�lm��t�r. MFS�li olgulardan izole edilen&nbsp; <i>C.
jejuni </i>�rneklerinde GQ1b benzeri epitoplar da bulunmu�tur. Bu bulgular,
y�zeyindeki antijenik yap�lar� gangliozidler gibi sinir dokusu yap� maddelerini
taklit eden mikroorganizmalara kar�� kona��n olu�turdu�u antikorlar�n sinir
dokusuna y�nelerek hastal�k s�recini ba�latabilece�ini d���nd�rmektedir (<i>molek�ler
taklit mekanizmas�, </i><b>Tablo 21</b>). GBS�li olgulardan izole edilen <i>C.
jejuni</i> su�lar�n�n gangliozidlerin karbonhidrat epitoplar�n� taklid eden
lipo-oligosakkaridler (LOS) olu�turduklar� g�sterilmi�, LOS tiplerinin
olu�umundan sorumlu olan bakteri gen k�meleri belirlenmi�tir. Bu k�melerdeki
belirli gen varyantlar� gangliozid benzeri LOS�lar�n ekspresyonundan sorumlu
g�r�nmektedir. Bu �ekilde belirli bir gangliozidin molek�ler yap�s�n�n LOS
taraf�ndan taklid edilmesi antigangliozid antikorlar�n �zg�ll���n� ve buna
ba�l� olarak, - s�z konusu gangliozidlerin sinir sisteminde bask�n oldu�u
b�lgelere g�re ortaya ��kacak GBS varyantlar�n� belirler g�r�nmektedir (<b>Tablo
20,21</b>). Saf motor/aksonal n�ropatisi olan hastalardan elde edilen <i>C.
jejuni</i> su�lar� y�zeylerinde GM1 ve GD1a benzeri LOS�lar sunarken,
oftalmopleji ile birlikte olan GBS olgular� ve MFS�li olgulardan elde edilenler
GD3, GT1a, GD1c benzeri LOS�lar sunmaktad�rlar. Bir tav�an modelinde GM1
benzeri LOS ile immunizasyon yoluyla anti-GM1 antikorlar ve klinik planda
aksonal polin�ropati olu�turulmu�tur. Molek�ler taklit mekanizmas� <i>H.
influenzae</i> gibi baz� ba�ka infeksiyon ajanlar� i�in de g�sterilmi�tir.
Di�er yandan, <i>C. Jejuni</i> infeksiyonu ge�iren ki�ilerin 1/1000�inden
az�nda GBS geli�mesi, gangliozidleri taklid eden <i>C. jejuni</i> varyantlar�
ile infekte olan ailelerde bile salg�nlar g�r�lmemesi gibi �zellikler, GBS�nin
ortaya ��k���nda kona�a ait fakt�rlerin de �ok �nemli oldu�unu g�stermektedir.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut-subakut seyirli olduk�a
saf bir otonom n�ropati olarak tan�mlanan <i>akut pandizotonomi</i> (<i>otoimmun
otonomik gangliopati</i>=AAG) ba�l�ca ortostatik hipotansiyon, yetersiz
terleme, g�zya�� ve salya salg�lanmas�nda azalma, gastrointestinal motilite
bozukluklar�, atonik mesane, impotans ve sabit kalp at�m h�z� ile seyreder. Bu
hastalar�n bir k�sm�nda da hastal��a �ncelik eden infeksiyon ya da a��lanma
gibi bir olay bulunur. AAG olgular�n�n �nemli b�l�m�nde gangliyonik tipte (</span><span
lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:TR'>a</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-3
tipi) nikotinik asetilkolin resept�rlerine kar�� antikorlar bulunur.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Laboratuvar Bulgular�</span></i></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>GBS�da tan�ya en �ok yard�mc� olan laboratuvar y�ntemleri elektrofizyolojik
incelemeler (EMG ve sinir iletim incelemeleri) ile BOS incelemesidir.</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Rutin laboratuvar incelemeleri:</span></i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'> Eritrosit sedimentasyon h�z�, l�kosit say�s� ve
CK d�zeyinde hafif art�� olabilir. Uygunsuz ADH sal�m�na ba�l� hiponatremi
g�r�lebilir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Beyin omurilik s�v�s� (BOS):</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Protein d�zeyi
artm��t�r. Genel olarak h�cre art��� g�r�lmez (<i>albuminositolojik
disosiyasyon</i>).&nbsp; Kan-BOS bariyerinin bozulmas�na ba�l� olan protein
art��� genellikle 48 saatten (daha belirgin olarak ilk haftadan) sonra ortaya
��kar ve 3.-4. haftada en �st d�zeye ula��r. Olgular�n %10 kadar�nda BOS
protein d�zeyi hi�bir bir zaman y�kselmez. GBS�li olgular�n BOS�lar�nda
oligoklonal bandlar�n varl��� g�sterilebilir. BOS�taki h�cre say�s� genel
olarak mm<sup>3</sup>�te 10 monon�kleer h�creyi ge�mez&nbsp; (nadiren 50/mm<sup>3</sup>
monon�kleer h�cre g�r�lebilir). BOS pleositozu ile seyreden bir GBS olgusunda
leptomeningeal malin hastal�klar, Lyme hastal���, HIV infeksiyonu ya da
poliomiyelit gibi di�er tan� olas�l�klar� d���n�lmelidir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Elektrofizyolojik incelemeler:</span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp; AIDP de
ilk anormal elektrofizyolojik bulgu genellikle uzun latansl�, d���k
persistansl� ya da kaydedilemeyen F yan�tlar�d�r. Bu bulgu sinir k�kleri ya da
pleksuslar gibi proksimal sinir segmentlerindeki
demiyelinizasyonu&nbsp;yans�t�r. F yan�tlar�n�n ara�t�r�lmas� s�ras�nda
g�zlenen tek (normal bireylerde g�r�lebildi�i tibial sinir F incelemesi hari�)
ve �zellikle multipl A dalgalar� da GBS�nun erken bir elektrofizyolojik tan�
bulgusu olarak ele al�n�r. �lerleyen haftalar i�inde multifokal
demiyelinizasyonla seyreden polin�ropatiyi g�steren elektrofizyolojik veriler
yerle�ir. Motor iletim incelemelerinde sinir iletim h�zlar� belirgin derecede
ve multifokal nitelikte bir yava�lama g�sterir, sinir �zerinde uyar�m noktas�
proksimale do�ru kayd�k�a iletim bloklar� ve kas yan�tlar�nda dispersiyonla
kar��la��l�r. Polin�ropatinin �iddetine ba�l� olarak duyusal aksiyon
potansiyelleri ge� latansl� ve d���k amplit�dl� olarak elde edilir ya da
kaydedilemez. �st ekstremite distallerinde median ve ulnar sinir duyusal aksiyon
potansiyelleri kaydedilemez ya da �ok d���k amplit�dl� bulunurken sural sinir
duyusal aksiyon potansiyelinin elde edilebilir olmas� inflamatuvar
demiyelinizan polin�ropatiler i�in olduk�a kuvvetli bir tan� kriteridir ve
GBS�nda erken d�nemden itibaren saptanabilir (<i>sural kurtulma patterni</i>).
��ne elektromiyografisinde erken d�nemde sadece motor �nite potansiyeli
seyrelmesi izlenir. �lerleyen haftalarda az ya da �ok miktarda sekonder
aksonal&nbsp;hasar�n geli�mesiyle fibrilasyon ve pozitif diken potansiyelleri
ile parsiyel denervasyon-reinnervasyon s�recinin di�er bulgular� g�r�lmeye
ba�lan�r. </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>AMAN&nbsp;olgular�n�n motor iletim incelemelerinde
bile�ik kas aksiyon potansiyeli (BKAP) amplit�dlerinin belirgin derecede d���k
oldu�u g�r�l�r.&nbsp; Bu olgular�n i�ne elektromiyografisinde yo�un
denervasyonu yans�tan fibrilasyon ve pozitif diken potansiyelleri ile seyrelmi�
motor �nite potansiyeli aktivitesi dikkati �eker. MFS olgular�n�n
elektrofizyolojik incelemelerinde ise ba�l�ca duyusal bir aksonopatiyi yans�tan
bulgular elde edilir. Duyusal aksiyon potansiyelleri kaydedilemez ya da d���k
amplit�dl� bulunurken, genellikle kayda de�er d�zeyde motor sinir iletim
bozuklu�u saptanmaz.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Motor iletim incelemelerinde ekstremite distalinden
yap�lan elektriksel uyar�mla elde edilen BKAP amplit�dlerinin �ok d���k olmas�
a��r motor akson hasar�n� g�sterebilece�inden, yeterli iyile�me a��s�ndan k�t�
prognozu i�aret eden bir fakt�r olarak ele al�n�r (Ayr�ca bak�n�z: N�rolojide
Laboratuvar �ncelemeleri, <u><span style='color:#3366FF'>Elektromiyografi</span></u>).
Di�er yandan, demiyelinizasyon bulgular� olan GBS olgular�n�n daha y�ksek
oranda solunum yard�m�na gereksinimi oldu�u bilinmektedir. Yeni bir �al��mada,
hastalar�n hastaneye yat�r�ld��� ilk g�nlerde yap�lan elektrofizyolojik
incelemelerde peroneal sinir proksimal/distal BKAP amplit�d oran�n�n %55�in
alt�nda bulunmas� ve vital kapasitede %20�den fazla kay�p bulunmas�n�n, solunum
yetersizli�i a��s�ndan y�ksek riskli hastalar�n belirlenmesinde erken
belirte�ler oldu�u g�sterilmi�tir. &nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Antigangliozid antikorlar:</span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Patogenez b�l�m�nde
s�z edildi�i gibi baz� antigangliozid antikorlarla baz� GBS formlar� aras�nda
ili�ki vard�r. Ancak bunlardan sadece IgG anti-GQ1b ile MFS aras�ndaki ili�ki
tan�ya yard�mc� olabilecek kadar y�ksektir. MFS varl��� d���n�len hastalar
d���ndaki GBS olgular�nda antigangliozid antikor ara�t�rmas�n�n belirgin bir
tan�sal yard�m� olmaz. Bununla birlikte, IgG anti-GM1, GD1a gibi antikorlar�n
y�ksek titrede varl��� AMAN tan�s�n� destekleyici bir bulgu olarak ele
al�nabilir.</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Sinir biyopsisi:</span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Klinik
veriler, elektrofizyolojik incelemeler ve BOS bulgular� tan� i�in hemen daima
yeterli oldu�undan GBS olgular�nda sinir biyopsisine gerek duyulmaz.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Ay�r�c� Tan�</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo <b>22�de</b> h�zl� geli�en genel kas zaaf� ile seyreden ve GBS ile
ay�r�c� tan�s� gereken hastal�k tablolar� verilmi�tir.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 22.</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> GBS�nu taklid
edebilecek durumlar </span><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>(IR Bella�dan
de�i�tirilerek)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=175 valign=top style='width:131.4pt;border-top:inset 1.0pt;
  border-left:none;border-bottom:inset 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'>Hastal�k</span></b></p>
  </td>
  <td width=415 valign=top style='width:311.4pt;border-top:inset 1.0pt;
  border-left:none;border-bottom:inset 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'>Ba�l�ca ay�rd edici
  �zellikler</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=175 valign=top style='width:131.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Myasthenia gravis</span></p>
  </td>
  <td width=415 valign=top style='width:311.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Tendon refleksleri korunur</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Ok�ler kaslardaki kuvvetsizlik belirgindir</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Antikolinesteraz ila�lara yan�t verir</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>EMG: ard�s�ra uyar�mla motor yan�tta dekrement, tek lif
  EMG�sinde artm�� jitter ve blok g�r�l�r.</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=175 valign=top style='width:131.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Botulizm</span></p>
  </td>
  <td width=415 valign=top style='width:311.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Belirgin bulber tutulma olur</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Otonomik tutulma (pupillalar)</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>EMG: normal sinir iletim h�zlar�, d���k amplit�dl� kas
  yan�tlar�, y�ksek frekansl� ard�s�ra uyar�mla ya da k�sa s�reli maksimal kas�
  ile kas yan�tlar�nda anlaml� amplit�d art��� g�r�l�r.</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=175 valign=top style='width:131.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kene paralizisi </span></p>
  </td>
  <td width=415 valign=top style='width:311.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1-2 g�nde h�zl� progresyon</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=175 valign=top style='width:131.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Toksik n�ropatiler</span></p>
  </td>
  <td width=415 valign=top style='width:311.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>EMG: genellikle aksonal
  polin�ropati ile uyumlu bulgular elde edilir.</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=175 valign=top style='width:131.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Organofosfor toksisitesi</span></p>
  </td>
  <td width=415 valign=top style='width:311.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut kolinerjik reaksiyon
  g�r�l�r</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=175 valign=top style='width:131.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Porfirik n�ropati</span></p>
  </td>
  <td width=415 valign=top style='width:311.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Mental bozukluk</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kar�n a�r�s�</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>EMG: Ba�l�ca motor aksonal bir polin�ropatiyi g�steren
  bulgular saptan�r</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=175 valign=top style='width:131.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Difterik n�ropati</span></p>
  </td>
  <td width=415 valign=top style='width:311.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�ncelik eden farenjit</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yava� geli�im</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Palatal fel�, akomodasyon felci</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Miyokardit</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=175 valign=top style='width:131.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Poliomiyelit</span></p>
  </td>
  <td width=415 valign=top style='width:311.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kaslarda kuvvetsizlik, a�r� ve duyarl�l�k</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Duyu korunmu�tur</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>BOS: Protein <b><i>ve</i></b> h�cre art���</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=175 valign=top style='width:131.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Periyodik paralizi</span></p>
  </td>
  <td width=415 valign=top style='width:311.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Refleksler normaldir</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kranyal sinirler ve solunum korunur</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Serum K<sup>+</sup> d�zeyi anormal bulunabilir</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=175 valign=top style='width:131.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kritik hastal�k
  polin�ropatisi</span></p>
  </td>
  <td width=415 valign=top style='width:311.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Sepsis ve multiorgan yetersizli�i (2 haftadan uzun)</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>EMG: Aksonal polin�ropati ile uyumlu bulgular elde
  edilir.</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td width=175 valign=top style='width:131.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut yo�un bak�m miyopatisi</span></p>
  </td>
  <td width=415 valign=top style='width:311.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kuadriparezi ve arefleksi vard�r</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�rom�sk�ler bloker ila� ve kortikosteroid kullan�m�n�
  izler</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Travma, status astmatikus, organ transplantasyonu vb.
  ile ilgili yo�un bak�m tedavisini izler</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>EMG ve di�er laboratuvar bulgular� miyopati ile
  uyumludur</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12'>
  <td width=175 valign=top style='width:131.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vask�litlere ba�l� n�ropati</span></p>
  </td>
  <td width=415 valign=top style='width:311.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Sistemik belirti ve bulgular</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Duyusal ve motor bulgularda asimetri vard�r</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Refleksler kas zaaf� ile orant�l� olarak azal�r</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13;mso-yfti-lastrow:yes'>
  <td width=175 valign=top style='width:131.4pt;border:none;border-bottom:inset 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kuduz</span></p>
  </td>
  <td width=415 valign=top style='width:311.4pt;border:none;border-bottom:inset 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Ate�</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Duyusal ve motor bulgular asimetriktir</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kas spazmlar�, ajitasyon, anormal mental durum s�z
  konusudur</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tedavi</span></i></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Destekleyici tedavi:</span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> Yukar�da anlat�ld��� gibi, GBS�nun seyri s�ras�nda
solunum yetersizli�i ba�ta olmak �zere hastan�n ya�am�n� tehlikeye sokan bir
�ok sorunla kar��la��labilir. A��r fel� ve �ok say�da t�bbi komplikasyonun
g�r�lebildi�i akut d�nemin ge�mesinden sonra ise hastalar�n �o�u i�in yeniden
normal, �retken bir ya�ama ba�lama olas�l��� vard�r. Bu nedenle GBS�nun akut
d�neminde dikkatli ve �zenli bir t�bbi bak�m�n uygulanmas� �ok �nemlidir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hastal���n erken d�neminde geli�ebilecek solunum
yetersizli�i a��s�ndan dikkatli bir g�zlem yap�lmas� gerekir.&nbsp; Kas
kuvvetsizli�inin progresyon g�sterdi�inden kayg� duyulan her hasta hastaneye
yat�r�larak izlenmelidir. Kuvvetsizli�i belirginle�en hastalar�n olanaklar
elverdi�ince yo�un bak�m �nitelerine al�nmas� gerekir. Bir hastan�n mekanik
ventilasyona gereksinimi olaca�� konusunda en dikkat �ekici parametreler,
hastal�k ba�lang�c�ndan hospitalizasyona kadar olan s�renin 7 g�nden k�sa
olmas�, ba��n� kald�rmada g��l�k, bulber fonksiyon kusuru varl��� ve hastan�n
vital kapasitesinin %60��n alt�na d��mesidir. Zorlu vital kapasite ve maksimum
inspirasyon bas�nc� s�k olarak (2 saatte bir) izlenmelidir. Yeterli
oksijenasyon ve geli�mesi muhtemel hiperkapninin arteriyel kan gazlar� ile
izlenmesi yararl� olur. Vital kapasitenin h�zl� d���� g�stermesi ya da 15
ml/kg��n alt�na inmesi halinde solunum yard�m� uygulanmal�d�r. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Hastada solunum yetersizli�ini g�steren klinik
belirtilerin de dikkatle izlenmesi gerekir. Bunlar huzursuzluk ya da uyuklama
hali, artan solunum say�s�, tek nefeste sesli olarak 20�ye kadar sayamama,
aksesuvar solunum kaslar�n�n kullan�lmas�, inspiriumda kar�n duvar�n�n
paradoksal i�e hareketi ve �ks�rme kuvvetinin azalmas�d�r. Solunum cihazlar�
ile yard�m i�in ba�lang��ta trakeal intubasyon yeterli olur. ��nk� solunum
yard�m� uygulanan hastalar�n yakla��k ��te birinde birka� g�n i�inde ekst�be
edilmelerini sa�layacak kadar h�zl� bir d�zelme olur. Solunum yetersizli�i bir
haftadan daha fazla uzayan olgularda trakeostomiye ba�vurulmas� gerekir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Otonom sinir sistemi bozukluklar�, �zellikle kan bas�nc�,
kalp ritmi ve s�v� dengesi a��s�ndan izlenmelidir. Hipotansiyonla m�cadele i�in
s�v� inf�zyonlar� yap�labilir. Hipertansiyon ancak uzun s�reli ve �iddetli
olmas� halinde tedavi edilmelidir (otonom disfonksiyon nedeniyle
antihipertansiflerle a��r� hipotansiyon olu�turma riski mevcuttur). Bu ama�la
k�sa etkili alfa-adrenerjik blokerler kullan�labilir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Hastan�n beslenmesi di�er �nemli bir genel bak�m
konusudur.&nbsp; Birka� g�nl�k bir intraven�z s�v� tedavisinin ard�ndan besin
yetersizli�ine ba�l� doku de�i�iklikleri ortaya ��kmaya ba�layaca��ndan,
yutamayan hastalar� ilk hafta i�inde nazogastrik t�p vaya gastrostomi ile
beslemeye ba�lamal� ya da parenteral n�trisyon uygulanmal�d�r. G���s
fizyoterapisi egzersizleri ile pulmoner hijyen korunmaya �al���lmal�d�r.
GBS�nin s�k g�r�len bir komplikasyonu olan bronkopn�moni �nlenmeye �al���lmal�,
geli�ebilecek solunum yolu infeksiyonlar� enerjik �ekilde tedavi edilmelidir.
Hastalar�n yata�a ba��ml� oldu�u d�nemde derin ven trombozu ve pulmoner
embolizme kar�� profilaktik subkutan heparin tedavisi uygulamas� gerekir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>A��r kas kuvvetsizli�i olan hastalar�n yatak i�indeki
pozisyonlar�n�n �ok s�k olarak de�i�tirilmesi, hem yatak yaralar�n� ve
kompresyon n�ropatilerini �nlemek, hem de ekstremitelerindeki a�r� ve
huzursuzluk hissini azaltmak a��s�ndan �ok �nemlidir.&nbsp;&nbsp; Hastan�n
yat�r�ld��� ilk g�nlerden itibaren hafif fizyoterapi egzersizlerine ba�lanmal�
ve ekstremitelerde kontrakt�rlerin geli�mesi �nlenmeye �al���lmal�d�r. GBS
seyrinde s�k g�r�len ekstremite ve s�rt a�r�lar�na kar�� hafif analjeziklerin
kullan�lmas� tercih edilmeli, narkotiklerden sak�n�lmaya �al���lmal�d�r
(konstipasyon olu�turma riski).</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp; </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�mm�noterapi:</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> GBS�nun immunolojik tedavisinde plazmaferez (PE) ya da intraven�z immun
globulin (IVIg) kullan�l�r. �ok merkezli kontroll� �al��malar, bu tedavilerin
hastal�k ba�lang�c�ndan itibaren ilk 3-4 hafta i�erisinde uygulanmas� halinde
tedavi verilmeyenlere oranla belirgin derecede daha h�zl� bir iyile�me
sa�lad���n� ve bu iki tedavi se�ene�inin etkinlikleri aras�nda kayda de�er bir
farkl�l�k olmad���n� g�stermi�tir. Tedaviye daha erken ba�lanmas� (ilk 2 hafta)
daha y�ksek etki sa�lar.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>PE genellikle 2 haftal�k bir s�re i�erisinde uygulanacak
5 seansta toplam 5 plazma vol�m� kadar de�i�im hedeflenerek yap�l�r. Hafif
olgularda 2 seans PE yeterli olurken, orta ve a��r �iddetteki hastalara 4 PE
seans�n�n gerekli oldu�u, a��r hastalar�n ek olarak uygulanan 2 seansl�k PE den
(toplam 6) ek bir yarar sa�lamad��� g�sterilmi�tir. PE iyi bir ven�z ula��m
yolu (santral ven�z kateter gibi) gerektirir ve ancak b�y�k t�p merkezlerinde
uygulanabilen bir tedavi y�ntemidir. Kardiovask�ler instabilitesi ve otonom
disfonksiyonu olan hastalar taraf�ndan tolere edilmesi, �ocuklara uygulanmas�
�ok g��t�r. Sepsis gibi a��r yan etkileri daha s�kt�r. Bu nedenlerle uygulanmas�
daha kolay olan (PE ile hemen hemen ayn� olan y�ksek maliyeti d���nda) IVIg
yayg�n kullan�m alan� bulmaktad�r. IVIg genel olarak 2 g/kg olan toplam dozun 5
g�n i�inde 0.4 g/kg lik g�nl�k dozlar halinde verilmesiyle uygulan�r.
Hastalar�n %10�dan az�nda gripal semptomlar, ba�a�r�s�, kimyasal menenjit,
bulant�, yorgunluk hali gibi hafif yan etkiler g�r�l�r. Bunlar tedavi �ncesinde
verilecek difenhidramin gibi antiallerjikler, parasetamol ve d���k doz
kortikosteroid uygulamas�yla �nlenebilir.&nbsp; A��r yan etkiler �ok nadirdir.
Bunlar aras�nda anafilaktik reaksiyon (ba�l�ca IgA yetersizli�i olan hastalarda
g�r�l�r, bu nedenle tedavi �ncesinde immunglobulin A d�zeylerine bak�lmas�
gerekir), b�brek yetersizli�i (daha �ok renal hastal��� olan hastalarda
g�r�l�r, tedavi �ncesinde b�brek fonksiyonlar� y�n�nden bir de�erlendirme
yap�lmas� yerinde olur) ve inmeye neden olabilen tromboembolik komplikasyonlar
say�labilir. PE ve IVIg tedavilerinin kombine edilmesinin tek tek
uygulanmalar�na bir �st�nl��� olmad��� g�sterilmi�tir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>PE ve IVIg uygulanan hastalar�n %3-10�unda tedavi
sonras�ndaki ilk bir iki hafta i�erisinde GBS n�ks� g�r�lebilir (Tedavi ile
ili�kili dalgalanma). Bu durumda genellikle ikinci bir IVIg k�r� uygulan�r (2-5
g�nde 2g/kg). Bu tablonun g�r�ld��� olgular�n akut ba�lang��l� CIDP�lerden
ay�rt edilip uygun tedavi verilmesinde g��l�kle kar��la��labilir. ��ten fazla
yeni k�t�le�me epizodu g�r�len ya da hastal�k ba�lang�c�ndan itibaren 9.
haftadan sonra k�t�le�en olgularda akut ba�lang��l� CIDP�yi d���nmek gerekir.
GBS�nu d���nd�ren akut bir ba�lang�c� oldu�u halde IVIg tedavisine yan�t
vermeyen olgularda da a��r seyirli, tedaviye k�t� yan�tl� GBS�nin yan�s�ra akut
ba�lang��l� CIDP olas�l���n� akla getirmek gerekir. </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>GBS�unda kortikosteroidler
genellikle etkisizdir. IVIg ile kortikosteroidlerin kombine kullan�m� da yaln�z
ba��na IVIg uygulamas�na oranla daha yararl� olmam��t�r. Yak�n zamandaki bir
�al��mada tedaviye eklenen mikofenolat mofetilin de yararl� bir katk�s�
g�sterilememi�tir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;GBS�da prognozu a��rla�t�ran ba�l�ca fakt�rler,
ileri ya�, ba�ka bir ciddi t�bbi hastal�kla birlikte olma, GBS�nun a��r ve
h�zl� seyretmesi, ilk elektrofizyolojik incelemelerde motor kas yan�tlar�n�n
ileri derecede d���k amplit�dl� olmas� ve hastal��a �ncelik eden C. jejuni infeksiyonunun
varl���d�r. Buna kar��l�k, bu a��r prognoz parametrelerinin t�m�n� ta��yan bir
hastan�n bile 6 ay sonra yard�ms�z y�r�yebiliyor olma �ans�, PE ya da IVIg
uygulanmas� halinde, tedavi g�rmeyenlere oranla iki kat fazlad�r (%20 ye kar��
% 40).</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Otoimmun otonomik gangliopati (AAG) olgular�nda yukar�da
anlat�lan immunolojik tedavilerin yan�s�ra antikolinesteraz ila�lar�n
uygulanmas� ile �zellikle ortostatik hipotansiyon tedavisinde ba�ar�n�n artt���
bildirilmi�tir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>GBS li olgular�n izlenmesi ve tedavisi ile ilgili prensiplerin bir �zeti <b>Tablo
23�te</b> verilmi�tir.</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 23. </span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>GBS tedavisi </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>(IR Bella de�i�tirilerek)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=565
 style='width:423.9pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=193 valign=top style='width:144.9pt;border-top:inset 1.0pt;
  border-left:none;border-bottom:inset 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Klinik durum</span></b></p>
  </td>
  <td width=372 valign=top style='width:279.0pt;border-top:inset 1.0pt;
  border-left:none;border-bottom:inset 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>�zleme ve tedavi</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=193 valign=top style='width:144.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�ok hafif GBS</span></p>
  </td>
  <td width=372 valign=top style='width:279.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Hastaneye yat�r�l�r.</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=193 valign=top style='width:144.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yard�ms�z y�r�yor, solunum sorunu yok</span></p>
  </td>
  <td width=372 valign=top style='width:279.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>G�zlenir.</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>PE veya IVIg (uygulanmas� d���n�lebilir).</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=193 valign=top style='width:144.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yard�mla y�r�yor, solunum sorunu yok</span></p>
  </td>
  <td width=372 valign=top style='width:279.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Olanak varsa yo�un bak�m �nitesine al�n�r, yoksa&nbsp;
  VK nin s�k olarak �l��lebilece�i, yo�um bak�m imkanlar�na ula��m�n nisbeten
  kolay oldu�u bir yerde tutulur.</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>AKG izlenir.</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IVIg veya PE (4 de�i�im) uygulan�r. </span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=193 valign=top style='width:144.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Y�r�yemiyor, hafif solunum yetersizli�i var</span></p>
  </td>
  <td width=372 valign=top style='width:279.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yo�un bak�m �nitesine al�n�r.</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>VK s�k olarak izlenir.</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>AKG izlenir.</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�u hallerde intubasyon yap�l�r:</span></p>
  <p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>VK &lt;15 ml/kg, ya da 4-6
  saat i�inde d��me e�ilimi g�steriyor,</span></p>
  <p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Orofaringeal parezi ve
  aspirasyon</span></p>
  <p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Solunum yorgunlu�u bulgular�
  ve VK 15 ml/kg.</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IVIG veya PE (4 de�i�im) uygulan�r.</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp; </span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;mso-yfti-lastrow:yes'>
  <td width=193 valign=top style='width:144.9pt;border:none;border-bottom:inset 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Y�r�yemiyor, solunum yard�m�na gereksinimi var</span></p>
  </td>
  <td width=372 valign=top style='width:279.0pt;border:none;border-bottom:inset 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yo�un bak�m �nitesine al�n�r.</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Otonom sinir sistemi disfonksiyonu izlenir</span></p>
  <p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hipotansiyona kar�� s�v�
  inf�zyonu ile m�cadele edilir.</span></p>
  <p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>S�rekli hipertansiyon
  varsa&nbsp; k�sa etkili <span style='mso-char-type:symbol;mso-symbol-font-family:
  Tahoma'><span style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'>&#61537;</span></span>-adrenerjik
  blokerler uygulanabilir.</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yatak yaralar�na ve kompresyon n�ropatilerine kar�� s�k
  olarak&nbsp; yata��nda �evirilir, pozisyonu de�i�tirilir.</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Fizik tedaviye ba�lan�r.</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IVIg veya PE (4 de�i�im) uygulan�r.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>VK: vital kapasite, AKG: arteriyel kan gazlar�</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kronik Seyirli �nflamatuvar Demiyelinizan Polin�ropatiler</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Kronik �nflamatuvar Demiyelinizan Polin�ropati (CIDP) </span></i></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>GBS�de oldu�u gibi otoimmun mekanizma ile geli�en ve periferik sinirlerde
multifokal demiyelinizasyonla seyreden bir hastal�kt�r. Prevalans� 100.000�de
3-4 aras�ndad�r ve her iki cinste e�it oranda g�r�l�r. Genel olarak,
ekstremitelerin distal ve proksimallerini olduk�a simetrik �ekilde tutan kas
kuvvetsizli�i s�z konusudur. Hastal���n erken evrelerinde kuvvetsizlik distal
kaslara s�n�rl� bulunabilir. GBS�den farkl� olarak, kas kuvvetsizli�i aylar
i�erisinde yava� ve d�zenli, basamakl� ya da remisyon ve alevlenmelerle giden bir
progresyon g�sterir. GBS olgular�n�n hemen t�m� hastal�k ba�lang�c�ndan sonraki
ilk ay i�inde progresyonunu tamamlad��� halde, CIDP tan�s� i�in 2 aydan daha
uzun bir progresyon �yk�s�ne gereksinim vard�r. Hastalar�n b�y�k k�sm� el ve
ayaklarda uyu�malardan, daha az� parestezilerden yak�n�r, a�r� nadirdir. Duyu
kusuru kas kuvvetsizli�ine g�re daha geri planda olmakla birlikte, ekstremite
distallerinde �zellikle vibrasyon ve pozisyon duyusu gibi kal�n miyelinli sinir
liflerini i�aret eden duyular�n azald��� g�r�l�r. Derin duyu kayb�na ba�l�
duyusal ataksi ve pozitif Romberg belirtisi izlenebilir. Tendon refleksleri
olduk�a simetrik olarak azalm�� veya kaybolmu�tur. Hastalar�n %10 kadar�nda
kal�nla�m�� hipertrofik sinirler palpe edilebilir (dirsekte ulnar, bilekte
radial sinir, peroneal sinir, posterior aurik�ler sinir gibi). GBS den farkl�
olarak kranyal ve otonom sinir tutulmalar� seyrek ve hafiftir. Solunum
yetersizli�ine neden olan interkostal kas ve diyafram tutulmas�na da nadir
olarak rastlan�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>CIDP�de en duyarl� laboratuvar y�ntemi BOS incelemesidir. Olgular�n
%90��nda (GBS�de oldu�u gibi) BOS�ta h�cre art��� olmaks�z�n protein y�kselmesi
&nbsp;(<i>albuminositolojik disosiyasyon</i>) mevcuttur. BOS h�cre say�s� 10/mm<sup>3</sup>��n
alt�ndad�r (daha y�ksek h�cre de�erleri HIV infeksiyonu, Lyme hastal��� ya da
sinir k�klerinin l�semik, lenfomat�z infiltrasyonunun ara�t�r�lmas�n�
gerektirir). Elektrofizyolojik testlerde, GBS�de oldu�u gibi, periferik
sinirlerde multifokal demiyelinizasyonu yans�tan bulgular saptan�r. �zellikle
motor iletim incelemelerinde farkl� periferik sinirler ve bu sinirlerin de�i�ik
segmentleri aras�nda farkl�l�k g�steren (�niform olmayan) iletim yava�lamalar�
ve iletim bloklar� g�sterilir. Bununla birlikte, hastalar�n seyrek rastlanan
bir b�l�m�n�n multisegmental demiyelinizasyonun bu tipik �zelliklerini
g�stermedi�ini, bunlar�n klinik �zellikleri ve di�er laboratuvar bulgular� ile
tan�nmas� gerekti�ini hat�rlamak gerekir.&nbsp; </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Sinir biyopsilerinde kronik segmental
demiyelinizasyon-remiyelinizasyona ba�l� de�i�iklikler, miyelinli lif kayb�,
endon�ral ve perin�ral �dem ve hafif derecede perivask�ler iltihabi h�cre
infiltrasyonu g�r�l�r (<b>�ekil 7</b>). Olas� komplikasyonlar�, elde edilen
histopatolojik bulgular�n bir �ok kere CIDP i�in �zg�n olmamas� ve hastalar�n
�o�una klinik ve di�er laboratuvar bulgular� ile tan� konabilmesi nedeniyle
sinir biyopsisine genellikle ba�vurulmaz. MRG incelemelerinde yer yer
geni�lemi�, intensitesi artm�� ve kontrast tutan periferik sinirler ve sinir
k�kleri g�r�lmesi de tan�ya yard�mc� olabilir (<b>�ekil 9</b> ).</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a href="pnp7a.JPG"><b>�ekil
7a.</b></a> CIDP olgusunun sural sinir biyopsisinde miyelinli akson
yo�unlu�unda azalman�n yan�nda �ap�na oranla ince miyelin k�l�f� olan (k�rm�z�
oklar) aksonlar (remiyelinizasyon) ve rejenerasyon oda�� (sar� ok) ve Schwann
h�cre proliferasyonu (siyah ok) g�r�lmekte. (Thioninle boyanm�� enine yar� ince
kesit. X40).</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue;mso-ansi-language:TR'><a
href="pnp7b.JPG">�ekil 7b.</a></span></u></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Bir CIDP olgusunda sinir lifi
ay�rma y�ntemiyle segmental demiyelinizasyon odaklar� (oklar) (Osmium
tetroksit, X10)</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Randomize kontroll� �al��malar CIDP tedavisinde kortikosteroidlerin (GBS
den farkl� olarak), IVIg ve PE�nin etkili oldu�unu g�stermi�tir.&nbsp; Bu
tedavilerden her biri ile hastalar�n %70-80�inde klinik d�zelme elde edilebilir.
Biri ile yan�t al�namayan ya da ba�lang��ta al�nd��� halde daha sonra olumlu
etkinin kayboldu�u hastalarda bir di�eri ile ba�ar�l� tedavi sa�lanabilir.
Olgular�n yakla��k %90��nda ilk aylar i�inde tedaviye olumlu yan�t al�n�r.
Ancak hastal���n tekrarlama e�ilimi �ok y�ksektir ve hastalar�n ancak ��te biri
kadar�nda bir d�nemde tedaviyi tamamen kesmek m�mk�n olur. Bu nedenle ilk
tedavi ile yeterli bir iyilik elde edildikten sonra relapslar� �nleyecek uygun
bir idame tedavisini y�r�tmek gerekir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kortikosteroidler, PE ve IVIg
aras�nda se�im yaparken bu tedavilerin yan etki profilleri (steroidlerde en
y�ksek), hastan�n bu yan etkilere kar�� tolerans� (diyabet ve gastrointestinal
problemleri olanlar i�in steroidlerin, b�brek yetersizli�i olanlar i�in IVIg�in
riskli olmas� gibi), fiyat� (PE ve IVIg pahal�d�r) ve tedavinin
ula��labilirli�i (PE ancak b�y�k t�p merkezlerinde uygulanabilmekte, IVIg zaman
zaman g��l�kle bulunmaktad�r) g�z �n�ne al�nmal�d�r. CIDP tedavisinin en ucuz
se�ene�i olan kortikosteroid uygulamas�na 1-1.5 mg/kg�l�k prednizolon
(eri�kinde 100 mg/g�n�e kadar) dozu ile ba�lan�r. Kuvvetsizli�in d�zelmeye
ba�lamas�yla birlikte g�na��r� tedaviye ge�ilir. Kas kuvvetinde olduk�a sabit
bir iyilik elde edildikten sonra ise doz yava��a azalt�l�r (bir ka� haftada bir
5 mg gibi). G�na��r� 20 mg gibi d���k dozlara var�ld�ktan sonra doz azalt�m�n�n
�ok daha yava� yap�lmas�, t�m tedavi s�ras�nda kronik steroid kullan�m�na ait
komplikasyonlar�n yak�ndan g�zlenmesi ve gerekirse tedavi edilmesi gerekir. A��r
seyirli ve tedaviye dire�li olgularda ya da uzun s�reli steroid kullan�m�n�n
yan etkilerinden ka��nmak amac�yla <i>pulse</i> kortikosteroid uygulamalar� da
yap�labilmektedir.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>IVIg, CIDP�nin bir di�er
standard tedavi y�ntemi haline gelmi� ve etkinli�i son 15 y�lda tamamlanan 8
randomize kontroll� �al��ma ile g�sterilmi�tir. Genellikle GBS�de oldu�u gibi 5
(veya 2) g�nde tamamlanan toplam 2g/kg�lik ilk k�rle ba�lan�r. Sonraki tedavi
s�reci ayn� dozun 1-1.5 ayda bir tekrarlanmas� ya da daha d���k dozlar�n
(0.4g/kg gibi) daha s�k aral�klarla verilmesi (haftada 1-2 kez) ile s�rd�r�l�r.
Zaman ge�tik�e daha d���k dozlar�n daha geni� aral�klarla verilmesi ama�lan�r.
Haftada bir gibi �ok s�k aral�kl� tedaviye ba��ml� hale gelen ya da aylar ve
y�llar ge�tik�e IVIg tedavisine refrakter hale gelen olgular vard�r. Bu ikinci
grup hastalarda arada uygulanacak PE tedavisi hastay� tekrar IVIg�e yan�t verir
hale getirebilir. PE ayn� zamanda h�zla k�t�le�en ve �abuk yan�t al�nmas�
istenilen durumlarda yararl� bir tedavi se�ene�idir. CIDP�nin kronik seyri
nedeniyle GBS�na g�re daha seyrek de�i�imler �eklinde uygulan�r. Yeni
geli�tirilmekte olan subkutan yolla uygulanabilir immunglobulin preperatlar�
gelecekte tedaviyi kolayla�t�rma ve maliyetini azaltma olas�l��� a��s�ndan umut
vermektedir.&nbsp; </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kortikosteroid ve IVIG�e cevap
al�namayan ya da yan etkiler nedeniyle bu tedavilerin uygulanamad��� olgularda
tedaviye sitostatik ila�lar eklenebilir (azatiopirin, metotreksat,
siklofosfamid, siklosporin). Mikofenolat mofetilin toksisitesi daha az olmakla
birlikte bu ila�la tamamlanm�� kontroll� �al��ma mevcut de�ildir.
�nterferon-beta uygulamas�n�n CIDP olgular�nda yararl� oldu�una ili�kin, ba�ka
�al��malarla netle�tirilmesi gereken bulgular yay�nlanm��t�r. Gelecekte
yap�lacak kontroll� �al��malarda rituksimab ve benzeri ila�larla ba�ar�l�
sonu�lar al�naca�� umulmaktad�r. Az say�da olguda takrolimus, etanersept gibi
ila�lar denenmi�tir. Otolog k�k h�cre transplantasyonu uygulanarak ba�ar�l�
�ekilde tedavi edilmi� olgular bildirilmi� olmakla birlikte, mortalitesi y�ksek
olan bu tedavinin etkisi ve uygulanabilece�i �zel gruplar�n�n ileri
�al��malarla belirlenmesi gerekmektedir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>CIDP ile birlikte olan hastal�klar</span></i></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>CIDP�nin klinik ve elektrofizyolojik �zelliklerini
g�steren polin�ropati tablolar� baz� sistemik hastal�klar ve di�er t�bbi
durumlarla birlikte olabilir. Bunlar�n ba�l�calar�, HIV infeksiyonu, iltihabi
barsak hastal���, sistemik lupus eritematozus, diyabetes mellitus, kemik ili�i
ve organ transplantasyonu (doku reddi ve �graft versus host disease�&nbsp;
durumlar�nda) ve lenfomalard�r. Bu hastal�k durumlar� ile birlikte olan ve
olmayan CIDP formlar� aras�nda olu�um mekanizmalar� ve seyir �zellikleri
a��s�ndan temel farkl�l�klar olup olmad��� iyi bilinmemektedir. �rne�in
diyabetik hastalarda geli�ebilen ve klinik, elektrofizyolojik �zellikler
a��s�ndan CIDP�ye �ok benzeyen polin�ropati tablosunun CIDP mi yoksa bir
diyabetik polin�ropati formu mu oldu�u konusu iyi bilinmemektedir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>CIDP�li olgular�n bir k�sm�n�n kan�nda bir monoklonal
protein (<i>M-proteini</i>) saptan�r, &nbsp;(t�m CIDP olgular�nda
immunofiksasyon elektroforezi ile monoklonal protein ara�t�r�lmal�d�r).
CIDP�nin tipik klinik ve laboratuvar bulgular� ile seyreden olgularda bu
M-proteini genellikle IgG veya IgA grubundand�r. Monoklonal protein saptanan
olgular�n bir k�sm�nda plazmositoma ya da lenfoma gibi lenfoproliferatif&nbsp;
bir hastal�k bulunur. Yap�lacak ara�t�rmalarla bu hastal�klar�n saptand���
durumlarda her biri i�in uygun olan tedavi uygulan�r.&nbsp; Bu hastal�klar�n
bulunmad��� M-proteini pozitif durumlar <i>anlam� belirsiz monoklonal gamopati</i>
<i>(MGUS)</i> olarak isimlendirilir (a�a��ya bak�n�z). MGUS�la birlikte olan
CIDP, M-proteini negatif CIDP�lerden klinik seyir ve tedaviye yan�t a��s�ndan
belirgin bir farkl�l�k g�stermez. MGUS�la birlikte olsun olmas�n, CIDP
olgular�n�n uzun s�reli takipleri s�ras�nda lenfoproliferatif bir hastal�k
geli�ebilir. Bu nedenle, �zellikle ba�lang��ta tedaviye yan�t verip sonradan
vermez olan hastalar, tedaviye yan�ts�z kronik progressif seyir izleyenler ve
MGUS�la birlikte olan t�m CIDP olgular�nda immunolojik durum aral�kl� olarak
yeniden de�erlendirilmeli ve kemik grafileri yap�lmal�d�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Lenfoproliferatif hastal�klar�n yan�s�ra k���k h�creli
akci�er karsinomu, pankreas, kolon kanserleri, kolanjiokarsinom ve melanomun
paraneoplastik komplikasyonu olarak geli�en CIDP olgular� yay�nlanm��t�r.
Prokainamid, siklosporin ve takrolimus gibi ila�lar�n toksik etkisi ile geli�en
CIDP�ye benzer n�ropatiler de bildirilmi�tir.</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Multifokal Motor N�ropati (MMN)</span></i></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Ekstremitelerde asimetrik kuvvetsizli�e neden olan otoimmun k�kenli bir
polin�ropatidir. CIDP�nin bir formu olup olmad��� konusu uzun s�re tart���lm��
olan bu n�ropati, art�k daha �ok ayr� bir hastal�k antitesi olarak ele
al�nmaktad�r. S�kl�kla �st, nadiren alt ekstremite distalinde asimetrik
kuvvetsizlikle ba�lar. Hasta hekime el kaslar�nda kuvvetsizlik, d���k el veya
d���k ayak gibi nedenlerle ba�vurur. Kas kuvvetsizli�i, belirli bir veya bir
ka� periferik sinirin innervasyon alan�na lokalize edilebilen bir da��l�m
g�sterir. Kuvvetsizli�in varl���na kar��n atrofi yoktur ya da ilerlemi�
olgularda g�r�l�r. Kaslarda kramp ve fasik�lasyonlar g�r�lebilir. Bunlar�n
yo�un oldu�u b�lgelerde n�rojenik kas hipertrofisi g�zlenebilir (<b>�ekil 8</b>)
Duyu kusu yoktur ya da �ok hafif derecededir. Tendon refleksleri korunmu�tur,
fakat zay�f ve atrofik ekstremitelerde azalm�� bulunabilir. Hastal�k aylar ve
y�llar i�inde yava� bir progresyonla ayn� ekstremitedeki di�er sinirlere ya da
di�er ekstremitelere do�ru yay�l�r. Yava� ve sinsi progresyonu y�z�nden
ba�lang�c�ndan tan�ya kadar ge�en s�re genellikle uzundur.</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:35.4pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue;mso-ansi-language:TR'><a
href="pnp8.JPG">�ekil 8.</a></span></u></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Sol el ba�parma��n�n
adduksiyon-opozisyonu �eklinde kas�lmalardan yak�nan MMN olgusunda sol tenar
kaslar�n hipertrofisi.</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue;mso-ansi-language:TR'><a
href="pnp9.jpg">�ekil 9.</a></span></u></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> MADSAM olgusunun koronal planda T2
a��rl�kl� MR kesitlerinde iki yanl� kal�nla�m�� ve hiperintens g�r�n�ml�
servikal sinir k�kleri ve brakial pleksuslar� (Dr. Fikret Aysal��n izniyle).</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>BOS genellikle normaldir. Elektrofizyolojik incelemelerde motor sinirler
�zerinde iletim bloklar�n�n ve multifokal demiyelinizasyonu g�steren di�er
bulgular�n saptanmas� tan�ya �ok yard�mc� olur. Hastalar�n %40-80�inin
serumlar�nda IgM grubundan anti-GM1, asialo GM1 veya GD1a gangliozid
antikorlar� saptan�r. Bu antikorlar�n y�ksek titrede pozitif olmas�&nbsp;MMN
i�in olduk�a spesifiktir. Fakat bu y�ntemin duyarl�l��� azd�r ve d���k titrede
anti-GM1 antikorlar di�er baz� otoimmun k�kenli n�ropatilerde de g�r�lebilir.
Bu nedenle, antigangliozid antikorlar�n aranmas�n�n tan�ya elektrofizyolojik
test verilerine ek bir katk� sa�lama olas�l��� d���kt�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>MMN�nin ay�r�c� tan� a��s�ndan �nemli bir �zelli�i amiyotrofik lataral
sklerozla (ALS) benzerlik g�stermesidir (Bak�n�z: <a
href="http://www.itfnoroloji.org/ozdemir/motornoron.htm">Motor N�ron
Hastal�klar�</a>). G�n�m�zde birisi tedavi edilebilen di�eri edilemeyen bu iki hastal���n
birbirinden ay�rd edilmesi, MMN�nin ALS�a oranla �ok daha seyrek oranda
g�r�lmesine kar��n �nemlidir (b�y�k t�p merkezlerinde ALS/MMN rastlanma s�kl���
50/1). MMN�de s�kl�kla �st ekstremitelerde asimetrik ba�layan kas kuvvetsizli�i
ve fasik�lasyonlar g�r�lmesi, duyu kusurunun olmamas� ALS�a benzerlik g�sterir.
Kas kuvvetsizli�inin ALS�deki gibi �n boynuz ya da radiks segmentlerine de�il,
periferik sinirlere uygun bir da��l�m g�stermesi, kas atrofisi bulunmamas� ya
da ALS�a oranla hafif olmas� MMN tan�s� y�n�ndeki klinik bulgulard�r. Tendon
reflekslerinde belirgin canl�l�k, klonus ve patolojik reflekslerin varl���,
bulber kaslar�n tutulmas� ALS�u d���nd�r�r. Yine de MMN ve ALS�un progressif
alt motor n�ron tutulmas� ile giden formunun klinik planda ayr�lmas� bazen �ok
g�� olabilir. Bu durumda motor iletim incelemelerinde sinir trunkuslar�
�zerinde iletim bloklar�n�n g�sterilmesi MMN tan�s�na ula��lmas�n� sa�lar.
Ancak, bazen ALS�li hastalarda da yalanc� iletim bloklar�na rastlanabilece�i
hat�rlanmal� ve elektrofizyolojik inceleme tekni�i a��s�ndan dikkatli
olunmal�d�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CIDP�den fakl� olarak, MMN
kortikosteroid ve PE tedavisine yan�t vermez. MMN�de etkilili�i g�sterilmi� ilk
ila� intraven�z siklofosfamiddir. �lk klinik serilerde 8 g�n i�erisinde verilen
3 g/m<sup>2</sup> lik ilk doz ve onu izleyen ayl�k 0.5-1 g/m<sup>2</sup>
intraven�z (veya 2 mg/kg oral) k�rlerle %70 olguda klinik iyilik sa�lanm��t�r.
Bu dozlarda yan etkilerin �ok fazla olmas� nedeniyle halen IVIg�e yan�t
vermeyen hastalar i�in 0.5-1 g/m<sup>2</sup> lik ba�lang�� dozu �nerilmekte,
idame dozunun yan etkilere ve hastan�n tolerans�na g�re ayarlanmas� tavsiye
edilmektedir. Alopesi, bulant�, kusma, hemorajik sistit ve �iddetli kemik ili�i
depresyonu tedbir al�nmas� gereken ba�l�ca yan etkilerdir. Siklofosfamid,
say�lan yan etkilerine ek olarak&nbsp; uzun vadede t�m�r geli�imi ile ili�kili
bulundu�undan, �o�u olduk�a gen� ya�ta olan ve uzun s�re tedavi edilmesi
gereken MMN�li hastalarda -IVIg�e yan�ts�z olanlar d���nda- g�n�m�zde
kullan�lmamaktad�r.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>G�n�m�zde MMN tedavisi i�in ilk
tercih edilen IVIg�dir. CIDP de anlat�ld��� �ekilde uygulanan IVIg tedavisine
hastalar�n �o�unda (%80) g�nler ya da haftalar i�inde iyi yan�t al�n�r. Ya�l�
ve belirgin atrofisi olan hastalar�n tedaviye yan�tlar� daha k�t�d�r. Tedaviye
yan�t vermeyen olgular�n yan�s�ra,&nbsp; s�rd�r�len IVIg uygulamas�na bir
derece yan�t veren ancak yava� �ekilde progresyon g�steren olgular da vard�r
(iletim bloklar�n�n ya da akson hasar�n�n s�regelmesi). Genellikle hastal���n
tekrarlamas�n� engellemek i�in aral�kl� IVIg uygulamalar� gerekir (CIDP
konusuna bak�n�z). MMN olgular�n�n CIDP�e oranla daha d���k dozda fakat daha
s�k uygulanan tedaviden yararland���na dair g�zlemler mevcuttur. Rituksimab
tedavisi ile olumlu sonu� bildiren �al��malar yay�nlanm��t�r. &nbsp;Siklosporin,
metotreksat, azatiopirin ve interferon beta-1a ile klinik durumu stabilize olan
az say�da olgu da bildirilmi�tir. </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Paraproteinemik N�ropatiler</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Nedeni bilinmeyen kronik
seyirli bir polin�ropatisi olan hastalarda monoklonal proteinlerin (<i>M
proteini</i>) varl��� ara�t�r�lmal�d�r. �dyopatik polin�ropatisi olan
hastalar�n yakla��k %10�unda bir monoklonal gamopati vard�r. Bir hastada M
proteinlerinin varl���n�n g�sterilmesi, primer amiloidoz, multipl miyelom,
lenfoma, osteosklerotik miyelom, Waldenstr�m makroglobulinemisi,
kriyoglobulinemi ve di�er lenfoproliferatif hastal�klar�n ara�t�r�lmas�n�
gerektirir. Ancak M proteini saptanan hastalar�n 2/3 kadar�nda altta yatan bir
hastal�k bulunamaz ve bu tablo <i>anlam� belirsiz monoklonal gamopati (MGUS;</i>
<i>monoclonal gammopathy of undetermined significance) </i>olarak
isimlendirilir. Bu ismin verilmesinin sebebi, bir k�s�m MGUS�lu hastan�n uzun
s�reli takiplerinde multipl miyelom ba�ta olmak �zere habis plazma h�cresi
diskrazilerinin ortaya ��kmas�d�r (10 y�l sonra yakla��k %20, 20 y�l sonra 1/3
�nde). M proteini bulunan hastalarda polin�ropatinin nas�l olu�tu�u kesin
olarak anla��lamamakla birlikte, baz� M proteinlerinin miyelin ve aksolemman�n
baz� komponentlerine kar�� antikor �zelli�i g�sterdi�i bilinmektedir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Rutin serum protein elektroforezi k���k miktardaki M proteinlerini
belirlemede genellikle yetersiz kal�r. �mm�n elektroforez veya tercihen
immunofiksasyonla M proteinleri saptan�r, a��r ve hafif zincir tipleri
belirlenir. �drar protein elektroforezi multipl miyelom ve primer amiloidozla
birlikte olan hafif zincir gamopatilerinin g�sterilmesini sa�layabilir. M
proteini ve n�ropatisi olan t�m hastalarda Bence-Jones protein�risi
ara�t�r�lmal�, immunglobulinler kantititif olarak incelenmeli, litik ya da
sklerotik kemik lezyonlar�n� ara�t�rmak amac�yla radyografiler yap�lmal�d�r.
Habis plazma h�cresi diskrazileri ile MGUS�un ay�rd edilmesi i�in kemik ili�i
aspirasyon ya da biyopsisi gerekebilir.</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Anlam� Belirsiz Monoklonal Gamopati (MGUS)</span></i></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�leri ya�taki ki�iler aras�nda MGUS prevalans� olduk�a
y�ksektir (50 ya��n �st�nde %1, 70 ya��n �st�nde %3). MGUS saptanan hastalar�n
%30-70�inde polin�ropati bulunur.&nbsp; Polin�ropatisi olan hastalar aras�nda
paraproteini IgM grubundan olanlar daha y�ksek orandad�r. MGUS n�ropatisi
genellikle orta ve ileri ya�taki hastalarda g�r�len, sinsi ba�lang��l�, aylar
ve y�llar i�inde yava� progresyon g�steren bir polin�ropatidir. Klinik tablo
s�kl�kla distal ve simetrik duyusal-motor bir polin�ropati �eklindedir. Daha
nadir olarak klinik ve laboratuvar bulgular� CIDP�ye benzeyen bir
poliradik�lon�ropati g�r�l�r. Elektrofizyolojik incelemelerde demiyelinizan ya
da kar���k aksonal ve demiyelinizan polin�ropatiyle uyumlu bulgular elde
edilir.&nbsp; Paraproteini IgM grubundan olan hastalarda daha belirgin duyu
kayb� ve duyusal ataksi ile elektrofizyolojik incelemelerde motor distal
latanslarda �ok belirgin uzama g�zlenebilir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>IgM MGUS�u olan hastalar�n en az yar�s�nda monoklonal
protein, baz� periferik sinir glikoproteinlerinin&nbsp; (miyelinle birlikte
olan glikoprotein=MAG, P<sub>0</sub>) bir karbonhidrat epitopu ile reaksiyon
g�sterir. Bu antikor benzeri aktivite, paraproteinemik n�ropatilerin otoimmun
hastal�klarda g�r�len mekanizmalarla ortaya ��kt���n� d���nd�rmektedir. MAG�a
kar�� antikor aktivitesi ELISA veya Western blot y�ntemi ile g�sterilebilir ya
da sinir dokusunda immunohistokimyasal y�ntemlerle ortaya konabilir. Elektron
mikroskopisinde miyelin lamellerinin aralar�n�n geni�lemi� g�r�n�m� (myelin
splitting) anti-MAG n�ropatileri i�in karakteristiktir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>N�rolojik bulgular� hafif ve hastal�k progresyonu yava�
olan olgular tedavi verilmeden periyodik kontrollerle izlenebilir. Progressif
n�rolojik defisiti olan hastalardan CIDP�ye benzer klinik ve ve
elektrofizyolojik bulgular� olanlar immunomod�lat�r tedavilere iyi yan�t
verirler. Bu hastalarda plazmaferez, IVIg veya&nbsp; prednizolon tedavileri
(bazen bir sitostatik ila�la birlikte olmak �zere) uygulan�r. IgM MGUS
olgular�nda �e�itli immunoterapi y�ntemlerine genel olarak IgG ve IgA MGUS�lu
hastalara oranla daha g�� yan�t al�n�r. </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Primer Sistemik Amiloidoz</span></i></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Primer amiloidozda amiloid hafif zincirleri (amyloid
light chain: AL) dokularda birikir. AL amiloidozu&nbsp; multipl miyelom ve
Waldenstr�m makroglobulinemisinde de g�r�l�r. Ya�l�larda ve erkeklerde daha s�k
rastlanan primer sistemik amiloidozda, hastalar�n yakla��k 1/5 inde uzunlu�a
ba��ml� distal aksonal dejenerasyonla seyreden bir polin�ropati geli�ir. Sinir
dokusunda amiloid ba�l�ca endon�ral k���k damarlar�n etraf�nda bir k�l�f
halinde birikir. Bu g�r�n�m amiloidozdaki sinir hasar�n�n hipoksiye ba�l�
olarak geli�ti�ini d���nd�r�r. Sinsi ba�lang��l� ve yava� progressif seyirli
polin�ropatide klinik tabloya ekstremite distallerinde a�r�lar, a�r� ve �s�
duyusunda bask�n hipoestezi ve otonom belirtiler hakimdir. Hastalar�n&nbsp;yakla��k
%25 inde fleksor retinakulumda amiloid birikimine ba�l� karpal t�nel sendromu
vard�r. </span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Olgular�n %90 kadar�n�n serum veya idrar immunofiksasyon
elektroforezinde monoklonal protein veya hafif zincirler (s�kl�kla <span
style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'><span
style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'>&#61548;</span></span>)
saptan�r. Tan�, dokularda amiloid birikiminin histopatolojik olarak
g�sterilmesi ile konur. Bu ama�la yap�lan abdominal ya� aspirasyonu, rektal
biyopsi ya da kemik ili�i aspirasyonu olgular�n %80 inde pozitiftir. Kombine
sinir ve kas biyopsisinde hastalar�n %90��nda amiloid birikimi saptan�r. Sinir
dokusunda amiloid birikimi bulunan fakat plazma h�cre diskrazisini g�sterecek
veri elde edilemeyen hastalar familyal amiloid n�ropatiler y�n�nden de
ara�t�r�lmal�d�r (Bak�n�z: Herediter Polin�ropatiler). Kalp ve b�brek tutulumu
olan hastalarda prognoz k�t�d�r (median sa�kal�m s�resi 6-7 ay). &nbsp;Organ
tutulmalar� olmayan amiloid n�ropatisi olgular�nda daha iyi prognoz (median
sa�kal�m s�resi 40 ay) vard�r. Aral�kl� oral melfalan ve prednizon tedavisi,
renal ve kardiyak amiloidozun progresyonunu&nbsp;yava�lat�r, fakat n�ropatinin
seyrini etkilemez. Otolog k�k h�cresi deste�i ile y�ksek doz IV melfalan
uygulamas�n�n se�ilmi� az say�daki hastan�n n�rolojik bulgular�nda d�zelme
sa�lad��� bildirilmi�tir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Multipl Miyelom</span></i></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Multipl miyelomda vertebra miyelomuna ba�l� omurilik ya
da sinir k�k� bas�lar� s�kt�r. Olgular�n %5 kadar�nda polin�ropati g�r�l�r.
Bunlar�n b�y�k k�sm� da multipl miyelom seyrinde geli�en AL amiloidoza ba�l�
oldu�undan ger�ekten bu hastal��a ba�l� polin�ropatiler nadirdir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Osteosklerotik
Miyelom:</span></i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> Miyelomlar aras�nda %2 oran�nda g�r�len osteosklerotik
miyelomlarda periferik n�ropati geli�me oran� %85 tir. Bu hastal�kta plazma
h�cresi proliferasyonu, sklerotik kemik lezyonlar� �eklinde kendini g�steren
tek veya multipl plazmositomlar �eklindedir. Multipl miyelomdan farkl� olarak
hastalar daha gen� ya�tad�r ve �o�u erkektir. Polin�ropati klinik ve
laboratuvar �zellikleriyle CIDP�ye benzer <i>(CIDP tablosu nedeniyle incelenen
t�m eri�kin hastalarda M proteini ve kemik lezyonlar� ara�t�r�lmal�d�r). </i>&nbsp;Motor
belirtileri bask�n, simetrik proksimal ve distal kas zaaf�yla seyreden edinsel
demiyelinizan bir polin�ropati tablosu g�r�l�r.&nbsp; BOS�ta protein miktar�
y�ksektir&nbsp;(genellikle &gt;100 mg/dl). Olgular�n %90��nda M proteini
bulunur (genellikle <span style='mso-char-type:symbol;mso-symbol-font-family:
Tahoma'><span style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'>&#61548;</span></span>
hafif zinciri ve IgG, IgA a��r zincirlerinden olu�ur). Hastalar�n �o�unda POEMS
(Crow-Fukase) sendromunun multisistem belirtilerinden bir veya birka�� vard�r <span
style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'><span
style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'>&#61531;</span></span><b>POEMS</b>=
<b>P</b>olin�ropati, <b>O</b>rganomegali, <b>E</b>ndokrinopati, <b>M</b>
proteini, Deri (<b>S</b>kin) de�i�iklikleri<span style='mso-char-type:symbol;
mso-symbol-font-family:Tahoma'><span style='mso-char-type:symbol;mso-symbol-font-family:
Tahoma'>&#61533;</span></span>. Ba�l�ca deride hiperpigmentasyon (<b>�ekil 10a
ve 10b</b>), hepatomegali, jinekomasti, testik�ler atrofi ve parmaklarda
�omakla�ma ile diyabet ve hipotiroidizm g�r�l�r. POEMS sendromunun
belirtilerinin neoplastik plazma h�crelerinin vask�ler endotelyal b�y�me
fakt�r� (VEGF) isimli sitokini a��r� miktarda �retmelerinden kaynakland���
d���n�lmektedir. &nbsp;Hastalar�n �o�unun serumunda �ok y�ksek d�zeyde VEGF
bulunur ve bu �zelli�in bir tan� testi olarak kullan�lmas� m�mk�nd�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Radyografilerde �zellikle vertebra, pelvis ve kaburga
kemiklerinde sklerotik veya kar���k litik-sklerotik lezyonlar g�r�l�r. Bu
lezyonlar�n ortaya konabilmesi i�in bazen direkt radyografiler yeterli olmaz,
��phe edilen b�lgelerde kemik dokusunun bilgisayarl� tomografi gibi daha ileri
bir g�r�nt�leme y�ntemiyle incelenmesi gerekebilir (<b>�ekil 10c</b>). �zole
plazmositomun varl���n� kan�tlamak i�in genellikle a��k biyopsi yap�lmas�
gerekir. Tek lezyonu olan hastalarda bu lezyonun total olarak ��kar�lmas� ya da
t�m�risidal irradyasyonu hastalar�n klinik bulgular�nda dramatik d�zelme
sa�layabilir. Multipl lezyonu olan hastalara kombine melfalan ve prednizolon
tedavisi uygulan�r. Yeni bir �al��mada otolog periferik kan k�k h�cresi
transplantasyonundan belirgin �ekilde yararlanan olgular bildirilmi�tir.</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><a href="pnp10a.jpg"><b><span style='font-size:
10.0pt'>�ekil 10a.</span></b></a></span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> POEMS sendromlu olgunun avu� i�inde
hiperpigmente lekeler.</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><a href="pnp10b.jpg"><b><span style='font-size:
10.0pt'>�ekil 10b.</span></b></a></span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Benzer lekelerin ayak taban�ndaki
g�r�n�m�.</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><a href="pnp10c.jpg"><b><span style='font-size:
10.0pt'>�ekil 10c.</span></b></a></span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Ayn� hastan�n pelvis bilgisayarl�
tomografisinde sa� ilyak kanatta litik-sklerotik lezyon g�r�lmekte.</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span class=msons><b><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR;text-decoration:none;text-underline:none'><span
class=msoIns><ins cite="mailto:Ihtiyar%20Balikci" datetime="2009-07-12T15:03">&nbsp;</ins></span></span></i></b></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Kronik Edinsel Demiyelinizan N�ropatilerin Klinik Olarak&nbsp;S�n�flanmas�</span></i></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Son y�llarda kronik seyirli edinsel demiyelinizan n�ropatilerde klinik
tan�y� ve tedavi yakla��mlar�n� kolayla�t�ran bir s�n�flama �ekli ileri
s�r�lm��t�r (<b>�ekil 11, Tablo 24</b>). Buna g�re CIDP tan�m�, bu hastal���n
simetrik proksimal ve distal kas kuvvetsizli�i ile seyreden klasik formu i�in
kullan�lmal�d�r. CIDP grubuna giren hastalar immun mod�latuvar tedavilere,
e�lik eden bir monoklonal gamopati olsun veya olmas�n iyi yan�t verirler. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Di�er bir grupta �n planda distal yerle�imli, duyusal bask�n belirti ve
bulgularla seyreden hastalar yer al�r. Klinik planda aksonal tipte uzunlu�a
ba��ml� bir n�ropatiyi d���nd�ren bu bulgulara kar��n elektrofizyolojik
incelemeler demiyelinizan bir polin�ropati ile uyumludur. Bu grup <i>distal
edinsel demiyelinizan simetrik n�ropati</i> (<b><i>d</i></b><i>istal <b>a</b>cquired
<b>d</b>emyelinating <b>s</b>ymmetric</i>=<i>DADS</i>) olarak isimlendirilir.
DADS fenotipli hastalar�n yakla��k 2/3��nde, hemen daima kappa hafif zinciri
olan bir IgM paraprotein vard�r. <i>DADS-M</i> ad� verilen bu grubun %80�den
fazlas�n� 6. dekad�n �zerindeki erkek hastalar olu�turur. Akademik merkezlerde
DADS-M olgular�n�n s�kl��� CIDP olgular�n�nki kadard�r. Olgular�n %70�inden
fazlas�nda anti-MAG antikorlar bulunur. Baz� olgularda sulfatidler, sadece SGPG
veya GD1b�ye kar�� antikorlar da saptan�r. N�ropatinin bu antikorlar�n miyeline
ba�lanmas� nedeniyle ortaya ��kt��� d���n�lmektedir. DADS-M�deki gamopati,
�er�evesi ve nedeni bilinen, lenfoproliferatif bir hastal��a d�n��me olas�l���
d���k bir gamopati oldu�undan MGUS olarak s�n�fland�r�lmaz. Hastalar�n ba�l�ca
yak�nmas� ekstremite distallerinde duyu bozuklu�u, dengesizlik ve ellerdeki
tremordur. Vibrasyon duyusu a�r� ve �s� duyular�na oranla daha bask�n �ekilde
bozulmu�tur.&nbsp; Hastalar�n ba�l�ca duyusal yak�nmalar� olmas�na kar��n,
motor sinir iletim incelemelerinde genellikle yayg�n ve olduk�a homojen bir
iletim yava�lamas� bulunur, iletim bloklar� nadirdir. Buna kar��l�k motor
distal latanslar daha proksimal segmetlerdeki yava�lamay� da a�an oranda,
belirgin derecede uzundur (Terminal latans indeksi &lt;0.25). Sinir biyopsisine
nadiren ba�vurulmakla birlikte, histopatolojik olarak miyelin intraperiod
�izgilerinde geni�leme g�sterilmesi bu hastal�k i�in olduk�a tipiktir.
Olgular�n immunmod�latuvar tedaviden yararlanma oranlar� �ok d���kt�r. IVIg ve
PE, kortikoteroidler ve sitostatik ila�lar, </span><span lang=TR
style='font-family:Symbol;mso-ansi-language:TR'>a</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>-interferon ve rituksimabdan bir
derece yararlanan hasta gruplar� bildirilmi�tir. Bununla birlikte hastal���n
seyri �ok yava�t�r ve genellikle belirgin bir sakatl��a yol a�maz. �yi gidi�li
olgular� immunmod�latuvar tedavi vermeden, sadece yak�nmalar�na y�nelik
semptomatik tedaviler uygulayarak izlemenin yarar� kan�tlanmam�� ve yan etkisi
y�ksek ila� uygulamalar�na oranla daha uygun oldu�u d���n�lmektedir. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>DADS fenotipli olgular�n IgM paraproteinemisi olmayanlar� <i>DADS-I</i> (<b>i</b>dyopatik)
ismi alt�nda grupland�r�l�r. Bu grup olduk�a heterojendir ve olgular�n bir
k�sm� immunmod�latuvar tedavilere olduk�a iyi yan�t verir.&nbsp; Bu grup
�duyusal CIDP� olarak adland�r�lm�� olan edinsel demiyelinizan polin�ropatiye
benzemekle birlikte, DADS fenotipi i�in uzunlu�a ba��ml� paternde distal
simetrik duyusal belirti ve bulgular aran�rken, duyusal CIDP olgular�nda
genellikle daha geni�-yayg�n duyu kayb� bulunur. Duyusal CIDP�li hastalar�n
elektrofizyolojik incelemelerinde daha belirgin motor iletim yava�lamalar� ve
iletim bloklar� saptan�r ve tedaviye daha iyi yan�t al�n�r. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Kronik seyirli edinsel demiyelinizan polin�ropatilerin fokal-multifokal
klinik belirti ve bulgularla seyredenleri ise <i>multifokal motor n�ropati</i>
(MMN, yukar�da anlat�ld�) ve <i>multifokal edinsel demiyelinizan duyusal ve
motor</i> (<b>m</b>ultifocal <b>a</b>cquired <b>d</b>emyelinating <b>s</b>ensory
and <b>m</b>otor=MADSAM, Lewis-Sumner sendromu) n�ropatidir. MADSAM, MMN gibi
daha �ok bir veya bir ka� periferik sinirin da��l�m�na uyan multifokal ve yava�
progressif bir seyir izler. Ancak, motor belirtilere duyusal belirti ve bulgular
e�lik eder. MMN�den farkl� olarak genellikle BOS proteini y�ksektir, duyusal
sinir iletim incelemelerinde patolojik bulgular elde edilir ve GM1
antigangliozid antikor pozitifli�i yoktur. Kortikosteroid ve IVIg tedavisine
yan�t yakla��k ayn� d�zeyde ve olduk�a iyidir (%70 kadar). </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Klinik �zellikleri multifokal motor n�ropati ile uyumlu olan, buna kar��l�k
elektrofizyolojik incelemelerinde segmental demiyelinizasyon �zelliklerinin
saptanmay�p sadece aksonal tutulma bulgular�n�n g�r�ld���, bir k�sm� immunomod�latuvar
tedaviye yan�t veren nadir olgular da bildirilmi�tir (<i>multifokal edinsel
motor aksonopati</i>, MAMA). B�yle �zellikleri olan hastalar�n bilinmesi,
tedaviye yan�tl� olabilecek az say�daki olgunun tan�nmas�n� sa�lamakla
birlikte, yan�t vermeyecek bir �ok hastada gereksiz, pahal� ve bazen zararl�
olabilecek tedavi giri�imlerine yol a�ma ihtimalini ortaya ��karmaktad�r. Bu
nedenle, immun k�kenli oldu�undan ku�kulan�lan fakat tan�sal s�n�flama
a��s�ndan teredd�de d���len olgular i�in polin�ropati tan� ve tedavisinde
tecr�be kazanm�� merkezlere dan��maya �al���lmal�d�r.</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<b><u><span
style='color:blue'><a href="pnp11.jpg">�ekil 11.</a> </span></u></b>Kronik
seyirli edinsel demiyelinizan n�ropatiler (DS Saperstein)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tablo 24.</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Edinsel demiyelinizan n�ropatiler (JS
Katz)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=642
 style='width:481.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=138 valign=top style='width:103.2pt;border:solid windowtext 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>CIDP </span></b></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>DADS-M</span></b></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>DADS-I</span></b></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>MADSAM</span></b></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>MMN</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=642 colspan=6 valign=top style='width:481.5pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Klinik �zellikler</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=138 valign=top style='width:103.2pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kuvvetsizlik</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Simetrik&nbsp; proksimal+distal</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Distal veya yok</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Distal veya yok</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Asimetrik </span></p>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Distal&gt;proksimal</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�st &gt;alt ekstremite</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Asimetrik </span></p>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Distal&gt;proksimal</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�st &gt;alt ekstremite</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=138 valign=top style='width:103.2pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Duyu kayb�</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Simetrik</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Simetrik</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Simetrik</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Multifokal</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yok</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=138 valign=top style='width:103.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Refleks kayb�</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Simetrik</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Simetrik</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Simetrik</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Multifokal veya yayg�n</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Multifokal veya yayg�n</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=642 colspan=6 valign=top style='width:481.5pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Elektrofizyoloji</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=138 valign=top style='width:103.2pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Anormal BKAP</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=138 valign=top style='width:103.2pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp; Yava�lama</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Simetrik</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Simetrik</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Simetrik</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Multifokal</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Multifokal</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=138 valign=top style='width:103.2pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp; Uzun distal latans</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Bazen</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Daima</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Bazen</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Bazen</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Bazen</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=138 valign=top style='width:103.2pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp; �letim blo�u</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>S�k</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Mutad</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Nadir</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>S�k</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>S�k</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=138 valign=top style='width:103.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Anormal DAP</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Genellikle simetrik</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Daima simetrik</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Genellikle simetrik</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>S�k, m�ltimultifokal</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Normal</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td width=642 colspan=6 valign=top style='width:481.5pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Laboratuvar</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12'>
  <td width=138 valign=top style='width:103.2pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Artm�� BOS Proteini</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Genellikle</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Genellikle</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Bazen</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Genellikle</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Normal</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13'>
  <td width=138 valign=top style='width:103.2pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Monoklonal protein</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>%20, genellikle IgG veya IgA</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>LPH&nbsp; a��s�ndan de�erlendirilmeli</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IgM-</span><span lang=TR style='font-size:9.0pt;
  font-family:Symbol;mso-ansi-language:TR'>k</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Tan�m gere�i</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>%20, IgG veya IgA</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>LPH&nbsp; a��s�ndan de�erlendirilmeli</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Nadir</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Nadir</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14'>
  <td width=138 valign=top style='width:103.2pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Anti-MAG&nbsp; antikor</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yok</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&gt;%70</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yok</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yok</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yok</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15'>
  <td width=138 valign=top style='width:103.2pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Anti-GM1 antikor </span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Nadir</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yok</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yok</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Nadir</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>%40-50</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16'>
  <td width=138 valign=top style='width:103.2pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Anti-sulfatid antikor</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yok</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Mutad de�il veya MAG�la kombine</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yok</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yok</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yok</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:17'>
  <td width=138 valign=top style='width:103.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Duyusal sinir biyopsisi:</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Demiyelinizasyon/</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>remiyelinizasyon</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>S�k</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>S�k</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>S�k</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>S�k</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Minimal bulgular</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:18'>
  <td width=642 colspan=6 valign=top style='width:481.5pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Tedaviye yan�t</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:19'>
  <td width=138 valign=top style='width:103.2pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Prednizon</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Evet</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Zay�f</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Muhtemel</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Evet</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Hay�r</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:20'>
  <td width=138 valign=top style='width:103.2pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Plazma de�i�imi</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Evet</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Zay�f</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Muhtemel</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>M�mk�n</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Hay�r</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:21'>
  <td width=138 valign=top style='width:103.2pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IVIg</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Evet</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Zay�f</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Muhtemel</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Evet</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Evet</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:22;mso-yfti-lastrow:yes'>
  <td width=138 valign=top style='width:103.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Siklofosfamid</span></p>
  </td>
  <td width=108 valign=top style='width:80.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Evet</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Zay�f</span></p>
  </td>
  <td width=103 valign=top style='width:77.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Muhtemel</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>M�mk�n</span></p>
  </td>
  <td width=100 valign=top style='width:74.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Evet</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>BKAP: Bile�ik kas aksiyon potansiyeli, DAP: Duyusal
aksiyon potansiyeli, LPH: Lenfoproliferatif hastal�k</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Periferik Sinir Vask�litleri</span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Damar cidarlar�nda inflamasyon ve nekroza yol a�an patolojik s�re�lere
ba�l� olarak geli�en vask�litik n�ropatileri <i>sistemik ve sistemik olmayan
vask�litik n�ropatiler</i> olarak iki b�y�k kategoriye ay�rmak m�mk�nd�r (<b>Tablo
25</b>). Sistemik vask�litler <i>primer sistemik vask�litler</i> (mikroskopik
polianjitis, poliarteritis nodoza [PAN], Churg-Strauss sendromu, Wegener </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>gran�lomatozu ) ve <i>di�er sistemik hastal�klara sekonder</i> vask�litler
(romatoid artrit ve Sj�gren sendromu gibi kollajen hastal�klar, viral
infeksiyonlar (mikst kriyoglobulinemi ile birlikte hepatit C, HIV ve CMV gibi
viral infeksiyonlar ve paraneoplastik) olarak iki alt gruba ayr�labilir.
Bunlar�n aksine, <i>sistemik olmayan vask�litlerde</i> yayg�n bir sistemik
tutulmaya ait bulgular yoktur veya �ok azd�r. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Sistemik nekrotizan
vask�litler,</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> orta ve k���k �apl� damarlar�n cidar�nda iltihap ve nekroz olu�turarak bu
damarlar�n okl�zyonuna ve sulama alanlar�nda iskemiye neden olurlar. Sinir
sistemi dahil olmak �zere bir �ok organ� etkileyen bu hastal�klarda ya�am�
tehdit eden ve tedavisi m�mk�n olan organ yetersizlikleri ortaya ��kt���ndan
erken tan� �nemlidir. Sistemik nekrotizan vask�litlerin seyrinde periferik
sinir sistemi tutulmas� s�kt�r (<b>Tablo 25</b>) .&nbsp; <i>PAN</i>, k���k ve
orta boy arterleri tutarak b�brekler, karaci�er, barsaklar, deri ve kaslar ile
merkezi ve periferik sinir sistemini tutar. Olgular�n yakla��k yar�s�nda
n�ropati geli�ir, 1/3-1/2 kadar�nda hepatitis B y�zey antijeni pozitiftir.
Hepatit B ile birlikte olan olgular�n daha agresif seyretti�i bildirilmi�tir. <i>Mikroskopik
polianjitis</i>te (overlap sendromu) arteriol, kapiller ve ven�ller etkilenir.
Glomer�lonefrit ve pulmoner hemorajiler s�k, periferik sinir tutulmas� PAN�a
g�re daha seyrektir.&nbsp;&nbsp; <i>Churg-Strauss sendromu</i>nda da bir �ok
organ etkilenmekle birlikte akci�erler �n planda tutulur. Pulmoner
infiltrasyonlar, tekrarlayan astma ataklar�, ate� ve eozinofili s�kt�r.
Periferik n�ropati geli�me oran� poliarteritis nodozadaki gibidir. <i>Wegener
gran�lomatozu</i> �st ve alt solunum yollar� ile b�brekleri etkiler. Solunum
yollar�nda gran�lomlar ve nekrotizan glomer�lonefrit s�kt�r. Astma ve
eozinofili yoktur. Olgular�n 1/5 kadar�nda n�ropati g�r�l�r. Orbita ve kavern�z
sin�slerdeki gran�lomlara ba�l� kranyal sinir tutulmalar� geli�ebilir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 25.</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Periferik n�ropatiye
neden olan sistemik vask�litlerin klinik �zellikleri ve tedavileri </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(KC
Gorson)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=775
 style='width:581.4pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=67 valign=top style='width:50.4pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Periferik
  sinir</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>%</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>�st solunum</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>%</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Alt solunum</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>%</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Renal</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gastro-intestinal</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>%</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Artralji</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Artrit</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>%</span></b></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kalp</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>%</span></b></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Deri</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>%</span></b></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>MSS</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>%</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>cANCA/</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>PR3</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>%</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>pANCA/</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>MPO</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Damar boyutu</span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di�er</span></b></p>
  </td>
  <td width=59 valign=top style='width:44.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tedavi</span></b></p>
  </td>
  <td width=49 valign=top style='width:36.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Viral</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=67 valign=top style='width:50.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Primer
  Vask�litler</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=59 valign=top style='width:44.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=49 valign=top style='width:36.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=67 valign=top style='width:50.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Wegener
  gran�lomatozu</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>40-50</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>95</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>70-85</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>70-80</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&lt;5</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>60-70</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>10-25</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>40-50</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>5-10</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>75-90</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>5-20</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>K���k-orta</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
  <td width=59 valign=top style='width:44.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Steroid+</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sitotoksik</span></p>
  </td>
  <td width=49 valign=top style='width:36.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=67 valign=top style='width:50.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Churg Strauss</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>60-80</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>50-60</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>40-70</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>10-40</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>30-50</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>40-50</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>10-40</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>50-55</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>5-30</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>3-35</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>2-50</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>K���k-orta</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ate�,
  eozinofili</span></p>
  </td>
  <td width=59 valign=top style='width:44.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Steroid</span></p>
  </td>
  <td width=49 valign=top style='width:36.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=67 valign=top style='width:50.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Poliarteristis&nbsp;
  nodosa</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>35-75</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>15-55</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>50-75</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>5-30</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>25-60</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>3-17</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nadir</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nadir</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Orta</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ate�,
  hipertansiyon </span></p>
  </td>
  <td width=59 valign=top style='width:44.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Steroid</span></p>
  </td>
  <td width=49 valign=top style='width:36.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hepatit B</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>%33-50</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=67 valign=top style='width:50.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Mikroskopik
  polianjitis</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>60-70</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>15-70</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>75-90</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>30</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>40-60</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>10-15</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>50-65</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>10-15</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>10-50</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>50-80</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>K���k</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ate�</span></p>
  </td>
  <td width=59 valign=top style='width:44.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Steroid+</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sitotoksik</span></p>
  </td>
  <td width=49 valign=top style='width:36.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=67 valign=top style='width:50.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sekonder
  Vask�litler</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=59 valign=top style='width:44.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
  <td width=49 valign=top style='width:36.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=67 valign=top style='width:50.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Romatoid
  vask�lit</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>50</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>5-30</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>10-25</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>10-30</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>90-100</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>10-30</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>30-90</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>5-15</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Orta</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ate�, kilo
  kayb�, nod�ller</span></p>
  </td>
  <td width=59 valign=top style='width:44.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Steroid</span></p>
  </td>
  <td width=49 valign=top style='width:36.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;mso-yfti-lastrow:yes'>
  <td width=67 valign=top style='width:50.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Mikst kriyo<span
  class=msons><span style='text-decoration:none;text-underline:none'><span
  class=msoIns><ins cite="mailto:can%20baykal" datetime="2009-06-14T23:15">-</ins></span></span></span>glob�line<span
  class=msodel0><span class=msoDel><del cite="mailto:can%20baykal"
  datetime="2009-06-14T23:15">-</del></span></span>mi</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>20-90</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>33-55</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>&lt;20</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>20-90</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>60-100</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hay�r</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>K���k</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yorgunluk</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Raynaud</span></p>
  </td>
  <td width=59 valign=top style='width:44.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>PEG-INF</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>+/- ribavirin</span></p>
  </td>
  <td width=49 valign=top style='width:36.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hepatit C</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:6.0pt;font-family:Tahoma;mso-ansi-language:TR'>%73-90</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
6.0pt;font-family:Tahoma;mso-ansi-language:TR'>cANCA=Sitoplazmik
immunofloresans paterni n�trofil serin proteaz proteinaz 3�e (PR3) y�nelik ANCA
; pANCA= Perin�kleer immunofloresans paterni miyeloperoksidaza (MPO) y�nelik
ANCA, PEG-INF: Pegile interferon</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Konnektif doku hastal�klar�</span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>n�n seyrinde
vask�lit geli�ti�inde ortaya ��kan patolojik ve klinik tablo poliarteritis
nodozadakine benzer. Romatoid artrit toplumda s�k g�r�len bir hastal�k
oldu�undan, <i>romatoid vask�lit</i> s�k kar��la��lan vask�litik n�ropati
nedenlerindendir. Ancak, modern antiromatizmal tedaviler ile insidans�
azalmaktad�r.&nbsp; PAN�daki gibi k���k ve orta boy arterleri tutar. Romatoid
vask�lit genellikle yerle�mi� romatoid artriti olan hastalarda g�r�l�r. Bu
nedenle, yerle�mi� romatoid artrit tan�s� bulunmayan, ancak romatoid fakt�r� pozitif
olan hastalarda di�er vask�lit nedenleri ara�t�r�lmal�d�r. <i>Hipersensitivite
vask�litleri</i>, serum hastal���, infeksiyon, ila� ba��ml�l���, hematolojik
malin hastal�klar ve Henoch-Sch�nlein purpuras� ile birlikte olur.&nbsp; Bu
vask�litler s�n�rl� bir seyir g�sterirler ve vask�ler endotel �zerine h�moral
bir ba����kl�k yan�t�n� tetikleyen s�rekli bir antijenik uyar�m�n varl���na
ba��ml�d�rlar. Klinik tabloya deri belirtileri hakim olmakla birlikte,
periferik sinir tutulmas� da olabilir. Dev h�creli arteritler geni� ve orta
�apl� arterleri etkilerler. Vask�lit periferik sinirleri besleyen arterleri
tuttu�unda monon�ropati veya monon�ropati multipleks tablolar� ortaya ��kar.
Vask�litik n�ropatisi olan hastalar�n %10 dan fazlas�nda malin hastal�klar
(k���k h�creli akci�er kanseri, lenfoma, l�semi, renal h�creli karsinom ve
di�er adenokarsinomlar), hepatit C vir�s veya HIV infeksiyonu vard�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Biyopsi ile kan�tlanm�� vask�liti olan hastalar�n 1/3 kadar�nda sistemik
bir hastal��� g�steren klinik ve laboratuvar bulgular� yoktur<i> (sistemik
olmayan/nonsistemik vask�litik n�ropati)</i>. Histopatolojik bulgular�n
sistemik nekrotizan vask�litlerin ayn�s� olmakla birlikte sadece periferik
sinir ve kas dokusuna s�n�rl� oldu�u bu tablo en s�k kar��la��lan vask�litik
n�ropatidir. Hastalarda sistemik tutulmay� d���nd�recek klinik ve serolojik
bulgular genellikle yoktur. Progresyonu yava�, ataklar� daha seyrek olan bu
hastal�kta ya�am� tehtid eden komplikasyonlar genellikle ortaya ��kmaz. Yine
de, ba�lang��ta sistemik bulgular� olmayan bu hastalar�n bir k�sm�nda deri
tutulmas� g�r�ld���n�, %10�dan az�nda zaman i�inde b�y�k organ etkilenmesine
giden bir sistemik yay�lma geli�ti�ini hat�rlamak gerekir.&nbsp; Tutulan
sinirlere ait belirti ve bulgular yava� fakat iyi bir d�zelme g�sterdi�inden,
n�rolojik tablonun prognozu da olduk�a iyidir. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Vask�litik n�ropatilerde �aplar� 50-300 <span
style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'><span
style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'>&#61549;</span></span>m
aras�nda de�i�en arteriol, kapiller, ven�l, k���k ve orta boy arterlerde yo�un
t�kanmalar geli�erek sinir dokusu iskemisine neden olur. �skemi sinir
liflerinde aksonal dejenerasyona yol a�ar. Vask�ler inflamasyonun mediyat�r�
oldu�u d���n�len ba�l�ca fakt�rler, dola�an immun kompleksler, anti-endotelyal
ve antisitoplazmik antikorlar, sitotoksik T lenfositleri ve gecikmi� tip a��r�
duyarl�l�kt�r. �la�lar, HIV, Hepatit B ve C vir�sleri gibi infeksiyon
ajanlar�&nbsp;ba����kl�k yan�t�n�n tetikleyicileri olarak d���n�lmekle
birlikte, olgular�n �o�unda etken belirlenememi�tir</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Vask�lit s�recinin dokular� multifokal ve rasgele bir �ekilde tutmas�na
ba�l� olarak sinirler asimetrik ve yamal� �ekilde lezyona u�rar. Bu nedenle
vask�litler multifokal/asimetrik periferik sinir tutulmas�na yol a�an
nedenlerin prototipini olu�turur (<b>Tablo 7</b>). Fakat vask�litlere ba�l�
periferik n�ropatiler farkl� klinik g�r�n�mlerde kar��m�za ��kabilir.&nbsp; Olgular�n
bir k�sm� <i>monon�ropati multipleks</i> tablosu ile hekimin kar��s�na gelir.
Bir k�sm�nda ise birden �ok sinire ait tutulma bulgular� olduk�a h�zl� �ekilde
birbirinin �zerine eklenerek bir veya birden �ok ekstremitede olduk�a yayg�n
fakat asimetrik kas zaaf� ve duyu kusuruna neden olan birle�ik (�konfluent�)
bir g�r�n�m al�r (asimetrik polin�ropati g�r�n�m�). Olgular�n %30 kadar�nda
yo�un ve yayg�n vask�litin neden oldu�u subakut seyirli, simetrik distal
duyusal-motor bir polin�ropati g�r�n�m� vard�r. Baz� hastalarda �yk�n�n
dikkatli al�nmas�yla n�rolojik belirtilerin fokal ve asimetrik ba�lay�p
basamakl� bir ilerleme g�sterdi�i ortaya ��kar�labilir. Monon�ropati multipleks
�eklinde klinik seyir g�sterenlerde genellikle akut ve a�r�l� ba�lang�� ve
h�zl� bir progresyon izlenir. Ancak, kronik ve yava� bir progresyonun s�z
konusu oldu�u hastalara da rastlan�r. Yukar�da belirtilen n�rolojik bulgular�n
ate�, k�r�kl�k, kilo kayb�, kas ve eklem a�r�lar�, solunum sistemi belirtileri,
hemat�ri, kar�n a�r�s�, cilt d�k�nt�s� ve gece terlemeleri gibi sistemik
belirtilerle ya da a��klanamayan di�er organ tutulmalar� ile&nbsp; birlikte
olmas� sistemik nekrotizan vask�litlerin varl���n� d���nd�rmelidir. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tan�ya yard�mc� olacak ba�l�ca laboratuvar incelemeleri
eritrosit sedimentasyon h�z�, tam kan say�m� ve l�kosit form�l�,&nbsp; idrar
incelemesi ve b�brek fonksiyonlar�na y�nelik di�er incelemeler,&nbsp; karaci�er
enzimleri, romatoid fakt�r, antin�kleer antikor, ekstrakte edilebilir n�kleer
antijenler, serum komplemanlar� (C3, C4, CH 50), antin�trofilik sitoplazmik
antikorlar, kriyoglobulinler, hepatit B antijen ve antikoru, hepatit C antikoru
ve serum immunofiksasyon elektroforezidir. �zg�ll��� d���k olmakla birlikte
antin�trofilik sitoplazmik antikorlar Wegener gran�lomatozu, Churg-Strauss
sendromu ve mikroskopik polianjitisin tan�s�nda yard�mc� olabilir <b>(Tablo 25)</b>.
Elektrofizyolojik incelemeler periferik sinirlerde akson hasar� ile seyreden
tutulmay� g�sterir. Ancak bir vask�litik n�ropati ata��n�n erken d�nemlerinde
lezyona u�rayan sinir segmentlerinde elektrofizyolojik olarak tam veya parsiyel
iletim blo�u bulgular� saptanabilir (Wallerian dejenerasyonun tamamlanmas�ndan
�nce ge�ici olarak). Bu bulgu vask�litik n�ropatinin kompresyon ve tuzaklanmaya
ba�l� sinir lezyonlar� ile ve inflamatuvar demiyelinizan n�ropatilerle
kar��t�r�lmas�na neden olabilir. Sinir iletim incelemeleri ve i�ne
elektromiyografisi, klinik olarak g�zden ka�an fokal ve asimetrik sinir
tutulmas� bulgular�n� ortaya koyarak tan�ya yard�mc� olabilir. BOS genellikle
normaldir. Vask�litik n�ropatilerin kesin tan�s� histopatolojik olarak damar
duvarlar�nda destr�ksiyonla birlikte transm�ral monon�kleer h�cre infiltrasyonu
ve&nbsp; nekrozun g�sterilmesi ile konur (<b>�ekil 10</b>). Deri lezyonlar�
olan hastalarda&nbsp; lezyon yerinden al�nacak deri biyopsisi tan�y� sa�lar.
Bir �ok kere vask�liti tespit etme olas�l���n� artt�rmak amac�yla kombine sinir
ve kas biyopsilerinin al�nmas� tavsiye edilir. Vask�litik n�ropati d���n�len
hastalarda uzun, komplikasyon riski y�ksek tedavilerin uygulanmas� s�z konusu
oldu�undan ve tedaviye ba�land�ktan sonra histopatolojik incelemeler
g��le�ece�inden doku biyopsisine bir an �nce ba�vurulmas� yerinde olur.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a href="pnp12a.JPG"><b>�ekil
12a.</b></a><b> </b>Damar�n t�m katmanlar�n� tutan monon�kleer h�cre
infiltrasyonu (non-nekrotizan vask�lit) (Y�zeyel Peroneal sinir biyopsisi, HE,
X20)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue;mso-ansi-language:TR'><a
href="pnp12b.JPG">�ekil 12b.</a> </span></u></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nekrotizan vask�lit. Y�zeyel
peroneal sinir biyopsisinde t�m�yle t�kal� bir damar�n cidar�nda fibrinoid
nekroz (ok) (X20)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue;mso-ansi-language:TR'><a
href="pnp12c.JPG">�ekil&nbsp; 12c.</a> </span></u></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Miyelinli
aksonlar�n hemen t�m�yle dejenere oldu�u ileri a�amada vask�lit olgusu. Waller
dejenerasyonunun �e�itli evrelerine ait bulgular� olan lifler (Oklar) (Thionin,
X40)</span></p>

<p class=MsoNormal style='margin-left:36.0pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue;mso-ansi-language:TR'><a
href="pnp12d.JPG">�ekil 12 d.</a></span></u></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Vask�litik n�ropati olgusunda
tam t�kal� epin�ral damarda endotelle d��eli revask�larizasyon alanlar�.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Vask�litlerin �nde gelen tedavi ajan� kortikosteroidlerdir. Sistemik
nekrotizan vask�litlerin tedavisinde, ilerlemekte olan multipl organ ve sinir
hasar�n� durdurmak amac�yla genellikle agresif bir yakla��m benimsenir.
Steroidler y�ksek dozla oral ba�lan�r (prednizolon, 1-2 mg/kg.g�n) veya
fulminan olgularda ba�lang��ta 3-5 g�n y�ksek doz IV (1000 mg/g�n) verildikten
sonra oral tedaviye ge�ilir. Wegener gran�lomatozu ve mikroskopik polianjitis
olgular�, multipl organ tutulmas� olan ve kortikosteroid tedavisine ra�men
ilerleyen olgularda kortikosteroid&nbsp; ve sitostatik ajan tedavisine kombine
olarak ba�lan�r. Remisyon olu�turmada en etkili olan sitotoksik ila�
siklofosfamiddir. Genellikle oral yolla 2 mg/kg.g�n dozda verilir. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�ntraven�z siklofosfamid uygulamas�n�n daha az yan etkisi
oldu�u, ancak n�ks riskini y�kseltti�ini d���nd�ren bulgular mevcuttur.
Siklofosfamid uygulanan hastalarda ilk ayda haftada bir, daha sonra ayda bir
tam kan say�m� yap�l�r. Total l�kosit say�s�n�n 3500/<span style='mso-char-type:
symbol;mso-symbol-font-family:Tahoma'><span style='mso-char-type:symbol;
mso-symbol-font-family:Tahoma'>&#61549;</span></span>l nin, n�trofil say�s�n�n
1500/<span style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'><span
style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'>&#61549;</span></span>l
nin alt�na d��mesi halinde dozun titre edilmesi veya ilac�n kesilmesi gerekir.
Hemorajik sistit geli�imini engelleyici tedbirler al�n�r Siklofosfamidle
remisyon elde edildikten sonra metotreksat veya azatiopirin ile idame
tedavisine ge�ilebilir. Ayn� ama�la mikofenolat mofetil ve leflonomid de
kullan�lm��t�r. Belirgin bir klinik iyile�me ortaya ��k�ncaya kadar iki drogla
birlikte tedavi yap�l�r. Klinik remisyon g�r�ld�kten sonra prednizolon tedavisi
yava� olarak g�na��r� uygulamaya d�n��t�r�l�r ve daha sonra azalt�l�r (ayda bir
5-10 mg, doz azald�k�a daha yava�). �dame tedavisi t�m hastal�k aktivitesi
kaybolduktan sonra 1 y�l daha s�rd�r�l�r. Kortikosterod ve sitostatik kombine tedavisi
sistemik nekrotizan vask�litlerde olduk�a iyi bir remisyon oran� sa�lad���
gibi, bu hastal�klara ba�l� �l�mleri de belirgin derecede azaltm��t�r.
Nonsistemik vask�litik n�ropati ve dev h�creli arteritlerde organ hasar�na
ba�l� ya�amsal tehlike olas�l��� d���k oldu�undan, tedaviye sadece
kortikosteroidle ba�lanabilir. Nonsistemik vask�lit n�ropatide spontan
remisyonlar da g�r�lebildi�inden, tedavi edilecek hastalar� se�mek g��t�r ve
klinik tablonun a��rl���na, seyir �zelliklerine dayan�l�r. Bu olgularda
kortikosteroid ve sitostatiklerin kombine edilmesinin d�zelme oran�n�
artt�rd���, ancak daha y�ksek oranda ilaca ba�l� yan etkilere sebep oldu�u
g�sterilmi�tir. Vask�litik olmayan immun k�kenli n�ropatilerde olduk�a yayg�n
�ekilde kullan�lan IVIg, kontrols�z a��k �al��malarda vask�litik n�ropatilerde
de denenmi� ve baz� olumlu sonu�lar al�nm��t�r. Gelecek i�in umut veren
tedaviler aras�nda t�m�r nekroz fakt�r� ve CD20 inhibisyonuna y�nelik olanlar
say�labilir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hepatit B, C ve HIV infeksiyonu
ile birlikte olan vask�litlerde kronik immunsupresyon viremiyi artt�rabilece�i
i�in genel olarak kontraindikedir. Ancak hepatit B ile birlikte olan PAN�da
k�sa s�reli olarak verilmektedir (1-2 haftal�k steroid uygulamas�n� izleyen
antiviral tedavi, interferon </span><span lang=TR style='font-size:10.0pt;
font-family:Symbol;mso-ansi-language:TR'>a</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-2b veya
lamiv�din). Hepatit C�nin tedavisinde pegile interferon </span><span lang=TR
style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:TR'>a</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-2 a
veya b&nbsp; ve genellikle ribavirin kullan�l�r. Hepatit C infeksiyonu
interferonla tedavi edilip hem kriyoglobulinemisi hem de vask�litik
n�ropatisinde d�zelme olan hastalar bildirilmi�tir. �nterferon tedavisine
ba�lanmas�n�n ard�ndan akut periferik n�ropati geli�en olgular da
bildirilmi�tir. Bu olgular�n �o�u tedavinin kesilmesiyle d�zelme g�stermi�tir.
Hepatit C ve kriyoglobulinemisi olan hastalarda rituksimab�n polin�ropati
bulgular�na yararl� etkisi oldu�unu bildiren a��k �al��malar mevcuttur. Tedavi
i�in plazma de�i�iminin yararl� olabilece�i de ileri s�r�lm��, ama bu konuda
kontroll� �al��ma yap�lmam��t�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'>METABOL�K
BOZUKLUKLARA BA�LI POL�N�ROPAT�LER</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Diyabetik N�ropati</span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Diyabetes mellitus (DM) geli�mi� bat� �lkelerinde periferik n�ropatilerin
en s�k nedenidir. Diyabetle birlikte ya�ama s�resi uzad�k�a n�ropati prevalans�
artar. Yirmibe� y�ll�k diyabeti olan hastalar�n yakla��k yar�s�nda diyabetik
n�ropati geli�ir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Diyabetik n�ropatilerin farkl� klinik g�r�n�mleri <b>Tablo 26</b> da
verilmi�tir. </span></p>

<p class=MsoNormal><span lang=TR style='font-size:11.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 26</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>. Diyabetik n�ropatiler </span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(PJB Dyck)</span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Simetrik</span></b></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Diyabetik polin�ropati (DPN) </span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Diyabetik otonom n�ropati </span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A�r�l� distal n�ropati ve kilo
kayb� (diyabetik ka�eksi) </span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�ns�lin nevriti</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ketoasidoz sonras� polin�ropati</span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Glikoz tolerans bozuklu�unda
polin�ropati* </span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Diyabette CIDP* </span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Asimetrik</span></b></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Radik�lopleksus n�ropatileri
(DRPN) </span></p>

<p class=MsoNormal style='margin-left:70.8pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lumbosakral (DLRPN) </span></p>

<p class=MsoNormal style='margin-left:70.8pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Torakal &nbsp;</span></p>

<p class=MsoNormal style='margin-left:70.8pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Servikal </span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Monon�ropatiler </span></p>

<p class=MsoNormal style='margin-left:70.8pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bilekte median n�ropati (karpal
t�nel sendromu)</span></p>

<p class=MsoNormal style='margin-left:70.8pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dirsekte ulnar n�ropati</span></p>

<p class=MsoNormal style='margin-left:70.8pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Fibula ba��nda peroneal
n�ropati* </span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kranyal n�ropatiler </span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;*: Ku�kulu durum</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Hiperglisemik N�ropati</span></i></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Yeni tan� konmu� veya iyi kontrol alt�nda olmayan diyabetik n�ropatilerde
g�r�l�r. Alt ekstremite distallerinde rahats�zl�k verici dizesteziler ve
a�r�larla seyreder. Gliseminin kontrol alt�na al�nmas� ile h�zl� �ekilde
d�zelir. Elektrofizyolojik incelemelerde yava� bulunan sinir iletim h�zlar� da
hipergliseminin d�zelmesini izleyerek h�zla normale d�ner.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Diyabetik Polin�ropati (DPN, Distal Simetrik Polin�ropati)</span></i></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>En s�k g�r�len&nbsp;diyabetik n�ropati �eklidir. Genellikle uzun s�re
hiperglisemiye maruz kalm��, retinopati ve nefropati gibi di�er
komplikasyonlar� da ortaya ��km�� olan tip I ve tip II DM�lu hastalarda
g�r�l�r. Bir �ok kere tip II DM�nin ortaya ��k�� zaman� kesin olarak
bilinemedi�inden hastal���n ilk klinik bulgusu olarak da kar��m�za ��kabilir.
Ekstremite distallerinde yanma, batma ya da s�zlama �eklinde a�r�lar,
paresteziler, hipoesteziden olu�an duyusal belirti ve bulgulara otonom sinir
sistemi tutulmas�na ili�kin bulgular ve hafif derecede distal motor zaaf ve
atrofi eklenir. Yak�nmalar alt ekstremite distallerinden ba�layarak sinsi
�ekilde proksimale do�ru yay�l�r. �st ekstremitelere ili�kin yak�nmalar
genellikle distal simetrik polin�ropatiye de�il, karpal t�nel sendromu gibi bir
monon�ropatiye ba�l�d�r (a�a��ya bak�n�z). �iddetli a�r�, genellikle san�lan�n
aksine, DPN�de s�k bir belirti de�ildir. Subakut ba�lang��l� �iddetli a�r� daha
�ok kilo kayb� ile birlikte olan a�r�l� distal n�ropati veya radik�lopleksus
n�ropatisinde g�r�l�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Hafif <i>otonom</i> tutulma hem tip I hem tip II DM olgular�nda g�r�l�r.
�iddetli otonom n�ropatiye ise hemen sadece tip I DM�de rastlan�r. Ba�l�ca
belirtiler cinsel fonksiyon bozuklu�u, gastroparezi, diyabetik diyare, mesane
atonisi, ayaklarda terleme kayb� ve �e�itli kardiyovask�ler bozukluklard�r.
Hastalar�n bir k�sm�nda aya�a kalk�nca ba� d�nmesi ya da senkop gibi postural
hipotansiyon belirtileri vard�r. Anormal kalp ritmi de�i�kenli�i ve buna ba�l�
kardiyak aritmilerin diyabetik hastalar�n uzun vadeli sa�kal�m oranlar�n�
azaltan �nemli fakt�rlerden oldu�u d���n�l�r. DM�li olgulardaki ani kardiyak
�l�mlerden diyabetik otonom n�ropati sorumlu tutulmu� olmakla birlikte, yak�n
zamandaki bir prospektif �al��ma aterosklerotik kalp hastal��� ve nefropatinin
bunlarla daha fazla korelasyon g�sterdi�ini ortaya koymu�tur. </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�n planda miyelinsiz ve ince miyelinli sinir liflerini etkileyen DPN
yerle�ti�inde b�y�k oranda geriye d�n��s�zd�r. Klinik tabloya ayak �lserleri ve
n�ropatik artropati <i>(Charcot eklemleri)</i> eklenebilir. Elektrofizyolojik
incelemelerde genellikle aksonal hasarla seyreden duyusal-motor bir
polin�ropatiyi yans�tan bulgular saptan�r. �n planda ince sinir lifleri tutulan
erken d�nem hastalar�nda sinir iletim incelemeleri normal bulunabilir.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>DPN tan�s�, uzun s�reli k�t� glisemik kontrole maruz kalan ve genellikle
di�er DM komplikasyonlar� olan hastalarda duyusal bask�n distal simetrik
aksonal polin�ropatinin varl���nda, benzer bir polin�ropatiyi olu�turacak di�er
nedenlerin de d��lanmas�yla konulur. Ay�r�c� tan�da de�erlendirilmesi gereken
di�er polin�ropatiler aras�nda amiloid n�ropatisi, herediter n�ropatiler, immun
k�kenli n�ropatiler (Sj�gren sendromu, paraproteinemi ile birlikte olanlar), B
vitamini yetersizliklerine ba�l� olanlar, hipotiroidi, �remik n�ropati, vb.
say�labilir.&nbsp;&nbsp; </span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Akut A�r�l� Diyabetik N�ropati [�Diyabetik N�ropatik
Ka�eksi� (Ellenberg, 1974)] </span></i></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Bu nadir g�r�len sendrom diyabetik duyusal
polin�ropatinin farkl� bir formunu olu�turur. �zellikle alt ekstremitelerde,
�ok nadir olarak �st ekstremiteler ve g�vde �zerinde akut ya da subakut
ba�lang��l�, geceleri belirgin, yan�c�, s�zlay�c� a�r� ile karakterizedir. Buna
deride yayg�n kontakt hiperestezisi e�lik eder. DM�un s�re ve �iddeti ile
ba��nt�s�z olan, bazen s�k� glisemi kontrol�n� izleyerek ortaya ��kan bu
tabloya �iddetli ve h�zl� kilo kayb�, depresyon ve impotans e�lik edebilir.
Objektif n�rolojik bulgu �ok azd�r. Tedavisi �ok iyi glisemi kontrol� ile olur
(tedavi ile presipite olan olgularda bile). Monofazik seyir g�sterir ve
genellikle 6-9 ayl�k bir s�re i�erisinde iyile�me g�r�l�r.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�ns�lin Nevriti (Caravati, 1933)</span></i></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�ns�lin tedavisine yeni ba�lanan hastalarda alt
ekstremite distallerinde ortaya ��kan duyusal belirtilerle karakterize olan bir
tablodur. N�rolojik muayene ve elektrofizyolojik testlerde �ok az objektif
bulgu mevcuttur. S�k� glisemik kontrol�n yol a�t��� tekrarlay�c� hipogliseminin
mi, yoksa ins�linin tetikledi�i ba�ka mekanizmalar�n m� bu tabloya yol a�t���
iyi bilinmemektedir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Ketoasidozla Birlikte Polin�ropati</span></i></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Diyabetik ketoasitozun ba�l�ca belirtileri merkez sinir
sisteminden kaynaklan�r. Bununla birlikte, ketoasidozla birlikte alt motor
n�ron ve kranyal sinir tutulmalar� olabilir. Akut ba�lang��l�, motor bask�n bir
polin�ropati s�z konusudur. Ketoasidozun h�zl� tan� ve tedavisi ile hemen ya da
haftalar i�erisinde d�zelme g�sterir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Glikoz Tolerans Bozuklu�unda Polin�ropati</span></i></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kontrols�z �al��malar glikoz tolerans bozuklu�u (IGT)
olan ki�ilerde idyopatik aksonal polin�ropati oran�n�n genel toplumdan daha
y�ksek oldu�unu g�stermi�, fakat bu bulgu kontroll� �al��malarla
do�rulanamam��t�r. S�z konusu polin�ropatinin distal belirti ve bulgular�
bask�n, uzunlu�a ba��ml� hafif bir aksonal polin�ropati �eklinde seyretti�i, bu
�zellikleri ile DPN�nin hafif bir formunu te�kil etti�i d���n�lmektedir.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Diyabette CIDP</span></i></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Baz� yazarlar diyabetlilerde CIDP s�kl���n�n genel
topluma oranla y�ksek oldu�unu �ne s�rm��lerdir. Bununla birlikte, �zellikle
DM�nin toplumda s�k rastlanan bir hastal�k olmas� nedeniye, bu iki hastal�k
aras�nda tesad�f�n �tesinde bir ili�ki bulundu�u kan�tlanamam��t�r. Yine de,
baz� diyabetik n�ropati formlar� ile CIDP aras�nda, BOS�ta protein art���,
sinir iletimlerinde demiyelinizan �zellikler ve immunmodulatuvar tedaviden
yararlanma gibi ortak �zellikler bulunmas� ilgi �ekicidir. DM�lu bir hastada
ortaya ��kan polin�ropatinin h�zl� ve motor belirtileri bask�n a��r bir seyir
g�stermesi, muayenede tendon reflekslerinde genel azalma bulunmas�, sinir
iletim incelemelerinde multifokal demiyelinizasyonun a��k bulgular�n�n
saptanmas� ve BOS proteininin �ok y�ksek olmas� halinde CIDP varl���
d���n�lerek tedavinin ona uygun �ekilde planlanmas� yerinde olur.</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp; </span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Diyabetik Radik�lopleksus N�ropatisi (DRPN, Proksimal Diyabetik N�ropati,
Diyabetik Amiyotrofi, Bruns-Garland Sendromu) </span></i></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Distal simetrik polin�ropatiye oranla daha az g�r�len (Tip II diyabette %
1.1, tip I de %&nbsp;0.3) bu diyabetik n�ropati formu, akut veya&nbsp; subakut,
g�r�lt�l� ve s�kl�kla asimetrik ba�lang�c� ile dikkati �eker. Daha �ok 5.
dekad�n �st�ndeki erkek hastalarda ve kilo kayb� ile birlikte g�r�l�r. Bu
hastalarda uzun s�reli ve k�t� kontrol edilen diyabet �yk�s�, ya da DM�un retinopati,
nefropati gibi komplikasyonlar� genellikle yoktur. En s�k g�r�len formu olan <i>lumbosakral
radik�lopleksus n�ropatisi (DLRPN)</i>, genellikle bir alt ekstremitede,
ba�l�ca kal�a ve uyluk �zerinde �iddetli a�r� ile ba�lar. S�kl�kla femoral
sinir alan�ndaki a�r� ile ba�lamas� nedeniyle <i>diyabetik femoral n�ropati</i>
ad� ile de an�l�r. Klinik tabloya g�nler i�inde ayn� ekstremitenin k�k
kaslar�nda belirgin olan kuvvetsizlik ve giderek atrofi eklenir. N�rolojik
muayenede tutulan tarafta femoral sinir ya da �st lumbosakral pleksusu
ilgilendiren alanda hipoestezi, k�k ve uyluk kaslar�nda zaaf ve atrofi, patella
refleksinin kayb� dikkati �eker. Olgular�n bir�o�unda a�r�, duyu kusuru, kas
kuvvetsizli�i ve atrofi ayn� ekstremitede dizalt�nda, siyatik sinirin motor ve
duyusal dallar�n� ilgilendiren alana da uzan�r. Akut a�r�y� izleyen proksimal
ve distal zaafla giden klinik tablo bir �ok kere kompresif lumbosakral
radik�lopati ile kar��t�r�l�r. Bilgisayarl� tomografi veya spinal MR
incelemelerinde hafif diskopati bulgular� olan hastalar (bu genel pop�lasyonda
�ok s�k rastlanan bir g�r�nt�leme bulgusudur) bu disklere y�nelik gereksiz
cerrahi giri�imlere maruz kalabilirler. Ayn� atak s�ras�nda, izleyen ataklarla
ya da bazen yava� progressif bir seyirle kar�� ekstremitede de benzer belirti
ve bulgular geli�ebilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Torakal radik�lopleksus n�ropatileri g�vde �zerinde band tarz�nda a�r� ve
nadir olarak kar�n kaslar�nda segmanter atoni ile seyreder. Bu olgulardaki
a�r�lar i�organ k�kenli a�r�lar ve herpes zoster infeksiyonu ile
kar��t�r�labilir.&nbsp; �st ekstremiteleri ilgilendiren ve n�raljik
amiyotrofiye (idyopatik akut brakiyal pleksusu n�ropatisi) benzeyen bir
servikal-brakiyal radik�lopleksopati de g�r�lebilir (Bak�n�z: <u><span
style='color:blue'><a href="../spinalsinir/spinalsinir.html">Spinal Sinirlerin
Hastal�klar�</a></span></u>). &nbsp;Proksimal diyabetik n�ropatiye genellikle
distal simetrik n�ropatiye ili�kin bulgular kat�labilir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�Diyabetik amiyotrofi� </span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>ad� alt�nda tan�mlanan klinik tabloyu da bu grupta ele
almak gerekir. Alt ekstremite k�k kaslar�nda simetrik a�r�s�z kuvvetsizlik ve
atrofi ile giden olgular bildirilmi� olmakla birlikte, bunlar�n yukar�da
tan�mlanan asimetrik ba�lang��l� �ekilden farkl�l��� ��phelidir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Proksimal diyabetik n�ropatinin olu�umundan, spinal sinir k�klerini ve
pleksuslar� asimetrik �ekilde tutan ve bazen otoimmun k�kenli vask�lit �eklinde
seyreden diyabetik mikroanjiopati sorumlu tutulur (a�a��ya bak�n�z). Genellikle
aylar i�inde spontan d�zelme g�r�lmekle birlikte, olgular�n bir k�sm�nda
iyile�me yetersiz olur. Hastalar�n %20 kadar�nda tekrarlama bildirilmi�tir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Sinir iletim incelemeleri genellikle distal simetrik polin�ropatiyi
yans�tan bulgular verir. ��ne elektromiyografisinde semptomatik ekstremitenin
lezyona u�rayan radiks-pleksus segmentlerinden innervasyon alan kaslar�nda ve
paraspinal kaslarda yo�un parsiyel denervasyon-reinnervasyonu g�steren bulgular
saptan�r. BOS proteini genellikle artm��t�r. Nadiren eritrosit sedimentasyon
h�z� ve romatoid fakt�r y�ksekli�ine, antin�kleer antikor ve immun arac�l�
hastal�klar�n di�er laboratuvar belirte�lerinin y�ksekli�ine rastlan�r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>DLRPN�nin ay�r�c� tan�s�nda spinal k�klerin disk f�t�klanmalar�na veya
di�er dejeneratif spinal s�re�lere ba�l� bas�lar�, intraabdominal t�m�ral veya
iltihabi kitlelere ba�l� sinir k�k�-pleksus bas� ve infiltrasyonlar�, alt ekstremitenin
arteriyel ve ven�z dola��m bozukluklar� ile kal�a ekleminin travmatik ve
dejeneratif a�r�l� s�re�leri akla getirilmelidir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Monon�ropatiler</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Kranyal n�ropatiler:</span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> Akut ba�lang��l� 3. ve 6. sinir fel�leri genellikle
ileri ya�ta, glisemi kontrol� k�t� olan hastalarda ortaya ��kar. Olgular�n
yar�s� kadar�nda g�z �evresi ve ard�nda �iddetli a�r� ile ba�lar. Aylar i�inde
spontan ve tam d�zelme g�sterir. Diyabetik 3. sinir felcine genellikle&nbsp;
pupilla kat�lmaz. Bunun nedeni, sinirin orta kesimindeki muhtemelen iskemik
k�kenli lezyondan sinirin periferindeki otonom liflerin etkilenmemesidir. Baz�
diyabetik olgular�n akut ba�lang��l� izole kranyal sinir fel�lerinden beyinsap�ndaki
k���k iskemik lezyonlar�n&nbsp;sorumlu oldu�u da g�sterilmi�tir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='layout-grid-mode:char'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Diyabetik
hastalarda 7. sinir felcinin de daha s�k g�r�ld��� iddia edilmi�tir. Ancak
diyabet ve Bell felci toplumda s�k g�r�lmektedir ve bu iki hastal�k durumu
aras�nda nedensel bir ba�lant� oldu�una ili�kin kan�tlar yoktur. Diyabetik bir
hastada geli�en periferik y�z felcinin bir diyabetik n�ropati formu olarak
de�il Bell felcinde (ya da bu sinirin di�er lezyonlar�nda) oldu�u �ekilde ele
al�nmas� uygun olur (Bak�n�z: <a
href="http://www.itfnoroloji.org/kranyalnoropatiler/Kranyalnoropatiler.html">Kranyal
N�ropatiler</a>). Baz� yazarlar DM varl���n�n Bell felcinin iyile�mesi
a��s�ndan k�t� bir prognostik fakt�r oldu�unu �ne s�rm��t�r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='layout-grid-mode:char'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tuzak n�ropatileri: </span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Diyabetik polin�ropati, tuzak n�ropatilerinin olu�umunu
kolayla�t�rabilir. Subklinik diyabetik polin�ropatisi olan bir hasta, en s�k
g�r�len tuzak n�ropatisi olan karpal t�nel sendromuna
ait&nbsp;klinik&nbsp;yak�nmalarla hekimin kar��s�na ��kabilir. Hastan�n yak�nma
ve bulgular�n�n �iddeti tuzak n�ropatisine y�nelik �zg�n tedavileri (cerrahi
giri�im gibi) gerektirecek d�zeye varabilir. Baz� hastalarda ise tuzak
n�ropatisinin belirti ve bulgular� olmaks�z�n elektrofizyoljik incelemelerde
sinirlerin mutad tuzaklanma yerlerinde (en s�k olarak bilekte median, dirsekte
ulnar sinir) iletim yava�lamalar� saptan�r (subklinik tuzak n�ropatisi). </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Patogenez</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 26�</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> da g�r�ld��� gibi diyabetik n�ropati formlar�n� genel olarak
distal-simetrik (duyusal-otonom-motor) ve fokal-multifokal (proksimal
asimetrik, lumbosakral-trunkal-kranyal) n�ropatiler olarak iki gruba ay�rmak
m�mk�nd�r. Distal-simetrik polin�ropatilerin olu�umuna daha �ok diyabete ba�l�
sinir metabolizmas� bozuklu�unun neden oldu�u, proksimal-asimetrik formlar�n
ise diyabetik k���k damar hastal���na ba�l� olarak ortaya ��kt���
d���n�lmektedir. T�m diyabetik n�ropati formlar�n� tek hipotezle a��klamaya
�al��an g�r��ler de vard�r. �rne�in, diyabetik k���k damar hastal���na ba�l�
multifokal �ok say�da lezyona ait belirtilerin bir araya toplanarak (konfl�ans
g�stererek) bir distal simetrik polin�ropati g�r�n�m� ortaya
��karabilece�i&nbsp;de savunulmaktad�r. <b>Tablo 27</b> DM�lu hastalarda
g�r�len farkl� n�ropati tablolar� i�in en olas� patogenetik mekanizmalar�
�zetlemektedir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 27.</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Diyabetik n�ropatilerin fizyopatolojik klasifikasyonu </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(PJB
Dyck)</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Fizyopatolojik
mekanizma&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; N�ropati
alt-tipi</span></b></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Metabolik-mikrovask�ler-hipoksik
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diyabetik
polin�ropati (DPN)</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Diyabetik otonom n�ropati</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Inflamatuvar-immun&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Radik�lopleksus n�ropatileri (DRPN)</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Kranyal n�ropatiler </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A�r�l� distal n�ropati ve kilo kayb� (diyabetik ka�eksi)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diyabette
CIDP </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kompresyon ve tekrarlay�c�
hasar&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bilekte
median n�ropati</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dirsekte ulnar n�ropati</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Fibula ba��nda peroneal n�ropati</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Diyabet komplikasyonlar�
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ketoasidoz n�ropatisi</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Kronik b�brek yetersizli�i n�ropatisi</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
B�y�k damar iskemisi ile birlikte n�ropati</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tedavi ile
ili�kili&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
�ns�lin nevriti</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:141.6pt;text-indent:35.4pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hiperins�lin
n�ropatisi</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Metabolik mekanizmalar:</span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> �Diabetes
Control and Complications Trial&quot; (DCCT) isimli klinik �al��ma kan �ekerini
�ok s�k� �ekilde kontrol alt�na alan yo�un ins�lin tedavisinin diyabetik
n�ropati geli�me riskini 5 y�lda % 64 oran�nda azaltt���n� g�stermi�tir. Bu
bulgu, y�ksek kan glikozunun yol a�t��� metabolik bozukluklar�n diyabetik
n�ropatiye yol a�abilece�ine&nbsp;ili�kin en kuvvetli kan�t� te�kil etmektedir.
Kronik hiperglisemi lipid, alkol �ekerleri ve miyoinozitol metabolizmas�nda
bozukluklara yol a�ar. �zerinde en �ok durulan ve �al���lan metabolik hipotez, <i>polyol
yolu</i> ile ilgili oland�r. Glikoz, aldoz red�ktaz enzimi taraf�ndan sorbitole
d�n��t�r�l�r. Hiperglisemi nedeniyle bu metabolik yolun a��r� �al��mas� h�cre
i�inde <i>sorbitol birikimi</i>ne yol a�ar. Bu birikim h�cre i�inde&nbsp;
miyoinozitol ve taurinin azalmas�na, bu da h�cre metabolizmas�n�n bozulmas�na
neden olur. H�cre i�inde miyoinozitol ve taurin azalmas�n�n Na<sup>+</sup>-K<sup>+</sup>-ATPaz&nbsp;
aktivitesi azalmas�na ve sinir iletim h�z�n�n d��mesine neden oldu�u
g�sterilmi�tir. Aldoz red�ktaz inhibit�rleri uygulamas� ve diyete miyoinozitol
eklenmesi ile diyabetik n�ropatiyi tedavi etmeyi ama�layan �al��malardan bug�ne
kadar y�z g�ld�r�c� ve klini�e uygulanabilecek sonu� al�namam��t�r. Bununla
birlikte, farkl� ila�larla yap�lacak yeni �al��malardan daha olumlu sonu�lar
al�nmas� beklenebilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>N�rotrofik fakt�rlere ili�kin bozukluklar�n diyabetik
n�ropatiden sorumlu olabilece�ine ili�kin bulgular da elde edilmi�tir. Hayvan
deneylerinde ve diyabetik hastalar �zerindeki �al��malarda sinir b�y�me fakt�r�
(NGF) d�zeyinin azald��� ve hedef dokulardan sinir h�cre g�vdesine retrograd
aksonal transportunun bozuldu�u g�sterilmi�tir. Ba�ka bir �al��mada diyabetik
hastalar�n derisinde NGF ekspresyonunun azalmas� ile ince lif n�ropatisinin
ba�lang�� bulgular� aras�nda bir korelasyon oldu�u g�r�lm��t�r. Di�er baz�
�al��malarda n�rotrofin-3 ve ins�line benzer b�y�me fakt�r� azal�m� ile
diyabetik n�ropati aras�nda ili�ki bulunmu�tur. N�rotrofik fakt�rlerle
n�ropatilerin �nlenmesi ve tedavisini ama�layan&nbsp;preklinik ara�t�rmalar
olumlu sonu�lar vermekle birlikte, bug�ne kadar yap�lan klinik �al��malarda
birbiri ile uyumsuz sonu�lar elde edilmi�tir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Diyabetik n�ropatinin patogenezinde rol ald��� d���n�len
ve tedavisi konusundaki �al��malar� y�nlendiren di�er metabolik hipotezler,
oksidatif stres ve serbest radikal sentezindeki art�� (alfa-lipoik asit
uygulamas� �al��malar�) ve kal�c� hipergliseminin yol a�t��� proteinlerin non
enzimatik glikasyonudur (y�k�lamayan artm�� glikasyon son �r�nleri). Yukar�da
s�z edildi�i gibi, bu hipotezlere dayan�larak g�n�m�ze kadar ger�ekle�tirilen
�al��malarda diyabetik n�ropatinin �nlenmesi ve iyile�tirilmesinde
kullan�labilecek, etkisi kan�tlanm�� klinik tedavi y�ntemleri ortaya
��kmam��t�r. Endon�ral kan ak�m�n� artt�rd��� �ne s�r�len prostaglandin
analoglar�n�n verilmesi, diyetin linolenik asitle zenginle�tirmesi (<i>evening
primrose</i>=ak�am �uha�i�e�i ya��), antioksidan olarak E vitamini ve alfa
lipoik asit uygulanmas� umut verici g�r�nmekte, ancak etkilerinin kan�tlanmas�
gerekmektedir. Baz� �lkelerde a�r�l� n�ropati tedavisinde yo�un �ekilde
kullan�lmakta olan alfa lipoik asit, bir �ift-k�r �al��mada etkili bulunmu�tur.
</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Vask�ler mekanizmalar:</span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> �zellikle
fokal/asimetrik diyabetik n�ropatilerin olu�umundan sorumlu tutulan vask�ler
mekanizmalara ili�kin en �nemli kan�tlar klinik ve histopatolojik verilerden
kaynaklanmaktad�r. Ger�ekten de, multifokal seyirli n�ropatilerin en �nemli
nedenlerinden birisi sinirleri besleyen k���k damarlar�n hastal���d�r (Bak�n�z:
Vask�litlere Ba�l� N�ropatiler). Histopatolojik olarak diyabetik mikroanjiopatide
damar duvarlar�nda kal�nla�ma ve endon�ral k���k damar l�menlerinde daralma
g�r�l�r. Bu patolojik s�recin ba�l�ca bile�enleri bazal lamina duplikasyonu,
endotel ve perisit h�crelerinin dejenerasyonu, endotelial fenestrasyon ve
ayr��mad�r. Diyabetik lumbosakral radik�lopleksopatisi olan hastalar�n sinir
biyopsilerinde mikroanjiopatiye sekonder iskemik de�i�ikliklerin varl���
g�sterilmi�tir (aksonal dejenerasyon, multifokal sinir lifi kayb�, fokal
perin�ral fibroz ve kal�nla�ma, hasar n�romalar�, neovask�larizasyon ve
organellerin birikti�i �i� sinir liflerinin varl���). Mikrovask�ler hasar�n
sinir liflerinde aksonal hasar�n yan�s�ra akson distrofisine ba�l� sekonder
segmental demiyelinizasyona da neden oldu�u g�r�lm��t�r.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Vask�ler hipotezle metabolik g�r��leri ve yayg�n
polin�ropati olu�um mekanizmas�n� ba�da�t�ran yorumlar da vard�r. Endon�ral
hipoksinin sinir liflerinde aksonal transportu ve Na<sup>+</sup>-K<sup>+</sup>-ATPaz
aktivitesini azaltt��� d���n�l�r. Bu bozukluklar da aksonal atrofiye ve sonu�ta
sinir iletim h�z�n�n yava�lamas�na neden olur.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Diyabetik n�ropatinin geli�iminde <i>otoimmun&nbsp;mekanizmalar</i>�n
rol� konusundaki g�r��ler n�ropatinin tedavisinde yeni yakla��mlar�n
tart���lmaya ba�lamas�na neden olmu�tur. �zellikle diyabetik radik�lopleksus
n�ropatisi olan hastalar�n sinir biyopsilerinde mikroskopik vask�lit varl���n�
(epin�ral k���k damarlar�n duvar ve �evrelerinde inflamasyon, damar duvar�nda
nekroz ve eski kanama bulgular�) g�steren �ok say�da �al��ma vard�r. Bu
bulgular, �zellikle fokal/asimetrik diyabetik n�ropatilerin tedavisinde
kortikosteroidler ve intraven�z immunglobulin (IVIg) gibi immunomod�latuvar
tedavilerin uygulanmas�n� g�ndeme getirmi�tir. Kendili�inden regresyon g�sterme
e�ilimi olan bu n�ropatilerde uygulanan immunmod�latuvar tedavilerin etkili
olup olmad��� tart���lmakla birlikte, bu tedaviler bir �ok merkezde a��r
seyirli ve yeterli d�zelme g�stermeyen olgular �zerinde denenmektedir.&nbsp;�ok
merkezli, prospektif, kontroll� bir �al��ma �al��ma ile IV metilprednizolon
uygulamas�n�n a�r� ve di�er duyusal belirtiler gibi ikincil sonlan�m kriterleri
�zerine etkili oldu�u, erken uygulanmas� halinde DLRPN olgular�nda yararl�
olabilece�i kan�s�na var�lm��t�r. Kortikosteroid uygulamas�n�n,glisemi
kontrol�n� k�t�le�tirme potansiyeli g�z �n�nde buldurarak- hastan�n
diyabetolo�unun yak�n kontrol� alt�nda yap�lmas� gerekir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tedavi</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Bug�n i�in diyabetik n�ropatinin �nlenmesi ve tedavisinde en etkin y�ntem
kan glikoz d�zeyinin iyi kontrol alt�nda tutulmas�d�r. Diyabetli hastalarda
n�ropati olu�umuna neden olan metabolik bozukluklar� d�zeltmeye y�nelik daha
�zg�n tedavi y�ntemlerinin etkisi �imdiye kadar kan�tlanamam��t�r ( Bunlar�n
�mit verici olan baz�lar�ndan yukar�da Patogenez b�l�m�nde s�z edilmi�tir).</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Diyabetik n�ropatinin a�r�, otonom bozukluklar ve duyu kayb� gibi
semptomlar�na y�nelik tedaviler �zel bir �nem ta��r. <i>A�a��da s�z edilecek
semptomatik tedaviler benzer belirtilerle seyreden b�t�n polin�ropatilerde
uygulanabilir. </i></span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>N�ropatik a�r�n�n tedavisinde en �ok farmakoterapiden yararlan�l�r. Bir
hastada hangi ilac�n yararl� olaca��n� �nceden belirlemek �ok zordur ve bir �ok
kere ila�lar�n s�ra ile �titre edilerek� denenmesi gerekir. N�ropatik a�r�
farmakoterapisinin temel prensipleri her keresinde tek bir ilac�n denenmesi,
bir ilaca en d���k dozla ba�lan�p maksimal yarar sa�lan�ncaya ya da tolere
edilemeyen yan etkiler ortaya ��k�ncaya kadar dozun yava��a
artt�r�lmas�,&nbsp;a�r� azalmas� anlaml�, yan etkiler tolere edilebilir, hasta
fonksiyon ve aktivitesi iyi oldu�u s�rece tedavinin s�rd�r�lmesi olarak
�zetlenebilir. Hastan�n tolere edebildi�i bir ilac�n etkisiz oldu�una karar
verilip bir ba�kas�na ge�meden �nce ilk ila�la 4-6 hafta tedavinin s�rd�r�lmesi
uygun olur (Bak�n�z: <u><span style='color:blue'><a
href="../noropatikagri/noropatikagri.htm">N�ropatik A�r�</a></span></u>). </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Otonom bozukluklara ait belirtiler �e�itli tedavi
giri�imleri ile azalt�labilir. Semptomatik ortostatik hipotansiyonu olan
hastalar�n uyuduklar� yataklar�n ba� k�sm�n� biraz y�kseltmek, yemeklerinde 2
fincan koyu �ay ya da kahve i�melerini, az ���nde �ok yemek yerine k���k ve �ok
say�da ���n halinde&nbsp;yemelerini �nermek, g�nl�k su ve tuz al�mlar�n�
artt�rmak yararl� olabilir.&nbsp; Bacaklardaki ven�z kapasitans� azaltmak i�in
varis �oraplar� yararl� olmakla birlikte hastalar taraf�ndan tolere edilmeleri
g��t�r.&nbsp; Plazma vol�m�n� artt�rmak i�in fludrokortizon (0.1-0.6 mg/g�n)
kullan�labilir. Alfa-agonist <i>midodrin</i> vazomotor ve venomotor tonusu
artt�rarak ayaktayken kan bas�nc�n� artt�r�r ve ortostatik hipotansiyon
belirtilerini azalt�r. Prostaglandin&nbsp;sentezini inhibe eden nonsteroid
anti-inflamatuvar droglardan <i>ibuprofen</i> ve <i>indometazin</i> ya da
do�rudan etkili bir alfa-agonist olan <i>fenilpropanolamin</i> ayn� ama�la
kullan�labilir. Gecikmi� mide bo�almas�na kar�� s�k ve k���k ���nler ve s�v�
diyet �nerilir. Yemeklerden yar�m saat �nce 10 mg <i>metoklopramid</i>
uygulamas� yararl� olur (y�ksek dozlar�nda ekstrapiramidal semptomlar
g�r�lebilir). Bir di�er alternatif drog <i>cisaprid</i>dir (yemeklerden �nce
10-20mg). Diyabetik diyarenin bakteriyel k�kenli oldu�u d���n�l�yorsa (bu
ama�la C<sup>14 </sup>solunum testi kullan�labilir) k�sa k�rler halinde <i>tetrasiklin</i>
veya <i>eritromisin</i> uygulan�r. Anormal motiliteden kaynakland��� kan�s�
olu�uyorsa<i> loperamid</i> verilebilir. Baz� hastalar�n rahats�z edici
diyarelerinde <i>klonidin</i> uygulamas� yararl� olur. Genito�riner yak�nmalar
konusunda genellikle bir �rolo�un i�birli�ine gereksinim olur. N�rojenik
mesanesi olan hastalar�n g�n i�inde s�k idrara giderek rezid�el idrar miktar�n�
azaltmalar� �nerilir. Daha �iddetli olgularda elle abdominal kompresyona ya da
hastan�n kendi ba��na uygulayaca�� aral�kl� kateterizasyona gereksinim do�ar.
Erektil impotans i�in �rolog kontrol� alt�nda oral s<i>ildenafil</i>, kavern�z
cisimler i�ine vazodilatat�r madde uygulamas� yap�labilir ya da penil implant
uygulamas�na gidilir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>N�ropatiye ba�l� duyu kusuru, ayak �lserlerine ve distal
eklemlerde hasara (<i>n�ropatik artropati</i>) neden olabilir. Diyabetik bir
hastan�n kronik ayak&nbsp;yaralar�, �o�u kez farkedilmeyen a�r�s�z travmalar,
vask�ler yetersizlik ve sekonder infeksiyonlar�n ortak sonucudur. Bunlar�n
�nlenmesi tedavisinden kolay oldu�undan, diyabetik n�ropatisi olan hastan�n
ayaklar� kendisi taraf�ndan her g�n, doktoru taraf�ndan s�k s�k muayene
edilmelidir. Yara olmas� muhtemel travma yerlerinde kronik bas� etkenlerinin
ortadan kald�r�lmas� ve geli�en yaralar�n derhal uygun �ekilde tedavi edilmesi,
gangren nedeniyle ekstremite kayb�n�n ve sepsis gibi sistemik komplikasyonlar�n
�nlenmesi a��s�ndan �ok �nemlidir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Polin�ropati semptomlar�n�n tedavisi planlan�rken
uygulanacak ila�lar�n yan etki profili dikkatle g�zden ge�irilmeli, n�ropatinin
kendisinin ya da �o�u kez ya�l� bir diyabetik olan hastan�n kardiovask�ler
sorunlar�n�n hastay� ila� yan etkilerine daha a��k bir hale getirdi�i
unutulmamal�d�r.</span></i><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'> �rne�in, a�r� tedavisi i�in y�ksek dozda ba�lan�lan
trisiklik antidepresan ila�lar, o ana kadar belirti vermeyen otonom n�ropatiye
ba�l� �iddetli ortostatik&nbsp;hipotansiyonun ortaya ��kmas�na neden olabilir.
Kardiyak otonom tutulmas� ya da primer kalp hastal��� olan hastalarda
meksiletin gibi kalp ritmini etkileyen ila�lar �ok dikkatle kullan�lmal�d�r.
Ortostatik hipotansiyona y�nelik&nbsp;plazma vol�m�n� artt�r�c� tedaviler
uygulanmadan �nce konjestif kalp yetersizli�i ya da iyi kontrol alt�na
al�nmam�� hipertansiyon bulunmamas�na dikkat edilmelidir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Diyabetik radik�lopleksus n�ropatisi, �iddetli a�r�n�n
yan� s�ra iyile�mesi bazen yava� ve yetersiz olan kas kuvvetsizli�ine de neden
olur. &nbsp;Bu nedenle, a�r�ya y�nelik tedavilerin yan�nda dikkatli bir
fizyoterapi ve psikolojik destek program�n�n uygulanmas� �nem ta��r. Hasta
mevcut tablonun genellikle monofazik �zellikte oldu�u ve mutlaka bir derece
d�zelece�i konusunda ikna edilmeye �al���lmal�d�r. �zellikle �al��ma �a��nda
olan hastalar�n, a�r�lar� azal�p klinik tablolar� d�zelmeye ba�lad���nda,
gere�inde ortotik cihazlardan da yard�m alarak, m�mk�n oldu�unca h�zl� bir
�ekilde i� ya�am�na d�nd�r�lmesine gayret edilmelidir. &nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�remik Polin�ropati </span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Kronik b�brek yetersizli�ine ba�l� polin�ropatiler 1960�l� y�llardan
itibaren, diyaliz ve transplantasyonun �remik hastalara daha uzun ya�ama �ans�
sa�lamas� ile tan�nmaya ba�lam��t�r. Kronik b�brek yetersizli�inde n�ropati
prevalans�, b�brek yetersizli�inin �iddet ve s�resine ba�l� olarak % 10 ile %
80 aras�nda de�i�mektedir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�remik n�ropati, muhtemelen b�brekle at�lamayan sistemik toksinlerin
birikimine ba�l� olarak geli�ir. N�ropatiye neden olan spesifik bir toksin
belirlenememi� olmakla birlikte, guanidin bile�ikleri, miyoinozitol,
parathormon, orta molek�ler a��rl�kl� maddeler ve hiperkalemi potansiyel n�rotoksik
fakt�rler aras�nda say�lmaktad�r. Bunun yan�s�ra, hastalar�n bir k�sm�nda ayn�
zamanda hem b�brek hastal��� hem de n�ropati geli�imine neden olabilecek
diyabet gibi sistemik hastal�klar bulundu�undan, polin�ropatinin geli�imi bir
ka� fakt�re birden ba�l� olabilmektedir. Ayn� nedenle, bir hastada �remik
n�ropatiden s�z edilebilmesi i�in aylardan beri devam eden kronik son a�ama
b�brek yetersizli�inin (kreatinin klirensi &lt;10ml/min) bulunmas�, periferik
sinirleri etkileyecek ila� toksisitesi ile diyabet, vask�lit, amiloidoz gibi
sistemik hastal�klar�n ekarte edilmi� olmas� gerekir. Nitrofurantoin ve
kol�isin b�brek yetersizli�i olan hastalarda s�k rastlanan toksik n�ropati
nedenleridir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�remik n�ropati erkeklerde kad�nlardan daha s�k g�r�l�r. Klinik �zellikler
distal ve simetrik, duyusal belirtileri bask�n duyusal-motor polin�ropati
�eklindedir. Ba�l�ca semptomlar�n� huzursuz bacaklar, bacak kramplar�, distal
parestezi ve uyu�ukluklar ile parmaklarda yanmalar olu�turur. �nde gelen
muayene bulgular� distal duyu kayb� (�zellikle vibrasyon duyusu), refleks
azalmas� ve ayak parmak ekstansiyonunda simetrik kuvvetsizliktir.
&nbsp;Nadiren, diyalizin ilk haftalar�nda GBS�nu taklit eden ani bir
ba�lang��la ortaya ��kabilir. Son a�ama b�brek yetersizli�i olan diyalizdeki
hastalarda bazen subakut motor bile�eni bask�n bir polin�ropati geli�ebilir. Bu
durumdaki baz� hastalar konvansiyonel hemodiyalizden y�ksek-ak�m hemodiyalizine
ge�ilmesi ile d�zelirler. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�remik hastalarda <i>karpal t�nel sendromu</i> arterioven�z fist�llere ya
da transvers karpal ligamentte (<span style='mso-char-type:symbol;mso-symbol-font-family:
Tahoma'><span style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'>&#61538;</span></span>-2
mikroglobulinle birlikte olan) amiloid birikimine ba�l� olarak ortaya
��kabilir. <i>�skemik monomelik n�ropati</i>, arterioven�z fist�ller nedeniyle
geli�en ve hemen daima birlikte aterosklerotik damar hastal��� olan diyabetik
�remik ki�ilerde ortaya ��kan bir komplikasyondur. Ani a�r�l� ba�lang�c� olan
bu komplikasyonda kal�c� n�rolojik defisitlerin �nlenmesi i�in fist�l�n h�zla
cerrahi olarak kapat�lmas� gerekir.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>�remik n�ropati patolojik olarak, periferik sinir
sisteminin en distal kesimlerinde belirgin olan aksonal dejenerasyonla
seyreder. Segmental demiyelinizasyon aksonal atrofiye sekonder olarak geli�ir.
Elektrofizyolojik incelemelerde sinir iletim h�zlar�nda genel yava�lama ve
distal latanslarda uzama izlenir. Sinir iletim yava�lamas�n�n olmad��� erken
a�amalarda ge� yan�tlar�n (H refleksi ve F yan�tlar�) latans� uzam�� bulunur.
BOS proteini s�kl�kla artm�� olmakla birlikte, �remik n�ropatisi olan
hastalarda bu incelemeye nadir olarak ihtiya� duyulur. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Diyaliz periferik n�ropatiyi �nler, stabilize eder ya da
iyile�tirebilir. Hemodiyaliz s�ras�nda n�ropatinin k�t�le�mesi diyalizin
s�kla�t�r�lmas� veya s�resinin uzat�lmas�n� gerektirebilir. Sinir
fonksiyonlar�na etki a��s�ndan hemodiyaliz ve periton diyalizi aras�nda belirgin
fark yoktur. B�brek transplantasyonunun n�ropatiyi d�zeltici etkisi daha
belirgindir. Transplantasyonu izleyen aylarda �iddetli �remik n�ropatilerde
bile d�zelme g�r�lebilir. Son a�ama b�brek yetersizli�i olan hastalarda y�ksek
ak�ml� hemodiyaliz ve eritropoetin uygulamas� B6 vitamin yetersizli�ine neden
olabilir. B�yle olgularda g�nl�k rejime 60mg pridoksin eklenmesinin duyusal
belirtleri azaltt��� g�sterilmi�tir. N�ropatik a�r� tedavisinde trisiklik
antidepresanlar doz ayarlamas�na gerek olmadan kullan�labilir. Gabapentin i�in
renal doz ayarlamas� yap�lmas� gerekir. &nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Karaci�er Yetersizli�ine Ba�l� Polin�ropati</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Karaci�er hastal��� olanlar�n sinir biyopsileri ve sinir
iletim incelemelerinde olduk�a y�ksek oranda anormallik bulunmakla birlikte,
semptomatik n�ropati nadir ve hafif �iddettedir. Prospektif �al��malar, kronik
karaci�er hastal��� olanlarda y�ksek oranda otonom tutulma varl���n�
g�stermi�tir. Karaci�er transplantasyonu bekleyen hastalar aras�nda otonom
n�nopati bulgusu olanlar�n �l�m oranlar�, olmayanlara oranla belirgin derecede
daha y�ksek bulunmu�tur. Bu nedenle transplantasyon bekleyen ileri karaci�er
hastalar�n�n otonom fonksiyonlar a��s�ndan incelenmesi ve otonom tutulmas�
olanlar�n erken transplantasyon a��s�ndan de�erlendirilmesi gerekti�i
savunulmaktad�r. Ba�ar�l� ortotopik transplantasyondan sonra n�ropatinin
d�zeldi�ine dair g�zlemler mevcuttur. Primer biliyer sirozla birlikte olan a��r
ataksik duyusal bir n�ronopati ile hiperlipidemi ve cilt ksantomlar�yla
birlikte olan a�r�l� dizestezik duyusal bir polin�ropati bildirilmi�tir. <b>Tablo
28</b> karaci�eri etkileyen hastal�klarla birlikte olan ve farkl�
mekanizmalarla geli�en ba�l�ca n�ropatileri �zetlemektedir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 28.</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Karaci�er hastal�klar�nda g�r�len n�ropatiler </span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(EP Bosch,
Kaynak Kitap 10�dan al�nm��t�r)</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Hastal�k</span></b></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�ropati</span></b></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Tedavi</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Viral hepatit A, B, C</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>AIDP, CIDP</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IVIg, plazmaferez</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>HCV, mikst kriyoglobulinemi ile birlikte veya de�il</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Duyusal, duyusal-motor polin�ropati,</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Monon�ropati multipleks</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Plazmaferez, kortikosteroidler, siklofosfamid,
  interferon alfa, ribavirin</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kronik karaci�er hastal���</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Duyusal n�ropati, kardiyovagal dizotonomi</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Karaci�er transplantasyonu</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Karaci�er transplantasyonu</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>CIDP</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>IVIg, plazmaferez</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Primer biliyer siroz</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Ksantomat�z n�ropati, duyusal n�ronopati</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>?</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;mso-yfti-lastrow:yes'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kolestatik karaci�er hastal���nda vitamin E eksikli�i</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Duyusal n�ropati veya spinoserebellar sendrom</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Vitamin E, TPGS</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>TPGS: Tokoferol polietilen 1000-glikol s�ksinat.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'>�NFEKS�YONLARA
BA�LI N�ROPAT�LER</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Lepra</span></b></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Eski �a�lardan beri bilinen ve orta�a�da Avrupa�da
endemik olan Lepra, halen ba�l�ca tropikal ve subtropikal b�lgelerde rastlanan
bir infeksiyondur. D�nya n�fusunun t�m�ne bak�ld���nda en s�k periferik
n�ropati nedenlerinden biridir. Ancak, sa�l�k ko�ullar�ndaki iyile�me ve �ok
droglu tedavi uygulamas� ile d�nyadaki prevalans� da d��mektedir. Kay�tl� olgu
say�s� 1991de 1980lerin ba��ndaki say�n�n yakla��k yar�s�na (5.4 milyon)
d��m��, 1996 da 0.9 milyona inmi�tir.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Lepra, periferik sinirlerin&nbsp; <i>Mycobacterium leprae</i>
taraf�ndan olu�turulan primer bir infeksiyon hastal���d�r. Bu aside diren�li,
Gram pozitif basil zorunlu bir intrasell�ler parazittir. B�t�n bakteriler
i�inde en d���k �o�alma h�z�na sahip oland�r (deneysel olarak infekte edilmi�
farede b�l�nme s�resi 13 g�n). �nsandan insana ge�i�i g��t�r. �st solunum yolu
ile al�nd���, nazal mukozadaki ilk kolonizasyondan sonra yava��a v�cuda
da��ld��� d���n�l�r. Tahmin edilen ink�basyon d�nemi 3-10 y�ld�r. Bakterinin �o�alabildi�i
dokular g�nl�k ortalama s�cakl��� 27-30<sup>0</sup> C olan b�lgelerde yer al�r.
Bu nedenle deri ve y�zeysel seyirli sinirler infeksiyondan etkilenen ba�l�ca
v�cut yap�lar�d�r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Hastal���n klinik belirtileri, kona��n <i>M. leprae</i>ya kar��
geli�tirdi�i ba����kl�k yan�t�n�n yo�unlu�u taraf�ndan belirlenir. Yo�un bir
h�cresel ba����kl�k yan�t� bakteriyi s�n�rlarken hastan�n dokular�n� tahrip
eder <i>(t�berk�loid lepra</i>). Buna kar��l�k, konak ba����kl�k yan�t� minimal
oldu�unda bakterinin �o�almas�na ve yay�lmas�na kar�� koymaz, lepra
antijenlerine kar�� anerji vard�r ve minimal inflamatuvar reaksiyonla birlikte
yayg�n deri ve sinir lezyonlar� olu�ur <i>(lepromat�z lepra)</i>. Hastal���n bu
iki u� formu aras�nda 3 ara formu tan�mlanm��t�r.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Lepran�n kardinal semptomu, �o�u kez a�r�s�z yaralanmalarla fark edilen
duyu kayb�d�r. Bakterinin s�cakl�kla ilgili gereksinimleri nedeniyle s�cakl���
d���k v�cut b�lgelerindeki deri sinirleri etkilenir. Bu nedenle, klinik tablo
tam olarak geli�ti�inde duyu kayb�n�n polin�ropatilerde g�r�lenden farkl�
olarak kulak kep�esi, zigomatik kemiklerin �zeri ve eklemlerin ekstans�r
y�zlerini se�en bir da��l�m g�sterdi�i izlenir.&nbsp;B�y�k sinirler y�zeye
yak�n seyrettikleri b�lgelerde tutulur. Bu sinirler sert ve �i�kin �ekilde
palpe edilebilir (b�y�k aurik�ler sinir, ulnar sinir dirsek segmenti, bilek
lateralinde radyal sinir deri dal�, peroneal ve sural sinirler). �zellikle
t�berk�loid formda deri sinirleri iyi s�n�rlanm�� bir alanda tutulur. Buna
dermis ve epidermis lezyonlar�n�n da kat�lmas� ile tipik hipopigmente anestetik
mak�ller olu�ur. Duyu bozuklu�unun a��r oldu�u olgularda �zellikle a�r� duyusu
kayb�, tekrarlayan travmalar sonucu ekstremite deformitelerine ve
otoamp�tasyonlara neden olur. Motor zaaf, duyu kayb� iyice yerle�meden �nce
ortaya ��kmaz, geli�ti�inde ise asimetrik bir da��l�m g�sterir (ay�r�c� tan�da
di�er monon�ropati multipleks nedenlerini d���nmek gerekir). Fasiyal sinirin
k���k dallar�n�n selektif tutulmas� sonucunda frontal kaslar ve orbik�laris
okuli kas�nda izole zaaf olabilir. Bazen n�ropatik bulgular deri lezyonlar�
olmadan ortaya ��kabilir (saf n�ritik lepra). Polin�ropatilerin �o�unlu�unda
azalan ya da kaybolan tendon reflekslerinin leprada genellikle korunmu� olmas�
ay�r�c� tan�da yard�mc� olur. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Lepran�n tan�s� deri ve gere�inde sinir biyopsilerinde <i>M. leprae�</i>nin
g�terilmesi ile konur. Deri biyopsilerinde bakteri yo�unlu�una bak�larak
infeksiyonun tedaviye yan�t� da izlenebilir. Tedavi spesifik kemoterapiden ve
hastal���n olu�turdu�u deformitelerin �nlenmesi ve d�zeltilmesinden olu�ur. Az
basilli t�berk�loid formlar�n tedavisinde 3 antibiyoti�in tek doz verilmesi
yeterli olur (rifampisin 600 mg, ofloksasin 400mg, minosiklin 100 mg). �ok
basilli formlarda (lepromat�z ve borderline)&nbsp; yine ��l� antibiyotik
tedavisi yap�l�r, fakat tedavi 1 y�l s�rd�r�l�r (dapson 50 mg/g�n, rifampisin
600mg/ay, klofazimin 50 mg/g�n ve 300 mg/ay).</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>HIV �nfeksiyonu ve N�ropati</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�ok aktif antiretroviral tedavinin (HAART) 1990�lar�n ortalar�ndan itibaren
kullan�ma girmesi ile HIV infeksiyonu olan hastalar�n ya�am s�releri uzam��;
ge� d�nem n�rolojik komplikasyonlar�na a��k olan bu hastalarda merkez sinir
sistemi komplikasyonlar� azal�rken periferik n�ropatiler s�k bir komplikasyon
olma �zelli�ini s�rd�rm��t�r (Bak�n�z: <u><span style='color:blue'>Sinir
Sistemi �nfeksiyonlar�</span></u>). HIV infeksiyonunun serokonversiyon
a�amas�ndan AIDS�in ileri devrelerine kadar farkl� d�nemlerinde bir �ok
periferik n�ropati tablosu ile kar��la��l�r (<b>Tablo 29</b>). HIV-1
infeksiyonlu hastalarda klinik bulgularla tan� konan periferik n�ropati
prevalans� %15-30 kadard�r. Elektrofizyolojik inceleme verileri kullan�ld���nda
bu oran belirgin derecede artmaktad�r. CD4 say�s� n�ropati s�kl��� ile ters
ili�ki g�sterir. CD4 say�s� normal olan hastalarda daha �ok inflamatuvar
demiyelinizan polin�ropatiler g�r�l�rken, d���k olanlarda distal simetrik
polin�ropatiler ve lumbosakral poliradik�lopatilere rastlan�r.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 29</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>. HIV infeksiyonlu hastalarda periferik n�ropatiler </span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(CH Chalk)</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Distal a�r�l�
n�ropati</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>N�trisyonel
yetersizli�e ba�l� n�ropatiler</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Antiretroviral ila�lara ba�l� n�ropatiler</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Guillain-Barr� sendromu</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CIDP</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Monon�ropati multipleks</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Akut lumbosakral poliradik�lopati</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Akut ve kronik inflamatuvar demiyelinizan polin�ropatiler</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> tipik olarak ba�ka
semptomu olmayan HIV infeksiyonlu hastalarda (bazen serokonversiyon d�neminde)
g�r�l�r. Klinik tablo HIV infeksiyonu olmayan hastalardaki gibidir. BOS�ta
lenfositik pleositoz (20-50/mm3)&nbsp; ve sinir biyopsilerinde belirgin
iltihabi h�cre infiltrasyonu g�r�l�r. <i>Bu nedenle inflamatuvar demiyelinizan
polin�ropatisi olan hastalarda HIV-1 risk fakt�rlerinin varl���, BOS�ta h�cre
g�r�lmesi, pozitif hepatit B serolojisi veya poliklonal hipergamaglobulinemi
varl��� HIV ara�t�r�lmas�n� gerektirir</i>. Bu olgulardaki akut (GBS) ve kronik
(CIDP) inflamatuvar demiyelinizan polin�ropatiler de, &nbsp;-HIV infeksiyonu
bulunmayan hastalarda oldu�u gibi- plazma de�i�imi ve IVIg tedavisine iyi yan�t
verir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Distal simetrik polin�ropatiler</span></i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'> HIV infeksiyonunun ge� evrelerinde s�k g�r�l�r.
Ba�l�ca belirtileri ayaklarda yanmalar, a�r�l� dizesteziler ve distal duyu
azalmas�d�r. Distal kaslarda hafif kuvvetsizlik ve otonom fonksiyon bozuklu�u
olabilir.&nbsp; Hastalar�n bir k�sm�nda polin�ropatiye yol a�abilecek B12
vitamini ve folat yetersizli�i, ya da n�rotoksik ila� uygulamas� </span><span
lang=TR style='font-family:Symbol;mso-ansi-language:TR'>[</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>vinkristin, dapson, INH,
talidomid, nukleosid revers transkriptaz inhibit�rleri (dideoksisitidin,
dideoksiinosin, stavudin)</span><span lang=TR style='font-family:Symbol;
mso-ansi-language:TR'>]</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> gibi nedenler bulunur. Bir k�s�m olgulardaki
polin�ropatinin nedeni ise belirlenememi�tir. Ara�t�rmac�lar�n �o�una g�re
n�ropatinin do�rudan HIV infeksiyonuna ba�l� olmas� ihtimali d���kt�r. Sinir
biyopsilerinde miyelinli ve miyelinsiz lif kayb� g�r�l�r. Distal simetrik
polin�ropatisi olan HIV-1 pozitif hastalar�n bir k�sm�nda nekrotizan vask�lit
bulunmu�tur.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Monon�ropati ve monon�ropati multipleks</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>: Tek veya iki yanl� fasiyal
paraliziler HIV-1 serokonversiyon d�neminde g�r�lebilir. Birka� kranyal veya
spinal sinirin tutuldu�u, CD4 say�s� 200/<span style='mso-char-type:symbol;
mso-symbol-font-family:Tahoma'><span style='mso-char-type:symbol;mso-symbol-font-family:
Tahoma'>&#61549;</span></span>l den y�ksek hastalarda n�ropatilerin prognozu
iyidir ve genellikle spontan d�zelme g�sterir. Buna kar��l�k, a��r defisite
neden olan monon�ropati multipleks tablolar� genellikle CD4 say�s� 200/<span
style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'><span
style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'>&#61549;</span></span>l
den az, immun yetersizli�i olan hastalarda ortaya ��kar. Bu hastalarda CMV
infeksiyonu ara�t�r�lmal�d�r. CMV infeksiyonunun ortaya konmas� ya da bundan
klinik olarak ��phe duyulmas� halinde hemen gansiklovir tedavisine ba�lanmas�
gerekir. CMV infeksiyonunun bulunamamas� halinde n�ropatinin en kuvvetli nedeni
periferik sinir vask�litidir. Bu olgular kortikostreoidler ba�ta olmak �zere
immunoterapiden yararlan�rlar.&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Akut lumbosakral poliradik�lopati (progressif poliradik�lopati):</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Genellikle CMV
infeksiyonunun neden oldu�u en a��r AIDS komplikasyonlar�ndan biridir.
Lumbosakral sinir k�klerinin CMV taraf�ndan invazyonuna ba�l� olarak h�zla progresyon
g�steren bir kauda ekuina sendromu (gev�ek bir paraparezi, sfinkter fonksiyon
bozuklu�u, perinede duyu azalmas� ve alt ekstremitelerde tendon reflekslerinin
kayb�) ile seyreder. �leri d�nemlerinde �st ekstremiteler ve kranyal alanda
tutulmaya ait bulgular ortaya ��kar. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>BOS�ta genellikle polimorfon�kleer a��rl�kl� (%40�tan �ok) olmak �zere
50/mm<sup>3</sup> ten fazla h�cre vard�r. Protein d�zeyinin artm��, glikozun
azalm�� olmas� beklenir. Ancak bu tipik BOS bulgular�na olgular�n ancak yar�s�
kadar�nda rastlan�r. Hastalar�n yine yar�s� kadar�nda BOS CMV k�lt�r�
pozitiftir. CMV DNA�s�n�n PCR ile g�sterilmesi g�venilir ve duyarl� bir tan�
testidir. MR g�r�nt�leme incelemesinde kauda ekuina liflerinin kontrast madde
tuttu�u g�sterilebilir. Mevcut klinik ve BOS bulgular� ile �CMV infeksiyonu
g�sterilememi� olsa bile- hemen gansiklovir ve foscarnet tedavisi (birlikte
veya monoterapi olarak) ba�lanmal�d�r. CMV ensefalitinde etkili oldu�u bilinen
cidofovirin progressif radik�lopatideki etkisi bildirilmemi�tir. Tedavi edilmeyen
olgular h�zla progresyon g�stererek 2-30 g�nde �l�mle sonlan�r. Tedavi ile
n�rolojik tablonun ilerleyi�inin durdurulmas� ve hatta&nbsp; d�zelmesi m�mk�n
olabilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Lumbosakral poliradik�lopatiye yol a�abilecek di�er
nedenler aras�nda sifiliz, mikobakteriyel infeksiyonlar, toksoplazmoz ve
leptomeningeal lenfomatoz say�labilir.&nbsp; HIV infeksiyonu ile birlikte olan
bir di�er tablo, habis olmayan bir CD 8 lenfositoz olan <i>diff�z infiltratif
lenfositoz sendromu</i>dur. Multipl i� organ ve periferik sinir tutulmas�
g�r�len bu sendrom kortikosteroid veya antiretroviral tedavi uygulamas�na cevap
verebilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Olduk�a yeni bir kavram olan <i>immun rekonstit�syon
inflamatuvar sendromu</i>�nda (IRIS), g��l� antiretroviral tedavi ile HIV-1 RNA
d�zeyleri azal�p CD4 h�cre say�lar� artan olgularda daha �nce var olan
infeksiy�z veya otoimmun hastal�klar�n �iddetlenmesi s�z konusudur. Yak�n
zamanda IRIS�le ili�kilendirilen 2 GBS olgusunda immunosupresan tedavi alt�nda
CD4 say�s�nda azalmayla birlikte klinik d�zelme g�zlendi�i bildirilmi�tir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>TOKS�K POL�N�ROPAT�LER</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>N�ropati olu�turan toksik maddeler �� grupta incelenebilir: ila�lar,
end�striyel toksinler ve �evresel toksinler (<b>Tablo 30</b>). Bir kimyasal
maddenin n�rotoksik oldu�unun kan�tlanmas� kolay de�ildir ve bunun i�in ideal
olarak hastada di�er n�ropati nedenlerinin d��lanm�� olmas�, toksine maruz
kalan �ok say�da ki�ide ayn� n�rolojik belirtilerin ortaya ��kmas�, toksinle
temas�n kesilmesini izleyerek n�ropatinin gerilemesi, n�rotoksisitenin hayvan
deneyi ve doku k�lt�rleriyle g�sterilmi� olmas� gerekir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'>�la�lar</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�la�lara ba�l� n�ropatilere olduk�a s�k rastlan�r (<b>Tablo 30</b>).
N�ropatisi olan bir hastan�n �yk�s�nde bu hastal��a neden olabilecek bir ila�
kullan�m�n�n ara�t�r�lmas� �nem ta��r. ��nki, kullan�lan ila� ile polin�ropati
aras�nda mant�kl� bir nedensellik ili�kisi kurulabilirse, mevcut
polin�ropatinin nedenini ara�t�rmak konusunda uzun ve yorucu ara�t�rmalar
yapmaya gerek kalmaz.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�la�lara ba�l� polin�ropatiler genellikle aksonal dejenerasyonla seyreder.
Klinikte ekstremite distallerinde bask�n simetrik duyusal ya da duyusal-motor
bulgular vard�r. A�r� s�k kar��la��lan bir yak�nmad�r. Toksik madde ile temas�n
kesilmesinden sonra&nbsp; aylar i�inde iyile�me olur. Baz� hastalarda sorumlu
ilac�n kesilmesine ra�men klinik bulgular haftalar s�ren bir progresyon
g�sterebilir (�<i>coasting</i>�). Baz� ila�lar ise distal aksonopati yerine
arka k�k gangliyonlar�n� etkileyerek ataksik duyusal bir n�ronopatiye
(sisplatin, piridoksin megadozu) ya da demiyelinizan bir polin�ropatiye
(perheksilen, amiodaron, suramin) yol a�arlar. &nbsp;<b>Tablo 31</b>�de&nbsp;
toksik n�ropatiler en �ok yol a�t�klar� belirtilere ve tutulan periferik sinir
yap�lar�na g�re gruplanm��t�r.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Gelecekte n�rotrofik fakt�rlerin kullan�m�n�n yayg�nla�mas� ve bu
maddelerin kemoterapi ile birlikte uygulanmas�n�n kanser ila�lar�n�n
polin�ropati yap�c� etkilerini engelleyece�i umulmaktad�r.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 30</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>. N�ropati nedeni olan ba�l�ca toksik maddeler </span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(RA Lewis�de
de�i�tirilerek)</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>)</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=631
 style='width:473.4pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
  <td width=115 valign=top style='width:86.4pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�evresel ve End�striyel Toksinler</span></b><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>A��r Metaller</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Heksakarbonlar</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Akrilamid</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Karbon Dis�lfid</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Etilen glikol</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Organofosfatlar</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yenilerek Al�nan</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>B�cek Sokmalar� ve Hayvan Toksinleri</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�rotoksik Bitkiler</span></p>
  </td>
  <td width=228 valign=top style='width:171.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Arsenik </span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kur�un</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Civa</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Platin</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Talyum</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N-heksan</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Metil-n-b�til keton</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Metil-etil keton </span><span lang=TR style='font-size:
  8.0pt;font-family:Tahoma;mso-ansi-language:TR'>(N-heksan� potansiyelize
  edebilir)</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:8.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:8.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:8.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:8.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Triortokrezil fosfat</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Ciguatera</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Paralitik deniz kabuklusu
  zehirlenmesi-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saksitoksin</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�i�en bal�k (fugu)-Tetrodotoksin</span><span lang=FI
  style='mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=FI style='mso-ansi-language:
  FI'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kene paralizisi</span><span lang=FI style='mso-ansi-language:
  FI'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Tropikal kurba�a derisi toksinleri</span><span lang=FI
  style='mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=FI style='mso-ansi-language:
  FI'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=FI style='mso-ansi-language:
  FI'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Cassava (</span><span lang=TR style='font-size:8.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Menihot esculenta</span><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)-siyanid</span><span
  lang=FI style='mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>T�rmanan zambak (</span><span lang=TR style='font-size:
  8.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gloriosa superba</span><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)</span><span
  lang=FI style='mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Mandrake (</span><span lang=TR style='font-size:8.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Podophyllium peltatum</span><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)-podofilotoksin</span><span
  lang=FI style='mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:8.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Cataranthus roseus</span><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-vinka
  alkaloidi</span><span lang=FI style='mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Tullidora (</span><span lang=TR style='font-size:8.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Karwinskia humbodtiana</span><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)</span><span
  lang=FI style='mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
  <td width=117 valign=top style='width:88.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�la�lar</span></b><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Antibiyotikler ve di�er Anti-infeksiy�z Maddeler</span><span
  lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kemoterapi ve Antikanser Maddeler</span><span lang=DA
  style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Antir�matik ve Immunsupresan Maddeler</span><span
  lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kardiyovask�ler �la�lar</span><span lang=DA
  style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Psikiyatrik ve Sedatif ila�lar</span><span lang=DA
  style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Di�er �la�lar</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  </td>
  <td width=171 valign=top style='width:127.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kloramfenikol</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Klorokin</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Dapson</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�zoniazid</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Metronidazol</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Nitrofurantoin</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Zalsitabin (</span><span lang=TR style='font-size:8.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>dideoksisitidin</span><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>) ve di�er
  n�kleosid analoglar� (</span><span lang=TR style='font-size:8.0pt;font-family:
  Tahoma;mso-ansi-language:TR'>dideoksiinozin</span><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)</span><span
  lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Sisplatin</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Paklitaksel</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Mizonidazol</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Suramin</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Talidomid</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Vinkristin</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Klorokin</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kol�isin</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Alt�n</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>FK 506 (Prograf)</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Amiodaron </span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Hidralazin</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Perheksilin</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Propafenon</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Simvastatin ve di�er statinler </span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Dis�lfiram (Antabus)</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Glutetimid</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Pridoksin (Vitamin B6)</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Fenitoin (</span><span lang=TR style='font-size:8.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Difenil hidantoin</span><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;color:#333333;
mso-ansi-language:TR'>Tablo 31.</span></b><span lang=TR style='font-family:
Tahoma;color:#333333;mso-ansi-language:TR'> Klinik ve patolojik �zelliklerine
g�re toksik n�ropatiler </span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;color:#333333;mso-ansi-language:TR'>(A. Pestronk)</span></p>

<table class=MsoNormalTable border=1 cellpadding=0 style='mso-cellspacing:1.5pt;
 mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=380 colspan=3 valign=top style='width:285.2pt;padding:0cm 0cm 0cm 0cm'>
  <p class=MsoNormal align=center style='text-align:center'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Aksonal</span></b></p>
  </td>
  <td width=125 valign=top style='width:93.55pt;padding:2.25pt 2.25pt 2.25pt 2.25pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Demiyelinizan</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></p>
  </td>
  <td width=96 valign=top style='width:72.35pt;padding:2.25pt 2.25pt 2.25pt 2.25pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kar���k</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=102 valign=top style='width:76.85pt;padding:2.25pt 2.25pt 2.25pt 2.25pt'>
  <p class=MsoNormal align=center style='text-align:center'><i><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Duyusal </span></i></p>
  </td>
  <td width=163 valign=top style='width:121.9pt;padding:2.25pt 2.25pt 2.25pt 2.25pt'>
  <p class=MsoNormal align=center style='text-align:center'><i><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Duyusal ve
  Motor</span></i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'> </span></p>
  </td>
  <td width=111 valign=top style='width:83.45pt;padding:2.25pt 2.25pt 2.25pt 2.25pt'>
  <p class=MsoNormal align=center style='text-align:center'><i><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Motor</span></i><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></p>
  </td>
  <td width=223 colspan=2 valign=top style='width:167.4pt;padding:2.25pt 2.25pt 2.25pt 2.25pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp; </span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=102 rowspan=2 valign=top style='width:76.85pt;padding:2.25pt 2.25pt 2.25pt 2.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Almitrin<br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#bortezomib#bortezomib"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Bortezomib</span></a><br>
  Kloramfenikol</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Dioksin<br>
  Doksorubisin<br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#ethambutol#ethambutol"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Etambutol</span></a><br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#ethionamide#ethionamide"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Etionamid</span></a><br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#vp16#vp16"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Etoposid
  (VP-16)</span></a><br>
  Gemsitabine<br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#glutethimide#glutethimide"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Glutetimid</span></a><br>
  Hidralazin<br>
  Ifosfamid</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�<a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#interferona#interferona"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>nterferon-&#945;</span></a><br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#isoniazid#isoniazid"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Isoniazid</span></a><br>
  Kur�un <br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#leflunomide#leflunomide"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Leflunomid</span></a><br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#metronidazole#metronidazole"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Metronidazol</span></a><br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#misonidazole#misonidazole"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Misonidazol</span></a><br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#nitrous#nitrous"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Nitr�z o</span></a>ksid<br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#nucleosides#nucleosides"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Nucleosid</span></a>ler<br>
  &nbsp; ddC; ddI;<br>
  &nbsp; d4T; 3TC<br>
  Fenitoin <br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#cis-platinum#cis-platinum"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Platin</span></a>
  analoglar�<br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#propafenone#propafenone"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Propafenon</span></a><br>
  <a href="http://neuromuscular.wustl.edu/nother/vitamin.htm#pyridoxineintox"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Pirido</span></a>ksin<br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#statin#statin"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Statin</span></a>ler<br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#thalidomide#thalidomide"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Talidomid</span></a>
  </span></p>
  </td>
  <td width=163 rowspan=2 valign=top style='width:121.9pt;padding:2.25pt 2.25pt 2.25pt 2.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Akrilamid<br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#etoh#etoh"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Alkol
  (Etanol)</span></a><br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#allyl#allyl"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Alilklorid</span></a><br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#arsenic#arsenic"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Arseni</span></a>k<br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#cadmium#cadmium"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Kadmium</span></a><br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#carbon#carbon"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Karbondisulfid</span></a><br>
  <a href="http://neuromuscular.wustl.edu/mother/myotox.htm#chlorphenoxy"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Klorfeno</span></a>ksi
  herbisidler<br>
  <a href="http://neuromuscular.wustl.edu/mother/chan.html#ciguatera"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Ciguatoksin</span></a><br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#colchicine#colchicine"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Kol</span></a>�isin</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Siyanid<br>
  Dapson<br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#dichloroacetate#dichloroacetate"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Dikloroasetat</span></a></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'><a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#disulfiram#disulfiram"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Dis�lfiram</span></a><br>
  Dimetilaminopropionitril<br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#ethylene#ethylene"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Et</span></a>ilen
  oksid<br>
  <a href="http://neuromuscular.wustl.edu/spinal/arachnoid.htm#scheroin"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Eroin</span></a><br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#lithium#lithium"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Lit</span></a>yum<br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#methyl#methyl"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Metilbromid</span></a><br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#nitrofurantoin#nitrofurantoin"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Nitrofurantoin</span></a><br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#organophosphorous#organophosphorous"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Organo</span></a>fosfatlar<br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#pcb#pcb"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Poliklorine</span></a>
  bifeniller (PCB)<br>
  <a href="http://neuromuscular.wustl.edu/mother/chan.html#saxitoxin"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Saksitoksin</span></a><br>
  �spanyol toksik ya��</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'><a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#taxol#taxol"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Taksol</span></a><br>
  <a href="http://neuromuscular.wustl.edu/mother/chan.html#tetrodotoxin"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Tetrodotoksin</span></a><br>
  Talyum <br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#tce#tce"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Tri</span></a>kloretilen</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Triortokrezil fosfat</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Vakor (PNO)<br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#vinca#vinca"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Vinka
  alkaloi</span></a>deri </span></p>
  </td>
  <td width=111 nowrap valign=top style='width:83.45pt;padding:2.25pt 2.25pt 2.25pt 2.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'><a
  href="http://neuromuscular.wustl.edu/msys/myoglob.html#bbungarotoxin"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>&#946;-bungaroto</span></a>ksin</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Botulizm<br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#dmab#dmab"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Dimetilamin</span></a></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'><a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#dmab#dmab"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Boran</span></a></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Gangliozidler<br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#bwspider#bwspider"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Latroto</span></a>ksin<br>
  &nbsp; Kara dul</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kur�un</span><span lang=FI style='mso-ansi-language:
  FI'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Civa<br>
  <a href="http://neuromuscular.wustl.edu/nanatomy/vii.htm#mobius"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Misoprostol</span></a><br>
  Tetanoz<br>
  Kene paralizisi </span><span lang=FI style='mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
  <td width=125 valign=top style='width:93.55pt;padding:2.25pt 2.25pt 2.25pt 2.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�Buckthorn� (Cehri)</span><span lang=FI
  style='mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Klorokin</span><span lang=FI style='mso-ansi-language:
  FI'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Difteri<br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#fk506#fk506"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>FK506
  (Takrolimus)</span></a><br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#hexachlorophene#hexachlorophene"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>He</span></a>ksaklorofen<br>
  Muzolimin<br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#perhexiline#perhexiline"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Perhe</span></a>ksilen<br>
  <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#procainamide#procainamide"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Pro</span></a>kainamid<br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#tellurium#tellurium"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Tellurium</span></a><br>
  Zimeldin </span><span lang=FI style='mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
  <td width=96 valign=top style='width:72.35pt;padding:2.25pt 2.25pt 2.25pt 2.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Amiodaron<br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#deg#deg"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Dietilenglikol</span></a><br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#ethglycol#ethglycol"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Etilengl</span></a>ikol<br>
  <a href="http://neuromuscular.wustl.edu/mother/myotox.htm#eosinophilia"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>1,1'-Etilidinebis</span></a><br>
  &nbsp; <a href="http://neuromuscular.wustl.edu/mother/myotox.htm#eosinophilia"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>[tryptophan]</span></a><br>
  Alt�n<br>
  Heksakarbonlar <br>
  &nbsp; <a
  href="http://neuromuscular.wustl.edu/nother/toxic.htm#hexacarbon#hexacarbon"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>n-Heksan</span></a><br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#cyanate#cyanate"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Na<sup>+</sup>
  </span></a>siyanat<br>
  <a href="http://neuromuscular.wustl.edu/nother/toxic.htm#suramin#suramin"><span
  style='color:windowtext;text-decoration:none;text-underline:none'>Suramin</span></a></span><span
  lang=FI style='mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;mso-yfti-lastrow:yes'>
  <td width=336 colspan=3 style='width:252.35pt;padding:2.25pt 2.25pt 2.25pt 2.25pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;color:#333333;
  mso-ansi-language:TR'>&nbsp;</span><span lang=FI style='mso-ansi-language:
  FI'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=FI style='mso-ansi-language:FI'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>End�striyel ve �evresel Toksinler</span></b><span
lang=FI style='mso-ansi-language:FI'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>End�stride kullan�lan bir kimyasal maddenin n�rotoksik etkisi, genellikle
ayn� i�yerinde �al��an bir �ok i��inin ayn� zamanda hastalanmas� ile ortaya
��kar. Toksik maddenin belirlenmesi ve i��ilerin bu madde ile temas�n�n
kesilmesi ile de �salg�n� kontrol alt�na al�n�r. End�striyel ortamda
polin�ropati yapm�� olan ba�l�ca maddeler akrilamid, alil klorid,
karbondis�lfid, dimetilaminopropionitril ve heksakarbon bile�ikleridir (</span><span
lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>N</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>-heksan ve metil </span><span
lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>N</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>-butil keton).
Sterilizasyonda kullan�lan etilenokside maruz kalan hastane �al��anlar�nda
polin�ropatiler g�sterilmi�tir. Triortokrezilfosfat kar��an g�da maddeleri ile
toksik n�ropati salg�nlar� g�r�lm��t�r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Heksakarbonlar</span></i><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> ortak metabolitleri olan 2,5
heksandion arac�l��� ile polin�ropatiye neden olurlar. Bu n�ropatide lokal n�rofilament
birikimine ba�l� multifokal aksonal �i�meler (dev aksonal n�ropati) ve sekonder
segmental demiyelinizasyon olur. Toksik n�ropatilerin �o�unda yayg�n aksonal
dejenerasyonu yans�tan elektrofizyolojik bulgular saptan�rken, heksakarbon
n�ropatilerinde iletim yava�lamas� ve parsiyel iletim bloklar�n�n saptanmas�n�n
nedeni budur. Klinik tablo ekstremite distallerinde parestezi ve duyu azal�m�
ile ba�lamakla birlikte, olgular�n �o�unda belirgin derecede kas kuvvetsizli�i
geli�ir. A��r olgularda kas zaaf�n�n olduk�a h�zl� yerle�mesi, ekstremite
distallerinin yan�s�ra proksimal kas gruplar�n� da etkilemesi nedeniyle
inflamatuvar demiyelinizan polin�ropatilerle kar��t�r�labilir.&nbsp;Sinir
iletim incelemelerinde demiyelinizasyon varl���n� g�steren bulgular�n saptanmas�
ay�r�c� tan�y� daha da zorla�t�rabilir. Heksakarbon n�ropatilerinde BOS
bulgular�n�n normal olmas�, ayn� i�yerinde bir �ok i��inin ayn� zamanda
hastalanmas� ve gere�inde yap�lacak sinir biyopsisinde tipik patolojik
bulgular�n g�sterilmesi tan� koydurur.&nbsp; Heksakarbonlar merkezi sinir
sisteminde �zellikle uzun traktuslara hasar verebildi�inden, a��r seyirli
olgular�n iyile�me a�amas�nda polin�ropati bulgular� azal�rken piramidal
iritasyon bulgular� ortaya ��kabilir. Baz� yap��t�r�c� sol�syonlarda ��z�c�
olarak bulunan </span><span lang=TR style='font-size:7.0pt;font-family:Tahoma;
mso-ansi-language:TR'>N</span><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>-heksan, yurdumuzda zaman zaman ayakkab� ve deri
e�ya �reten at�lyelerde �al��an i��iler aras�nda olduk�a a��r polin�ropatilere
yol a�m��t�r. Benzer yap��t�r�c�lar� inhale ederek uyu�turucu etkisinden
yararlanmaya �al��an ki�ilerde de ileri kas zaaf� ile seyreden polin�ropatiler
bildirilmi�tir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Metaller</span></i><span lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Metaller genellikle element hallerinde de�il, organik ve inorganik
bile�enler halindeyken n�rotoksiktir. Metal n�ropatilerinin tan�s�na birlikte
olan hematolojik ve di�er sistemik bulgular yard�mc� olur.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Arsenik</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> zehirlenmesinde polin�ropatiye kar�n a�r�s�, kusma ve pansitopeni e�lik
eder. Akut ba�lang��l� ve a��r seyirli olgular Guillain-Barr� sendromu ile
kar��t�r�labilir. Avu� i�leri ve ayak tabanlar�nda hiperkeratoz ve soyulma, t�rnaklarda
soluk transvers bandlar (<i>Mees �izgileri</i>) g�r�lebilir.&nbsp; <i>Kur�un</i>
n�ropatisiyle birlikte kar�n a�r�s� ve anemi g�r�l�r. N�ropati motor
a��rl�kl�d�r ve klasik olarak radial siniri �n planda etkileyip d���k el
tablosuna yol a�t��� bilinir. <i>Talyum</i> zehirlenmesinde gastrointestinal
semptomlar ve a�r�l�, distal duyusal-motor polin�ropati olur. En g�ze �arpan
belirti, genellikle&nbsp; n�ropatinin ba�lang�c�ndan 2-3 hafta sonra ortaya
��kan alopesidir. Talyum zehirlenmesinde de Mees �izgileri g�r�lebilir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Metal n�ropatilerinde tan�, hastal�k �yk�s�nde intoksikasyon ��phesi
bulunan, polin�ropati bulgular�na sistemik yak�nma ve bulgular�n eklendi�i
olgular�n kan, idrar, sa� ve t�rnaklarda y�ksek metal d�zeylerinin g�sterilmesi
ile konur. Tedavi toksik madde temas�n�n kesilmesiyle olur. Tedavide yayg�n
�ekilde kullan�lm�� olan penisilamin, BAL, EDTA gibi �elat�r maddelerin
muhtemelen yararl� etkisi vard�r. Ancak bunlar�n toksik n�ropatilerin
tedavisindeki&nbsp; etkilerini ara�t�ran kontroll� �al��malar da mevcut de�ildir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Organofosfat �ntoksikasyonlar�</span></i><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Organofosfat bile�ikleri d�nyada insektisit olarak yayg�n �ekilde
kullan�lmakta, intoksikasyonlar�, tar�m ve bah�e bak�m� amac�yla p�sk�rt�l�rken
inhalasyon veya deri yoluyla al�narak, intihar amac�yla ya da kaza eseri yutularak
olmaktad�r. Piyasalarda var olan binlerce organofosfat markas�n�n geli�mekte
olan �lkelerdeki kontrol�, muhtemelen Bat� �lkelerine oranla daha zay�ft�r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Organofosfat intoksikasyonlar�n�n en s�k g�r�len <i>Tip I</i> sendromu,
asetikolinesteraz enziminin geri d�n��s�z inhibisyonuna ba�l� yo�un muskarinik
stim�lasyon nedeniyle geli�ir. �iddeti al�nan bile�i�in toksisitesine ve
al�nd��� miktara g�re de�i�ir. Toksik maddenin al�nmas�ndan sonraki ilk g�n
i�inde ortaya ��kan bulant�, kusma, diyare, terleme, hipersalivasyon, istemsiz
idrar ve gaita yapma, ta�ikardi veya bradikardi g�r�l�r. �leri olgularda
emosyonel labilite, yorgunluk, kognitif bozukluklar ve uyan�kl�k bozuklu�u,
konv�lsiyon ve koma gibi merkez sinir sistemi belirtileri g�r�lebilir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Ara Tip veya Tip 2</span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> organofosfat sendromu iskelet kas�ndaki nikotinik
asetikolin resept�rlerinin a��r� uyar�lmas�na ba�l�d�r. Toksik maddeye maruz
kal�nmas�ndan 12-96 saat sonra ortaya ��kar. Akut ve ara sendromlar aras�nda
genellikle 1-4 g�nl�k semptomsuz bir d�nem vard�r. Solunum yetersizli�i
genellikle ilk belirtidir. Bunu proksimal kaslar ve boyun fleksorlar�nda
kuvvetsizlik izler. Kranyal alan kaslar� tutulabilir, fakat distal ekstremite
kaslar� genellikle kurtulur. �yile�me 5-15 g�nde ba�lar. Atropin, muskarinik
resept�rlere �zg�l oldu�u i�in ara sendromun engellenmesi veya tedavisinde i�e
yaramaz.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Baz� organofosfat bile�ikleriyle intoksikasyondan 7-21 g�n sonra bir <i>gecikmi�
polin�ropati</i> tablosu ortaya ��kar. Bu n�ropatinin geli�mesinin, hastan�n
daha �nce Tip 1 ve Tip 2 sendromlar� ge�irmi� olmas� ile bir ili�kisi yoktur.
Baz� hastalarda toksik maddeye kronik maruz kalma sonucunda ortaya ��kt���
d���n�lmektedir. Sinir sisteminde <i>n�rotoksik esteraz</i> veya <i>n�ropati
target esteraz</i> ismi verilen resept�r proteinin fosforilasyonu sonucu
geli�ir. Genellikle subakut ba�lang��l�, en �iddetli haline yakla��k 2 haftada
ula�an, duyusal �motor, periferik-santral bir aksonopati �eklindedir.
Bacaklarda a�r�l� paresteziler ve kramplar ortaya ��kar. Alt ekstremite
distallerinden ba�layan motor belirtiler d���k ayak, daha sonra el kaslar�nda
kuvvetsizlik ve ge� d�nemde yayg�n kas kuvvetsizli�i g�r�n�m�ndedir. Uzun
s�reli intoksikasyona ba�l� amiyotrofik lateral skleroza benzer tablolar
bildirilmi�tir. Bulan�k g�rme ve ataksi olabilir. Medulla spinalisin uzun
traktuslar�n�n tutulmas�na ba�l� spastisite ve hiperrefleksi bulunabilir.
Elektrofizyolojik incelemeler aksonal bir polin�ropati ve sekonder
demiyelinizasyonu yans�t�r. Polin�ropati aylar i�erisinde yava� bir d�zelme
g�sterir, ancak omurilik tutulmas�na ait belirtiler genellikle gerilemez.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Triortokrezil fosfat</span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> insektisit olmayan, sanayide �e�itli ama�larla
kullan�lan bir organofosfatt�r. Bir �ok �lkede, g�dalara kar��mas� ile ciddi
aksonal polin�ropati tablolar�na yol a�m��t�r.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>BESLENME YETERS�ZL���NE VE ALKOL�ZME BA�LI
POL�N�ROPAT�LER</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> (Ayr�ca bak�n�z: <a href="http://www.itfnoroloji.org/beslenme/beslenme.htm">Sinir
Sisteminin Nutrisyonel Hastal�klar�</a>)</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Beslenme yetersizliklerine ba�l�
polin�ropatiler genellikle �iddetli k�tl�k �ekmekte olan toplumlarda ya da esir
ve konsantrasyon kamplar�nda kalanlarda g�r�lm��t�r. Starvasyona ba�l�
polin�ropatilerde beslenmede eksik olan ve polin�ropatiye yol a�an as�l maddeyi
belirlemek g�� olmakla birlikte, B grubu vitaminlerinden bir veya bir ka��n�n
eksikli�i s�z konusudur. Bu n�ropatilerde genellikle distal aksonal
dejenerasyonla seyreden duyusal ya da duyusal-motor bir polin�ropati ortaya
��kar. Olgular�n bir �o�unda merkez sinir sistemi ve kalp, deri gibi gibi di�er
organlar�n tutulmas�na ba�l� bulgular vard�r. <i>Vitamin yetersizli�ine ba�l�
polin�ropatilerde tedavinin ana kural� hastaya vakit ge�irmeden uygun
vitaminlerin verilmesidir. Bununla birlikte,&nbsp; polin�ropatisi olan b�t�n
hastalara vitamin tedavisi uygulaman�n hi� bir bilimsel dayana�� yoktur. </i></span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Nutrisyonel yetersizli�e ba�l�
polin�ropatilerin prototipi olan <i>Beriberi,</i> <i>B1 vitamini</i> (<i>tiamin</i>)
yetersizli�inde ortaya ��kar. Ba�l�ca belirtileri kalp yetersizli�i ve
polin�ropatidir. �lk olarak ekstremite distallerinde a�r�l� duyusal yak�nmalar
ortaya ��kar. Hastal���n ilerlemesi ile distal kaslarda kuvvetsizlik geli�ir.
Tedavi oral (absorbsiyon bozuklu�u varsa parenteral) tiamin uygulamas� ve
dengeli beslenmenin sa�lanmas� ile olur.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Nikotinik asid</span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>in<i> (niasin)</i> diyetteki eksikli�i <i>pellegra</i>ya
neden olur. Bu sendromda olgular�n yakla��k yar�s�nda bir duyusal-motor
polin�ropati geli�ir. Hastalarda dermatit ve diyarenin g�r�lmedi�i durumlarda
klinik tablo tiamin yetersizli�ine ba�l� n�ropatilerden ayr�lamaz.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>B6 vitamini</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> (<i>piridoksin</i>) yetersizli�i izoniazid (INH), hidralazin ve nadiren
penisilamin tedavisi s�ras�nda ortaya ��kar.&nbsp; Bu ila�lar yap�sal olarak B6
vitaminine benzer ve piridoksin koenzim aktivitesi ile �at���rlar. Genellikle
sinsi ba�lang��l� distal ve simetrik duyusal-motor bir polin�ropati geli�ir.
INH tedavisine piridoksinin eklenmesiyle (100 mg/g�n) polin�ropati �nlenir.
Piridoksinin �ok y�ksek dozda al�nmas� da (600-3000 mg/g�n) duyusal bir
polin�ropatiye neden olur.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>B12 vitamini</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> yetersizli�inde <i>subakut kombine dejenerasyon</i> ortaya ��kar (Bak�n�z:
<a href="http://www.itfnoroloji.org/omurilik/omurilik.htm">Omurilik
Hastal�klar�</a>). Bu tabloya hafif bir polin�ropati eklenebilir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Malabsorbsiyona ba�l� <i>E vitamini</i> yetersizli�i ekstremite ve y�r�me
ataksisi, bozulmu� vibrasyon ve pozisyon duyusu, arefleksi, oftalmopleji ve
pigmenter retinopati ile seyreden bir spinoserebellar sendroma yol a�ar (Ayr�ca
bak�n�z: <u><span style='color:blue'>Ataksiler</span></u>). Klinik belirtiler
kronik E vitamini eksikli�inin ba�lang�c�ndan y�llar sonra ortaya ��kar ve
yava� ilerler. Arka k�k gangliyonu h�crelerinin periferik sinirlerde ve medula
spinalis arka kordonlar�nda uzanan geni� �apl� liflerinin dejenerasyonu ile
giden bu tablodan, muhtemelen n�ronlar�n E vitamini eksikli�ine ba�l�
antioksidan korunmalar�n�n kaybolmas� sorumludur. Tan�, klinik bulgular,
serumda �ok d���k E vitamini d�zeyleri (&lt;5<span style='mso-char-type:symbol;
mso-symbol-font-family:Tahoma'><span style='mso-char-type:symbol;mso-symbol-font-family:
Tahoma'>&#61549;</span></span>g/ml) ve bozuk ya� absorbsiyonunun g�sterilmesi
ile konur. E vitamini uygulamas� hastal���n progresyonunu durdurur.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Alkolik polin�ropati</span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>nin - yetersiz diyet, bozulmu� absorbsiyon ya da alkol�n
metabolizasyonu i�in artm�� gereksinim nedeniyle geli�en tiamin ve di�er B
grubu vitaminlerin yetersizli�i sonucunda ortaya ��kt��� d���n�lmektedir.
Geli�mi� bat� �lkelerinde beslenme yetersizli�ine ba�l� ba�l�ca polin�ropatiler
alkolizm nedeniyle ortaya ��kanlard�r. �n planda yayg�n distal aksonal hasarla
seyreden bu n�ropatinin ba�l�ca semptomlar�, alt ekstremite distallerinde
belirgin yan�c�, bat�c� a�r� ve paresteziler ile buna eklenen distal kas zaaf�
ve kramplard�r. Muayenede ekstremite u�lar�nda duyu azalmas� ve a�r�l� a��r�
duyarl�k, tendon reflekslerinin kayb� ve hafif distal kas zaaf� bulunur.&nbsp;
�lerlemi� olgularda pozisyon duyusu kayb�na ba�l� ataksi ile alkolik serebellar
ataksi birlikte g�r�lebilir. Alkolik n�ropatiye neden olacak alkol al�m
miktar�n� belirlemek g��t�r. Bununla birlikte, hafif-orta miktarda alkol alan,
iyi beslenen ve kronik karaci�er hastal��� belirtileri ta��mayan bir hastada
alkolik polin�ropati bulunma olas�l��� d���kt�r. Bu durumdaki bir hastada di�er
polin�ropati nedenlerinin de ara�t�r�lmas� gerekir. Alkolik n�ropati
tedavisinin ba�l�ca bile�enleri&nbsp; alkol al�m�n�n kesilmesi, dengeli
beslenmenin sa�lanmas� ve bunun&nbsp; tiamin uygulamas� ile desteklenmesidir.
�iddeti gastrointestinal semptomlar� olan hastalara tiamin parenteral olarak
verilmelidir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kritik Hastal�k Polin�ropatisi</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Yo�un bak�m �nitelerinde olduk�a s�k kar��la��lan bir sorundur. Genellikle
n�rolojik olmayan bir hastal�k nedeniyle yo�un bak�m �nitesinde yatmakta olan,
sepsis ve multipl organ yetersizli�i bulunan hastalarda ortaya ��kar. S�kl�kla
hastan�n respirat�rden ayr�lmas�ndaki g��l�k nedeniyle fark edilir. Bir �ok kez
<i>septik ensefalopati</i> bulgular� olan, sedasyon uygulanm�� ve int�be
edilmi� durumda bulunan hastalar�n n�rolojik de�erlendirilmesinde g��l�kle
kar��la��l�r. Genel bir gev�ek fel� vard�r, tendon refleksleri yayg�n olarak
kay�pt�r. �yi muayene edilebilen hastalarda ekstemite distallerinde
eldiven-�orap �eklinde duyu kusuru saptanabilir.&nbsp; Kranyal sinirler
genellikle tutulmaz, nadiren iki yanl� fasiyal zaaf g�r�lebilir. Otonom sinir
sistemi tutulmas� nadirdir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Yayg�n distal akson hasar�yla seyreden bu polin�ropatiden <i>sistemik
inflamatuvar yan�t sendromu</i>nun sorumlu oldu�u d���n�lmektedir. Bu sendromda
infeksiyon, travma vb. gibi nedenlerle faaliyete ge�en humoral ve sell�ler
mekanizmalar�n, �e�itli organlar�n mikrosirk�lasyonunu etkileyerek bu
organlarda yetersiz perf�zyona ve multipl organ yetersizli�ine neden oldu�u
d���n�lmektedir. Elektromiyografi ve sinir iletim incelemelerinde aksonal
polin�ropati ile uyumlu bulgular saptan�r. BOS bulgular� normaldir. Genel
durumu d�zelip yo�un bak�mdan ��kar�labilen hastalarda polin�ropati aylar
i�inde yava� bir d�zelme g�sterir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Hastal��a yol a�t��� d���n�len septik kaskada y�nelik bir
�ok&nbsp; tedavi y�ntemi denenmi� fakat anlaml� sonu� elde edilmemi�tir.
Etkileri kan�tlanmam�� olmakla birlikte, yo�un ins�lin uygulamas� ile periferik
glikoz al�m�n�n uyar�lmas�, anormal lipid profillerinin d�zeltilmeye
�al���lmas�, rekombinant aktive insan protein C�si verilmesi ve IV
immunoglobulin uygulamalar� morbidite ve mortaliteyi azaltma a��s�ndan umut
verici g�r�nmektedir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kronik hastal�k polin�ropatisinin ay�r�c� tan�s�na giren
hastal�klardan birisi Guillain-Barr� sendromu, di�eri ise <i>yo�un bak�m
miyopatisi</i>dir. Yo�un bak�m miyopatisi, yo�un bak�m �nitesinde y�ksek doz
kortikosterod ve n�rom�sk�ler bloker ila� uygulanm�� olan hastalarda akut
olarak ortaya ��kar. Kas�n histopatolojik incelemesinde kal�n filamentlerin
kayb� izlenir. Serum CPK d�zeyi artm�� olabilir. Elektrofizyolojik
incelemelerde duyusal sinir iletimlerinin normal, i�ne elektromiyografisi
bulgular�n�n kas tutulmas� ile uyumlu olmas� tan� konmas�n� sa�lar. Benzer
klinik bulgular n�rom�sk�ler bloker ila�lar�n at�lma bozuklu�una ba�l� olarak
ta ortaya ��kabilece�inden elektrofizyolojik incelemelere n�rom�sk�ler iletim
bozuklu�unu ara�t�ran y�ntemler (ard�s�ra uyar�m testleri ve tek lif
elektromiyografisi) eklenmelidir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>G�r�ld��� gibi, yo�un bak�mda ortaya ��kan yayg�n kas
zaaf� tablolar�n�n ay�r�c� tan�s�na giren t�m hastal�k durumlar�n�n olduk�a
tipik elektrofizyolojik bulgular� vard�r. Bu nedenle elektrofizyolojik
y�ntemler bu hastal�klar�n tan�nmas�nda temel bir rol oynar. Ancak, yo�un bak�m
�nitelerinde bu incelemelerden yararl� sonu�lar almakta g��l�klerle
kar��la��labilir. Bir yandan yo�un bak�m �nitelerinin elektrikle �al��an �ok
say�da aletle donanm�� olmas� elektrofizyolojik test cihazlar�nda artefaktlara
yol a�arken, di�er yandan hastalar�n incelemeye i�birli�i yapamamas� ya da bir
�ok kez �demli olan ekstremiteleri g�venilir kay�tlamalar yapmay�
zorla�t�rabilir. Tan�mlanm�� metodlara uygun yap�lan frenik sinir motor iletim
�al��malar� ve diyafram kas�n�n i�ne elektromiyografisi, hastan�n ventilat�rden
ayr�lamama sebebinin yo�un bak�m n�ropati/miyopatisine ba�l� oldu�unu ortaya
koymada yard�mc� olabilir. &nbsp;Kas biyopsisi, kas dokusunu de�erlendirme
konusunda tecr�beli bir merkeze g�nderilmesi halinde, yo�un bak�m miyopatisinin
tan�nmas�nda �ok yararl� olabilir.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kronik Kriptojenik (�dyopatik) Duyusal Polin�ropati</span></b><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>[ya da distal, a�r�l�,
aksonal, idyopatik n�ropati (distal-PAIN)]</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Edinsel duyusal ya da duyusal-motor polin�ropatilerin b�y�k k�sm�nda iyi
bir ara�t�rma ile polin�ropati nedeni ortaya konulabilir. Ancak bir grup
hastada b�t�n ara�t�rmalara ra�men b�yle bir neden belirlenemez.&nbsp;
Polin�ropatiler i�inde bu&nbsp; kriptojenik grubun oran� eski serilerde %50-70
civar�ndayken, yak�n zamanlardaki �al��malarda -yeni polin�ropati nedenlerinin
tan�mlanmas� ve geli�en diyagnostik y�ntemlerin katk�s�yla- %10-30 olarak
verilmektedir. Son zamanlarda kriptojenik n�ropatisi olan hastalardan bir
b�l�m�n�n belirti, bulgu ve seyirleri a��s�ndan olduk�a homojen �zellikler
g�sterdi�i dikkati �ekmi�, bu olgular �<i>kronik kriptojenik (idyopatik)
duyusal polin�ropati</i>� ismi alt�na toplanm��t�r.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Genellikle 50 ya��n �zerinde olan bu olgularda �n planda duyusal aksonal
bir polin�ropati s�z konusudur. Alt ekstremite distallerinden ba�lay�p �ok yava�
�ekilde y�kselen yan�c�, geceleyin artan a�r� ve uyu�malar ba�l�ca yak�nmay�
olu�turur. Tendon refleksleri korunmu� ya da ekstremite distallerinde
azalm��t�r. Kas kuvvetsizli�i nadirdir. Elektrofizyolojik incelemelerde sinir
iletimleri normal ya da duyusal aksiyon potansiyelleri d���k amplit�dl�
bulunur. Genellikle ince sinir liflerinin tutuldu�u bu polin�ropatilerde
kantitatif duyusal testler ve deri biyopsileri tan� i�in yol g�sterici
olabilir. Bu grubun en �nemli �zelli�i prognozunun iyi olmas�, hastalar�n
genellikle fonksiyonel k�s�tl�l��a neden olmayan bir klinik platoya ula�malar�,
hatta k�smen d�zelme g�stermeleridir. Hastal���n hareket kayb�na yol a�acak
derecede ilerlemesi nadirdir. Bu nedenle a�r� tedavisinin �nemli bir par�as�,
hastan�n e�itimi ve iyi prognoz hakk�nda bilgilendirilmesidir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Bir hastaya bu tan�y� koymadan �nce aksonal, �n planda
ince lifleri tutan polin�ropati nedenleri konusunda ayr�nt�l� bir ara�t�rma
yap�lmas� �nem ta��r (Bak�n�z: <u>Polin�ropatili Hastada Tan�</u>). S�z konusu
testlerin negatif kald��� ve kronik idyopatik duyusal n�ropati tan�s� d���n�len
olgular da klinik seyirleri a��s�ndan g�zlem alt�nda tutulmal� (ilk y�l birka�
ayda bir, sonra daha seyrek), gere�inde tan� testleri tekrarlanmal�d�r.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'>KAYNAKLAR</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Kitaplar ve Kitap B�l�mleri</span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<ol style='margin-top:0cm' start=1 type=1>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Aminoff MJ (Ed) .
     Neurology and General Medicine. 4. Bask�. Philadelphia: Churchill
     Livingstone-Elsevier, 2008</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Asbury AK, Thomas
     PK (eds). Peripheral Nerve Disorders 2. Oxford: Butterworth-Heinemann,
     1995.</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Bella IR. Acute
     inflammatory demyelinating polyradiculoneuropathy. ��inde: Deymeer F (ed).
     Neuromuscular Diseases: From Basic Mechanisms to Clinical Management.
     Monogr Clin Neurosci. Basel: Karger, 2000: 147-162. </span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Bosch EP, Smith
     BE. Disorders of peripheral nerves. ��inde: Bradley WG, Daroff RB,
     Fenichel GM, Jankovic J (Eds). Neurology in Clinical Practice. 4. Bask�.
     Philadephia: Butterworth Heinemann, 2004: 2299-2402</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Bromberg MB, Smith
     G (Eds). Handbook of Peripheral Neuropathy. Boca Raton:Taylor and Francis,
     2005 </span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Dyck PJ, Thomas PK
     (Eds). Peripheral Neuropathy. Cilt I ve II. 4. Bask�. Philadelphia:
     Elsevier Saunders, 2005</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Feldman EL,
     Grisold W, Russell JW, Zifko U. Atlas of Neuromuscular Diseases. A
     Practical Guideline. Viyana, New York: Springer, 2005</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Katirji B,
     Kaminski HJ, Preston DC, Ruff RL, Shapiro BE (Eds). Neuromuscular
     Disorders in Clinical Practice. Boston: Butterworth Heinemann, 2002</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Mendell JR, Kissel
     JT, Cornblath DR (Eds). Diagnosis and Management of Peripheral Nerve
     Disorders. Oxford: Oxford University Press, 2001</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Noseworthy JH
     (Ed). Neurological Therapeutics. Principles and Practice. Vol III.&nbsp;
     2. Bask�. Oxon: Informa Healthcare, 2006</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Plant�-Bordeneuve
     V, Said G. Neuropathies h�r�ditaires. EMC ( Encyclop�die
     M�dico-Chirurgicale. 1996; 17-112-A-50.</span><span lang=FR
     style='mso-ansi-language:FR'><o:p></o:p></span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Poyraz M. Otozomal
     dominant ve resesif demiyelinizan CMT hastal���n�n klinik, genetik ve
     histopatolojik incelenmesi (Uzmanl�k Tezi). �� �stanbul T�p Fak�ltesi
     N�roloji Anabilim Dal�, �stanbul, 2004.</span></li>
</ol>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Dergi ve Makaleler</span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<ol style='margin-top:0cm' start=1 type=1>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>Asbury AK. New concepts of Guillain-Barr� syndrome. J Child Neurol
     2000; 15: 183-191</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>Durand MC, Porcher R, Orlikowski D, Aboab J, Devaux C, Clair B, Annane
     D, Gaillard JL, Lofaso F, Raphael JC, Sharshar T.&nbsp; Clinical and
     electrophysiological predictors of respiratory failure in Guillain-Barr�
     syndrome: a prospective study. Lancet Neurol. 2006 ;5:1021-8.</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>Dyck PJ, Dyck JB, Grant IA, Fealey R. Ten steps in characterizing and
     diagnosing patients with peripheral neuropathy. Neurology 1996;47:10-14</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>England JD et al. Evaluation of distal symmetric polyneuropathy: The
     role of autonomic testing, nerve biopsy, and skin biopsy (an
     evidence-based review). Muscle Nerve 2009; 39: 106�115. </span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>England JD et al. Evaluation of distal symmetric polyneuropathy: The
     role of laboratory and genetic testing (an evidence-based review). Muscle
     Nerve 2009; 39: 116�125. </span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>Gorson KC. Vasculitic neuropathies. An update. The Neurologist
     2007;13: 12�19</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>Hughes RAC, Swan AV, Raphael JC, Annane D, van Koningsveld R, van
     Doorn PA. Immunotherapy for Guillain-Barr� syndrome:a systematic review.
     Brain 2007; 130: 2245-2257</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>Kusunoki S, Kaida K, Ueda M. Antibodies against gangliosides and
     ganglioside complexes in Guillain�Barr� syndrome: New aspects of research.
     Biochimica et Biophysica Acta 2008; 1780: 441�444</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>L�ger JM. Diagnosis of chronic neuropathy. J Neurol 1999; 246: 156-161</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>Lewis RA. Toxic and Deficiency Neuropathies. AAN Continuum Vol 9. No
     6, December 2003 (Peripheral Neuropathies):160-181</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>Lunn MPT, Willison HJ. Diagnosis and treatment in inflammatory
     neuropathies J Neurol Neurosurg Psychiatry 2009;80:249�258.</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>Pareyson D. Hereditary Neuropathies: Molecular basis for distinction
     and diagnosis. European Neurological Society (ENS) Peripheral Neuropathy
     teaching course 1. Ninth Meeting ENS. June 5-9 1999; 20-32</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>Parman Y, Ciftci F, Poyraz M., et al X-linked Charcot-Marie-Tooth
     disease and multiple sclerosis. J Neurol 2007;254:953-955</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Pourmand R (ed).
     Acquired Neuromuscular Diseases. Neurol Clin 1997;15 (No:3, August)</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Sahenk Z.
     Neurotrophins and peripheral neuropathies. </span><span lang=TR
     style='font-size:11.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Brain Pathol
     2006;16:311-319.</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Schaublin GA,
     Michet CJ, Dyck PJB, Burns TM. An update on the classification and
     treatment of vasculitic neuropathy. Lancet Neurol 2005; 4: 853�65.</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Thomas PK, Harding
     AE. Inherited Neuropathies: The interface between molecular genetics and
     pathology. Brain Pathology 1993; 3: 129-133</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Thomas PK.
     Diabetic neuropathy: mechanisms and future treatment options. J Neurol
     Neurosurg Psychiatry 1999; 67: 277-281</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>van Doorn PA, Ruts
     L, Jacobs BC.&nbsp; Clinical features, pathogenesis, and treatment of
     Guillain-Barr� syndrome. Lancet Neurol 2008; 7: 939�50</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Vernino S,
     Sandroni P, Singer W, Low PA. Invited Article: Autonomic ganglia: target
     and novel therapeutic tool.&nbsp; Neurology. 2008;70:1926-32.</span></li>
 <li class=MsoNormal style='color:#231F20;mso-list:l1 level1 lfo2;tab-stops:
     list 36.0pt'><span lang=TR style='font-family:Tahoma;color:windowtext;
     mso-ansi-language:TR'>Willison HJ, Yuki N. Peripheral neuropathies and
     anti-glycolipid antibodies. Brain 2002; 125: 2591-2625</span><o:p></o:p></li>
 <li class=MsoNormal style='color:#231F20;mso-list:l1 level1 lfo2;tab-stops:
     list 36.0pt'><span lang=TR style='font-family:Tahoma;color:windowtext;
     mso-ansi-language:TR'>Yuki N. Ganglioside mimicry and peripheral nerve
     disease. Muscle Nerve </span><span lang=TR style='font-family:Tahoma;
     mso-ansi-language:TR'>35: 691�711, 2007</span><o:p></o:p></li>
</ol>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Elektronik Materyal ve �nternet</span></b></p>

<ol style='margin-top:0cm' start=1 type=1>
 <li class=MsoNormal style='mso-list:l0 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Apfel SC (1999).
     Diabetic polyneuropathy. <span style='color:#3366FF'><a
     href="http://www.medscape.com/viewprogram/705"><span style='color:#3366FF'>http://www.medscape.com/viewprogram/705</span></a></span></span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo3;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>Barohn RJ. Evaluation of patients with peripheral neuropathy and
     neuronopathy: a pattern recognition approach. American Academy of
     Neurology. Syllabi-on-CD- ROM.&nbsp; AAN, 2006.</span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Dyck PJB. Diabetic
     Neuropathies. Classification, clinical features and pathological </span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>basis. <span
     style='color:black'>American Academy of Neurology. Syllabi-on-CD- ROM. 2FC
     003. Peripheral neuropathy. AAN, 2008.</span></span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:TR'>Dyro
     FM. Organophosphates. <a
     href="http://emedicine.medscape.com/article/1175139-overview">http://emedicine.medscape.com/article/1175139-overview</a>
     </span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:TR'>Katz
     JS. Complexities in diagnosing the chronic acquired demyelinating
     neuropathies. American Academy of Neurology. Syllabi-on-CD- ROM. 2FC 003.
     Peripheral neuropathy. AAN, 2008</span></li>
 <li class=MsoNormal style='color:#3366FF;mso-list:l0 level1 lfo3;tab-stops:
     list 36.0pt'><span lang=TR style='font-family:Tahoma;color:windowtext;
     mso-ansi-language:TR'>Pestronk A (2008). Polyneuropathy differential
     diagnosis. </span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'><a href="http://www.neuro.wustl.edu/neuromuscular/naltbrain.html"><span
     style='color:#3366FF'>http://www.neuro.wustl.edu/neuromuscular/naltbrain.html</span></a></span><o:p></o:p></li>
 <li class=MsoNormal style='color:blue;mso-list:l0 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;color:windowtext;mso-ansi-language:TR'>Quan
     D.</span><span lang=TR style='font-family:Tahoma;color:#3366FF;mso-ansi-language:
     TR'> Diabetic Neuropathy. </span><span lang=TR style='font-family:Tahoma;
     mso-ansi-language:TR'><a
     href="http://emedicine.medscape.com/article/1170337-overview">http://emedicine.medscape.com/article/1170337-overview</a>
     </span><o:p></o:p></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Rutchik JS. Toxic
     neuropathy. <span style='color:blue'><a
     href="http://emedicine.medscape.com/article/1175276-overview">http://emedicine.medscape.com/article/1175276-overview</a></span></span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Saperstein DS. The
     phenotypes of chronic acquired demyelinating neropathies. <span
     style='color:black'>American Academy of Neurology. Syllabi-on-CD- ROM.
     Peripheral neuropathy. AAN, 2007.</span></span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Saperstein DS.
     Selecting diagnostic tests in peripheral neuropathy patients. <span
     style='color:black'>American Academy of Neurology. Syllabi-on-CD- ROM. 2FC
     003. Peripheral neuropathy. AAN, 2008.</span></span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Smith BE. Approach
     to the patient with peripheral neuropathy. <span style='color:black'>American
     Academy of Neurology. Syllabi-on-CD- ROM. 2FC 003. Peripheral neuropathy.
     AAN, 2008.</span></span></li>
</ol>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

</div>

</body>

</html>
